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Introduction and outline of thesis. 
In 1990 cancer of the urinary bladder accounted for 1.9% of all cancer related 
deaths (9,700 deaths/year) in the USA [1]. In all, 4.7% of newly diagnosed cancers 
are located in the bladder (49,000/year). About two-third of bladder tumors will 
present as superficial (pTa, pTl, carcinoma in situ {CIS}) transitional cell 
carcinomas (TCC). The recurrence rate can be as high as 70%-80%, most frequently 
in the first years after transurethral resection (TUR) of the tumor [2]. Superficial 
bladder cancer is a heterogeneous disease and three groups of patients with 
superficial bladder cancer are seen. The first group is a minority and consists of 
patients with a relatively benign form of disease. After one superficial tumor these 
patients will stay free of recurrences for a long time with or without adjuvant 
treatment after TUR. Progression to muscle invasive disease is seldom in this group. 
In these patients adjuvant treatment seems to be unnecessary. In the second group 
the majority of patients with superficial bladder cancer can be found. These patients 
have recurrent tumors at regular intervals. Intravesical chemotherapy or 
immunotherapy is able to delay recurrences, but not to prevent them. Some of these 
patients will finally show progression of the disease, but it is difficult to predict this. 
Before progression takes place a change to a more aggressive approach (e.g. radical 
surgery) should be considered. The third group of patients also presents with 
superficial disease, but they show progression within a short period, despite maximal 
conservative treatment. Cutler hypothesized that 25% of all superficial bladder 
tumors are 'Ïad" tumors from the start [3]. 
These puzzling aspects of superficial bladder cancer were the basis for further 
research, that resulted in this thesis. In the line of treating a patient with superficial 
bladder cancer one first should know something about the patient and the disease 
(chapter 2), than one should decide whether or not to treat the patient based on 
experience and prognostic factors (chapters 3-6), and finally one should decide 
which treatment to give, for how long and what side effects to expect (chapters 7-
11). 
Epidemiologic information about superficial bladder cancer and patients suffering 
from this disease is essential basic knowledge. Until now, most studies dealing with 
these aspects of superficial bladder cancer were based on rather small case series in 
more or less selected groups of patients. Furthermore, it is not always easy to 
"translate" results from selected groups and other investigators to your own practice. 
Therefore, we wanted to have information about our own patient population and 
registered many data in a large unselected group of patients with primary superficial 
bladder cancer, treated in our cooperative urological group between 1983 and 1990. 
The peak incidence of bladder cancer occurs between 50 and 70 years of age. In 
the first 4 decades of life the incidence is about 1% [4,5]. It is not clear whether the 
biological behaviour of bladder tumors in this younger age group is similar to that in 
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the older patients [5-8], or that it is less aggressive [4,9]. Regular referrals of young 
bladder cancer patients to our University Hospital was the reason to look into this 
dilemma in a subgroup of patients less than 40 years of age. 
An increase in bladder cancer mortality is seen in nearly all western communities, 
especially in males. These figures are consistent with trends by birth cohort for 
cigarette smoking, which strengthens the hypothesised association between cigarette 
smoking and bladder cancer [10]. Data of the Netherlands from 1955 to 1988 are 
used to study temporal variations in mortality. 
Epidemiological aspects, disease outcome under the age of 40 years and bladder 
cancer mortality are described in chapter 2. 
Patients with superficial bladder cancer have a good prognosis with a 5-year 
relative survival of 80-90% [11]. Therefore, reducing mortality is not the only goal in 
the treatment of this type of cancer. Reducing the high recurrence rate is also of 
major concern. With the help of prognostic factors tumor recurrence and 
progression into muscle invasive disease can be predicted and proper treatment can 
be planned. Many factors have been described in the last decades, but none is able 
to predict recurrence or progression in an individual patient. Our experience with 
superficial bladder cancer patients in daily practice has learned us to estimate the 
future clinical course of a patient using factors like tumor grade, stage, size and 
multiplicity. With the help of literature the objective value of daily used clinical and 
histo-pathological factors is described in chapter 3. The value of several other, more 
or less experimental, prognostic factors (blood group antigens, cytogenetic factors 
like DNA content and chromosomal abnormalities, biochemical factors and tumor 
associated antigens) is discussed. 
One of the factors which is used in daily practice, concomitant abnormalities of 
the mucosa, seems to suggest a worse prognosis with regard to recurrence rate, 
progression and tumor related survival [12-16]. However, studies dealing with 
mucosal biopsies and carried out until now are dealing with small numbers of 
patients, have limited follow-up periods and are not adjusted for other prognostic 
factors. Therefore, we started a prospective multicenter study to objectivate the 
prognostic value of bladder biopsies of normal looking mucosa with regard to the 
risk of recurrent or progressive disease. The results of this multivariate analysis are 
described in chapter 4. 
The ultimate goal of prognostic assessment is the ability to predict disease 
outcome on an individual level. Very often studies on prognostic factors focus on 
the discrimination between certain risk groups, using highly statistically significant 
prognostic factors. The relevance of one or more of these factors for predicting 
disease outcome in individual patients, however, may well tum out to be poor. With 
the available prognostic factors from a group of 1674 unselected patients with 
superficial bladder cancer, the prediction of prognosis is tested with a split sample 
method for subgroups of patients. In a second analysis the validity of such a 
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prediction for individual patients is tested. The results of these analyses are 
described in chapter 5. 
For the two studies described in chapters 4 and 5 data are used of a large Dutch 
documentation project on bladder cancer, which includes 1745 patients with primary 
superficial TCC of the urinary bladder. This project is done without review 
pathology. Review of literature reveals clear limitations with regard to pathology 
classification [17-22]. There is a large inter- and intra-observer variability. In a 
multicenter study with several pathologists, these pathology limitations cause 
inconsistencies which might influence the outcome of the study and prognostic factor 
analysis. The absence of a review pathologist has always been a point of concern of 
this multicenter documentation project To get insight in the influence of pathology, 
we used a multicenter study on superficial bladder cancer in which both local and 
review pathology are available in all patients. This study is carried out in the same 
urological group as the documentation project. In chapter 6 the influence of local 
and review pathology on the study outcome (risk of recurrent disease) and on the 
prognostic factor analysis is discussed. 
In chapter 7 a practicle guideline on the management of superficial bladder 
cancer is presented. The initial treatment of choice is TUR, but many patients will 
have to be treated adjuvantly by intravesical instillations. In case of a complete 
TUR these instillations are used to delay or prevent tumor recurrences 
(prophylaxis). In case, however, of an incomplete resection (e.g. CIS), or 
contraindications against surgery, instillations are used to eradicate tumor 
(treatment). Instillations can be done with chemotherapeutic agents (e.g. thiotepa, 
doxorubicin, ethoglucid, mitomycin-C) or immunotherapeutic agents (e.g. interferon, 
Bacillus Calmette-Guerin {BCG}). Of chemotherapeutic drugs the molecular weight 
and the subsequent systemic absorption and toxicity is important. Local side effects, 
like drug induced cystitis, are the main adverse effects. Experience with intravesical 
immunotherapy for interferon is very limited. BCG immunotherapy, however, is 
widely used. Since 1976 BCG has been used in the treatment of superficial bladder 
cancer. After several experimental reports and animal studies Morales was the first 
to treat men with intravesical BCG instillations [23]. At the moment BCG is widely 
used and it seems the drug of choice in patients with CIS. It also seems to be the 
only drug which does not only lower the recurrence rate, but also reduces tumor 
progression and even bladder cancer death [24,25]. Several aspects of intravesical 
BCG treatment are still unclear (mechanisms of action, optimal dosage, best strain, 
best clinical schedule). Other questions have been answered, like the best route of 
administration, although for localisations of TCC outside the bladder cavity other 
routes of administration can be used, such as the percutaneous route for TCC of 
the upper urinary tract [26-31]. It is also clear that toxicity of BCG is significantly 
higher than side effects of intravesical chemotherapy and in most studies efficacy 
results indicate superiority of BCG over intravesical chemotherapy. In chapter 8 an 
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overview of the use of intravesical BCG is given and our own experience with the 
use of BCG outside the bladder cavity is described. 
A study that does not show superiority of BCG over intravesical chemotherapy is 
a study in which BCG-RIVM (the Dutch BCG strain) and Mitomycin-C (MMC) are 
compared [32]. As a result the efficacy of BCG-RIVM is doubted by some 
investigators. This led to the necessity to compare BCG-RIVM to a widely used 
BCG strain with proven efficacy (BCG-Tice) and to a potent chemotherapeutic 
agent. MMC was selected as chemotherapeutic agent because of its proven efficacy 
in papillary tumors and the high response rate in patients with CIS [33-35]. We 
carried out a large randomized multicenter study to compare intravesical MMC, 
BCG-Tice and BCG-RIVM with regard to toxicity and treatment efficacy in patients 
with superficial TCC. The results are described in chapter 9. 
Another question about the use of intravesical BCG remains the optimal clinical 
schedule. In the study described in chapter 9 BCG is given as 1 or 2 courses of 6 
weekly instillations. This treatment might be suboptimal. In high risk patients 
maintenance therapy is advocated. The question of the optimal BCG schedule has 
become even more important since Lamm observed an improved survival in patients 
treated with maintenance therapy after response to the initial 6-week course [25]. 
Therefore, we carried out a trial in which patients with recurrent superficial bladder 
cancer, failing previous chemotherapy, were treated with BCG instillations during 1 
year. When this study was started (1986), there was no consensus about the value of 
intradermal BCG inoculations together with the intravesical administration. Patients, 
therefore, were randomised to intravesical BCG with or without intradermal 
inoculations. Toxicity and efficacy of the maintenance therapy in high risk patients 
and the value of the intradermal injections are discussed in chapter 10. 
Because the exact mode of action of BCG still is unknown, the influence of 
concomitant medication is unclear. An important first step in the development of an 
antitumor activity seems to be attachment of BCG to fibronectin [36]. This 
attachment can be decreased by fibrin clot inhibitors, which appears to have an 
adverse effect on the efficacy of BCG therapy in a recent study of Hudson et al. 
[37]. On theoretical grounds, however, the use of fibrin clot inhibitors at the time of 
the TUR and during BCG treatment may influence tumor recurrence in different 
ways. We therefore studied this question in 183 patients treated with BCG, of which 
42 did and 141 did not use fibrin clot inhibitors. The results of this study are 
described in chapter 11. 
Finally, in chapter 12 a summary and the conclusions of this thesis are presented 
in English and in Dutch. 
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/. Clinical epidemiology of superficial bladder cancer. 
Introduction. 
Until now, all knowledge of disease characteristics of superficial bladder cancer 
(such as stage distribution, the risk of recurrences and disease progression, and 
survival) has been based on rather small case series which are often selective in one 
or more respects. In the first part of this chapter, quantitative data of clinical 
epidemiological features of superficial bladder cancer are presented from a large 
case series in the Netherlands. 
Patients and methods. 
In the south-eastern part of the Netherlands, there is a close cooperation between 
urologists, pathologists and radiotherapists from 23 district hospitals, 1 university 
hospital and 6 radiotherapy centres since 1981 (the Dutch South-East Cooperative 
Urologica! Group). In 1983, this resulted in a consensus report on the diagnosis and 
treatment of patients with bladder cancer. Furthermore, it was agreed that the 
participating urologists would document every newly diagnosed bladder cancer 
patient. This documentation project started in 1983. Intake registration continued 
until January 1990. Follow-up registration continued until July 1991. 
The following items of each patient with a primary bladder tumour were 
registered: date of birth, sex, date of histological confirmation, main complaint, 
tumour morphology, grade of differentiation according to the WHO grading system 
[1], TNM classification [2], tumour multiplicity, localisation, and intravenous urogram 
result. Furthermore, all participating urologists were asked to take (and document) 
four random quadrant biopsies in macroscopically normal looking urothelium (left 
and right lateral wall, trigone and dome) at the time of resection of the tumour(s). 
The therapy to be applied was transurethral resection of the tumour (TUR) in all 
patients. Urologists were advised to consider adjuvant intravesical instillations in the 
case of multiple tumours and more aggressive therapy in pTl grade 3 patients. To 
detect recurrences, cystoscopy and urine cytology were used every three months in 
the first years after treatment. Follow-up data concerning disease and Ufe status 
were collected for each patient once every year. 
Between 1983 and 1990, 2805 cases were documented. In 1991, all data in the 
documentation project were reviewed using the medical files. After this check, the 
records of 100 cases were excluded. Of these, 30 had an inverted papilloma, 58 had 
recurrent instead of primary disease at first registration and 5 had transitional cell 
carcinoma (TCC) in the upper urinary tract. In the records of 7 cases, there were 
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major inconsistencies, which could not be corrected with information from the 
medical files. Of the remaining 2705 cases, 1745 cases (64.5%) had superficial TCC, 
defined as tumour extension limited to the mucosa (pTa) or the lamina propria 
(pTl) of the bladder wall with or without carcinoma in situ (CIS). In urology 
practice, primary carcinoma in situ (pTis) is considered to be very different from 
pTa and pTl tumours because of its relatively aggressive clinical behaviour. For that 
reason, patients with primary pTis (N=52 in our series) were not evaluated in this 
study. 
Survival free of recurrence, survival free of progression, and survival itself were 
measured from the date of histological diagnosis to the date of first recurrence, first 
evidence of disease progression, and date of death, respectively. Survival curves were 
based on the life table method, statistical significance being determined by the log 
rank test. The independence of host and tumour characteristics in determining 
survival free of recurrence and progression was evaluated multivariately using the 
Cox proportional hazards model [3]. 
Although the case series in this documentation project is large, registration is not 
population based, which implies that incidence rates cannot be calculated from the 
project. However, nine Comprehensive Cancer Centres in the Netherlands keep 
population based regional cancer registries. One of these registries (IKL), covering a 
population of approximately 850,000 in the southern part of the Netherlands, has 
complete data on incidence of superficial bladder cancer since 1986 [4]. Information 
from this registry from the period 1986-1989 was used to calculate age and sex-
specific incidence rates. The population based cancer registry was also used to check 
whether patient intake in the documentation project was selective in any way. There 
appeared to be hardly any difference in age, sex, stage and grade distribution 
between the cancer registry and our case series, indicating no under or over 
representation in our series. 
Results. 
Incidence. 
In the southern part of the Netherlands, the total bladder cancer incidence rate per 
10s person-years (age-standardised to the European standard population) is 36.3 for 
males and 6.7 for females. Superficial bladder cancer incidence rates for males and 
females are 23.7 and 3.9, respectively. This accounts for 65% of the total bladder 
cancer incidence in males and 58% in females. The proportion of all bladder 
cancers diagnosed as superficial disease is higher in the younger age categories than 
in the older ones (figure 1). In males, the lifetime risk of developing bladder cancer 
(before the age of 75) is 2.8%. The risk of superficial bladder cancer is 1.9%. In 
females, these risks are 0.5% and 0.4%, respectively. 
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Figure 1: Age-specific incidence rates of total bladder cancer and superficial bladder 
cancer in males and females in the province of Limburg (NL), 1986-1989. Source: 
comprehensive cancer centre JKL, Maastricht, the Netherlands. 
Initial presentation. 
In the documentation project, 1745 patients with superficial TCC were registered. 
Characteristics of this group of patients at initial presentation are listed in table 1. 
Random biopsies of macroscopically normal looking urothelium were taken in 1044 
patients. In 22% of these patients, dysplasia or CIS was diagnosed in at least one 
biopsy specimen. 
The median age at the time of diagnosis is 67 years. There is a clear shift 
towards a higher disease stage with increasing age (figure 2). In patients under the 
age of 40, pTa grade 1 or 2 disease accounts for more than 85% of the superficial 
tumours, compared with only 52% in patients over 80 years of age. The proportion 
of patients diagnosed with multiple tumours is also different for these age groups: 
13% versus 37%. 
From the total group of patients, 1116 (64%) were treated with transurethral 
resection only, additional intravesical instillations were administered in 558 patients 
(32%) and more extensive therapy was given in 71 patients (4,1%, radiotherapy 
and/or (partial) cystectomy). The latter 4,1% were excluded from the analyses of the 
risks of recurrence and progression. 
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Table 1. Clinical characteristics at disease presentation and applied therapy in 1745 
patients with primary superficial TCC 
N 
Sex 
Age 
Main complaint (N=1227) 
Stage 
Grade (#) 
Multiplicity 
Areas involved 
Quadrant biopsies (N=1044) 
Men 
Women 
<= 39 
40-49 
50-59 
60-69 
70-79 
80+ 
Haematuria 
pTa 
pTl 
1 
2 
3 
Solitary 
Multiple 
Unknown 
Neck 
Trigone 
Posterior wall 
Right wall 
Left wall 
Dome 
Anterior wall 
2 Areas 
3 Areas 
>= 4 Areas 
Normal 
Dysplasia 
CIS 
1415 
330 
46 
103 
295 
550 
546 
205 
991 
1187 
558 
669 
793 
283 
1223 
510 
12 
27 
55 
123 
384 
390 
38 
25 
373 
166 
164 
816 
142 
86 
81.1 
18.9 
2.6 
5.9 
16.9 
31.5 
31.3 
11.7 
80.8 
68.0 
32.0 
38.4 
45.4 
16.2 
70.1 
29.2 
0.7 
1.5 
3.2 
7.0 
22.0 
22.3 
2.2 
1.4 
21.4 
9.5 
9.4 
78.2 
13.6 
8.2 
(#) In cases with different grades in one tumour, the highest grade was 
documented. 
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Figure Ζ- Distribution (%) of stage and grade by age category in patients with superficial 
TCC of the bladder. 
First recurrence. 
The risk of recurrent disease after primary treatment in superficial bladder cancer is 
very high. Within 5 years nearly 60% of cases had at least one recurrence (figure 3). 
The risk of recurrent disease was dependent on a number of prognostic indicators. 
This is described in chapter 5. A proportion of this group of patients with a 
recurrence were prone to having more recurrences. The risk of recurrent disease in 
the first year of follow-up was 33% (95% confidence interval (CI): 31%-35%). In 
the second year of follow-up this risk was as high as 47% among patients who had 
already had recurrent disease, compared with only 18% among patients without 
recurrence in the first year of follow-up. 
Progression. 
In the documentation project, disease progression was defined as a shift to a higher 
stage category (or the development of metastases). The three-year actuarial risk of 
progressive disease is 10.2% (95% CI: 8.6-11.8%). After five years this risk had 
hardly increased: 13.3%. As is the case with the risk of recurrence, disease 
progression depended on several prognostic factors, outlined in chapter 5. 
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Figure 3: Actuarial risk (percentage) of recurrent disease in patients with superficial 
TCC of the bladder (with 95% CI). N=1722, cystectomy patients excluded. 
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Figure 4: Actuarial survival (percentage) in patients with superficial TCC of the bladder 
(with 95% CI), compared with age and sex matched Dutch population. 
Survival. 
The actuarial risk of dying within 5 years after diagnosis is 25% (95% CI: 23% 
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27%) (figure 4). Ibis risk has to be compared with the expected risk of dying from 
all causes given the age and sex distribution of this group of patients. Using data 
from the Registration of Causes of Death from the Dutch Central Bureau of 
Statistics, we calculated the expected risk to be 13%. Therefore, the relative 5-year 
survival of patients with superficial bladder cancer was (100-25) / (100-13) = 86%. 
Thus, the excess risk of dying within 5 years was approximately 14%. 
Discussion. 
The reported distributions of disease characteristics at initial diagnosis in patients 
with primary superficial TCC, may not be representative for the situation in other 
countries. Especially the distribution of grade and cold biopsy results may differ 
because there are still not yet objective criteria available to enable all pathologists 
to classify urothelium specimens in a reproducible manner [5-7]. Although the stage 
distribution is believed to be a better measure for comparison, different 
interpretations of the pT category by different pathologists are also possible [8-11]. 
Another factor which very often influences the distribution of disease characteristics 
is the inclusion of patients with recurrent instead of primary disease. 
Over the past 15 years, it is likely that an increasing number of "papillomas" have 
been classified as papillocarcinomas (until 1978, the UICC listed only the category 
pTl for superficial bladder cancer). For that reason, comparison with other case 
series is only worthwhile if these series were documented fairly recently. In a recent 
study by Abel, 107 (62.6%) out of the 171 cases wit bladder cancer had superficial 
disease at presentation [12]. Of these, 71% were classified as pTa. Of all cases, 
60.7% (compared with 70.1% in our study) had solitary tumours. Grade 1, 2 and 3 
accounted for 6.5%, 85.0% and 8.4% of all tumours, respectively. This distribution, 
which is very different from the finding in our study, illustrates the need for better 
reproducible methods for assessment of certain indicators used for prognosis. In a 
recent Danish study, 61% of 500 bladder cancer cases had superficial disease of 
whom 69% had stage pTa [13]. These numbers are very similar to those in our 
study. In the Danish case series, 7.9% of pTa/pTl patients had CIS in cold-cup 
biopsy specimens taken at first presentation of disease. Another 15.4% showed 
atypia grade 2. In a study by Flamm and Dona, CIS was found in quadrant biopsy 
specimens of 6% of 216 patients. Dysplasia was found in 18% [14]. In our study, the 
corresponding percentages are 8.2 and 13.6, respectively. In a recent study by 
Solsona et al. [15], 48 of 306 patients with superficial bladder tumours had 
associated CIS but this high number was caused by inclusion of random-area as well 
as suspicious-area biopsies. 
Nearly 60% of all patients in our study had at least one recurrence within 5 
years; most of them within 2 years (two-year recurrence risk: 45%). In fact, the 
recurrence risk in superficial bladder cancer is so high that (as apposed to other 
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cancer sites) a second occurrence of TCC in the bladder is always interpreted as a 
recurrence, although this is theoretically incorrect [16]. 
Superficial bladder cancer patients have a relatively high survival rate. In our 
study the five-year survival is 75%, compared to 87% for the Dutch population 
adjusted for age, sex, and calendar period. This finding is very similar to the 88% 
five-year survival rate for early stage bladder cancer (adjusted for normal life-
expectancy) in the USA [17]. In a recent study in the United Kingdom, the five-year 
survival in 150 pTa and 85 pTl patients was 80 and 69%, respectively [18]. Flamm 
and Havelec [19] found a tumour-related mortality rate of 12.5% in 345 patients 
with primary superficial TCC treated with TUR and intravesical instillations. 
Despite the fact that the excess mortality in superficial bladder cancer is small, it 
may be asked why there is any excess mortality at all. Theoretically, it is possible 
that some of the superficial bladder cancers were already higher stage cancers at 
initial diagnosis. It is not exceptional for the pathologist to receive a resection 
specimen that does not contain any muscle tissue. Thus, some T2 tumours (with a 
poorer prognosis) may have been staged as pTl tumours. In the surveillance 
program of the U.S.A. National Bladder Cancer Collaborative Group, for example, 
there was no muscle tissue present in the specimens of 40 out of 95 tumours 
classified as pTl [20]. By contrast, in a recent study by Abel et al. [8], muscle tissue 
was present in 95% of pTa/pTl biopsy specimens. Unfortunately, comparable 
information was not available in our project. 
Another possible explanation for excess mortality is undertreatment. Especially 
multiple high grade tumours extending into the lamina propria are often seen to 
progress to higher disease stages [20-22]. But until now, this knowledge has not led 
to a consensus policy of treating all "high risk" tumours with (at least) intravesical 
instillations. According to our data, a surprisingly high number (26%) of patients 
with multiple pTl grade 3 tumours were treated with TUR-only. However, it is 
dubious whether intravesical instillations prevent progression. Intravesical therapy 
will usually decrease the rate and number of recurrences, but does not necessarily 
alter the ultimate outcome of the disease [19,23-26]. The five-year risk of 
progressive disease in our study did not differ for patients treated with TUR-only 
and patients treated with TUR + intravesical instillations. Because the group of 
patients who received adjuvant therapy had a poorer prognostic profile, the risk of 
progression in this group was even higher than in the patients treated with TUR 
alone (12% versus 8%). This finding, however, has to be interpreted with caution 
because our study was not initiated to study therapy effects and hence not 
randomised. 
Summary. 
Even though the majority of patients with bladder malignancies initially present with 
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low stage disease, the clinical epidemiology of these so-called superficial bladder 
tumours is not well known. In this paper, disease characteristics at initial 
presentation and during follow-up are described in 1745 primary cases documented 
prospectively in the Netherlands. The risk of recurrent disease after primary 
treatment is very high: in 60% of cases, at least one recurrence is diagnosed within 
5 years. In patients with a small solitary pTa grade 1 tumour the 3-year recurrence 
risk is 37%. In patients with multiple large high grade pTl tumours, this risk is as 
high as 77%, despite a significant beneficial effect of adjuvant intravesical 
instillations. The actuarial risk of disease progression is 10.2% after 3 years (95% 
CI: 8.6%-11.8%). The risk of progression depends on the patient's age at diagnosis, 
tumor stage, grade, multiplicity and the presence of dysplasia or CIS in random 
urothelial biopsies. The use of intravesical instillations after TUR did not prevent 
progressive disease, although this finding is difficult to interpret from a non-
randomised study. The five-year relative survival in patients with superficial TCC of 
the bladder is 86% (95% CI: 84%-88%). 
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//. Bladder cancer mortality in the Netherlands between 
1955 and 1988. 
Introduction. 
An increase in the incidence and mortality rates of bladder cancer is seen in nearly 
all Western communities [27]. In Alberta, Canada, male age-standardised incidence 
rates per 105 person-years increased from 10.8 in 1964 to 20.3 in 1984 [28]. National 
cancer survey data from the USA showed a 51% increase in age-standardised rates 
among white men from 14.1 to 21.3 cases per 10s person-years in 1937 to 1939 and 
1969 to 1971 respectively. In the same period the rates in Connecticut rose from 
10.6 to 23.4 [29]. In Denmark, the age-standardised incidence rates for men incre-
ased from 10.8 in 1953 to 1957 to 24.7 in 1978 to 1982 [30,31]. Trends in bladder 
cancer incidence among women are less consistent. Although a number of registries 
showed increasing rates, in the US national cancer survey data for example, 
decreasing rates were found for women. 
In the Connecticut analyses males show a consistent rise in (invasive) bladder 
cancer rates beginning at least with those born in 1870 and a peak in those born 
around 1930, whereas for females a sharp rise begins around 1900 with the increase 
persisting into at least the 1940 cohort [32]. According to the authors these findings 
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are consistent with trends by birth cohort for cigarette smoking, which strengthens 
the hypothesised association between cigarette smoking and bladder cancer. 
In this chapter temporal trends in the occurrence of bladder cancer in the 
Netherlands are summarised. There is no national cancer registry in the Netherlands 
from which incidence data can be obtained yet Mortality statistics from the Dutch 
Central Bureau of Statistics (CBS) from 1955-1988 are therefore used for analyses. 
The results are used to obtain some indication of a change in temporal trend in the 
near future. 
Methods. 
In the Netherlands, the CBS has registered underlying causes of death since 1900. 
The number of men and women with bladder cancer as cause of death, as well as 
age and sex specific numbers of the Dutch population, were abstracted from the 
annual publications of the CBS for the years 1955 to 1988 [33,34]. In this time 
period 4 revisions of the International Classification of Diseases were used. Only a 
small difference exists between the ninth revision and the former 3: in the ninth 
revision the urachus is coded under "bladder cancer", whereas in the former editions 
the urachus is coded under "other urinary organs". Ages under 35 were ignored 
because of the rarity of mortality from the disease under this age. 
To compare bladder cancer mortality rates in different calendar periods, 
adjustment for the change in age distribution of the Dutch population is necessary. 
Thus mortality rates in 7 successive calendar periods from 1955-1959 to 1985-1988 
were age-standardised to the European standard population. 
Results. 
From 1955 to 1959 the age-standardised bladder cancer mortality rates per 10s 
person-years were 7.5 in men and 2.9 in women. From 1985 to 1988 these rates 
were 12.4 and 3.0 respectively (figure 5). 
The increasing temporal trend in men seems to originate from a higher risk of 
dying from bladder cancer in the four oldest age groups. In men over 65 years of 
age the rates doubled in this 34-year time period. In women such an increase was 
not seen in the older age groups. Mortality rates were stable over time in all age 
groups, reflecting a situation of no temporal trend. 
The variation in bladder cancer mortality rates is best explained by birth cohort 
effects. Defining the 1910 cohort as a reference group, the relative risks of bladder 
cancer mortality in Dutch men are illustrated in figure 6. It can be seen that 
mortality increased until this 1910 cohort, and decreases thereafter. For example, 
compared with men bom in 1910, the risk of dying from bladder cancer for men (of 
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the same age) bom in 1940 is only 67%. 
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Figure 5: Trend in bladder cancer mortality (deaths per 100,000) in the Netherlands 
between 1955 and 1988 (age-standardised to the European standard population). 
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Figure &· Relative risk of male bladder cancer mortality in the Netherlands according to 
year of birth and registration period 
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Discussion. 
When the incidence rates of a particular cancer are changing with time, the first 
question is whether the change represents a real change in disease occurrence or 
simply a change in diagnostic/registration practice or acuity. Examples of changes in 
diagnostic/registration practice might be changes in (1) the definition of the malig-
nancy, (2) histological confirmation, (3) autopsy rate and (4) diagnostic accuracy 
[35]. Differences or changes in applied therapeutics are another possible explanation 
of trends in mortality. Changes in diagnostic and registration accuracy probably have 
less impact on bladder cancer mortality than on bladder cancer incidence. One of 
the most important registration problems in bladder cancer incidence is the 
distinction between papillomas with a benign behaviour and low grade low stage 
superficial TCC. This change in registration may bias bladder cancer incidence rates 
but will have less effect on bladder cancer mortality. 
In recent decades, survival rates of patients suffering from bladder cancer have 
shown a tendency to increase. In Alberta, Canada, the 5-year survival rate for men 
increased from 52% in 1964 to 65% in 1988 [28]. However, if this increase is due to 
an increase in the proportion of superficial bladder cancers (pTa and pTl), the 
apparent improvement in treatment results may have little effect on mortality 
statistics [27]. It is not known whether this is the case in the Netherlands. 
Whereas no temporal trend was observed in female bladder cancer mortality in 
the Netherlands, for male bladder cancer mortality the increasing trend was found 
to be due mainly to a cohort effect. This difference between male and female trends 
in mortality is seen all over the world [27,36-39]. The fact that there is no temporal 
trend in mortality in women also lends support to the idea that the temporal trend 
in men is not caused by an artefact. 
The cohort effect in men shows an increasing trend for successive birth cohorts 
until those born after 1910. The same was reported for England and Wales male 
mortality by Armstrong and Doll [36]. In Italian male mortality the increasing trend 
lasts at least until the 1935 cohort [40]. 
Almost all authors correlate the cohort effect with the rise in cigarette 
consumption, the best known risk factor in bladder cancer. Differences in trends in 
males and females could also be attributed to smoking [27,36-38,41-44]. If cigarette 
consumption is indeed the etiologic factor responsible for the increasing bladder 
cancer mortality and incidence rates, then presumably trends will decline in the near 
future, since more and more people will be life-long non-smokers. For example, in 
the Netherlands there has been a sharp fall in the proportion of smokers among 
men from 90% in 1958 to 44% in 1984. Such a decline in mortality is not yet visible 
in the more or less standard method of illustration of temporal trends (figure 5). 
When it can be expected is hard to tell. Among other factors, this depends 
especially on the proportion of the disease attributable to smoking and the length of 
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the latent period of bladder cancer. Considering the relative risks for successive 
male birth cohorts (figure 6), perhaps the decline will be seen within the next 
decade when more cohorts with a decreasing relative risk will reach ages over 70. In 
this respect, it is also illustrative that the incidence of lung cancer and laryngeal 
cancer is already declining in Scotland [45], since the length of the latent period for 
these smoking-related cancers is presumed to be shorter than that for bladder 
cancer [27,42,46]. Perhaps the relatively long latency for bladder cancer is also the 
reason why, contrary to lung cancer mortality in females, which has been rising 
steeply since 1980 [47], an increasing trend for bladder cancer mortality is not seen 
in Dutch women. 
Summary. 
In 1955, 234 men and 116 women died from bladder cancer in the Netherlands. In 
1988 the numbers were 794 and 317 respectively. After adjusting for the ageing of 
the Dutch population since 1955, female mortality rates per 105 person-years appear 
to be very stable: 2.9 from 1955 to 1959 and 3.0 from 1985 to 1988. By contrast, an 
increasing trend exists in males. From 1955 to 1959 and from 1985 to 1988, bladder 
cancer mortality rates per 105 person-years were 7.5 and 12.4 respectively. For men 
in particular, increasing mortality (and incidence) rates are seen all over the world, 
which might be explained by changes in smoking behaviour in the male population. 
Statistical modelling of bladder cancer mortality data from 1955 to 1988 in the 
Netherlands shows that the increasing temporal trend in men can also be described 
as a cohort effect: the risk of dying from bladder cancer increases from the 1875 
birth cohort to the 1910 birth cohort, but decreases thereafter. It is concluded that 
this decreasing risk for generations born after 1910 will probably result in a 
decreasing trend in mortality in the near future, when more and more of these 
"youngsters" reach the age of 70+. 
///. Bladder cancer in patients less than 40 years of age. 
Introduction. 
Carcinoma of the bladder is an epithelial tumor, and therefore uncommon in the 
first decades of life. The peak incidence occurs in patients between 50 and 70 years 
of age. The incidence in the first 4 decades of life is 1% [48,49]. The belief that the 
biological behaviour of bladder tumours in this younger age group is similar to that 
in the older patients is only of recent origin [49-52]. There are, however, also recent 
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reports suggesting that TCC of the bladder is a less aggressive disease in younger 
patients [48,53]. To get more insight in this dilemma, we analyzed our own data in 
this respect. 
Material and methods. 
Between march 1983 and march 1988 2068 patients with bladder cancer were 
registered. 49 of these patients (2.4%) were less than 40 years of age. Of all 
patients an accurate registration was performed of presenting data and symptoms, 
Г и results, tumor stage and localisation, bladder biopsies, therapy and follow up 
data. The diagnosis was confirmed by differentiated resection of the tumor 
associated with cold biopsies of the mucosa. The tumor category was determined 
according to the TNM system [54]. Follow up ranged from 9 to 60 months, with a 
mean of 36.5 months. 
Results. 
49 patients less than 40 years of age were registered, of whom 7 patients under 30 
years. The age ranged from 15 to 39 years, with an mean of 34.0 years. There were 
39 men and 10 women, giving a male predominance of 3.9:1. 
The presenting symptoms were haematuria (40/49 = 81.6%), irritative bladder 
symptoms (5/49 = 10.2%) and not urological (4/49 = 8.2%). Of the 49 IVU's only 7 
were abnormal showing obstruction (lx), dilatation (2x) and a lesion in the bladder 
(4x). The bladder tumours were TCC in 47 patients, adenocarcinoma in 1 patient, 
and a leiomyosarcoma in 1 patient. The Τ classification is shown in table 2. Cold 
biopsies showed dysplasia 10 patients, CIS and sarcoma both in 1 patient. Only 1 
patient had tumor spread outside the bladder (pT3N2Mlgr3). The 47 transitional 
cell tumours were well differentiated in 27, moderately differentiated in 13, and 
poorly differentiated in 7 patients. The therapy used in these patients is shown in 
table 3, and shows a clear relation with tumor stage. 
In the follow up period 15 patients had one (12) or more (3) recurrences. 3 
patients with recurrences showed progression, 2 from pTa to pTl, and 1 from pTl 
to pT2. No correlation could be found regarding recurrence and pT classification, 
tumour grade, at random biopsies, or therapy. Of course this partly can be 
explained by the fact that the figures are small. Of the endoscopically resected 
superficial tumours (41x) all recurrences were found in the group of 36 patients 
between 31 and 39 years of age. 
In all, 3 patients died due to metastatic bladder cancer. One patient died in the 
third follow up year after a cystectomy for a pT2 gril TCC with dysplasia in the 
biopsies. Two patients died in the first follow up year. One after TUR and 
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intravesical chemotherapy for a pTis grill TCC with CIS in the biopsies, and one 
after a radical cystectomy for a pT4a grill TCC. 
Table 2- pT classification and age. 
age number pTO pTis pTA pTl pT2 pT3 pT4a 
15 
18 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
1 
1 
1 
1 
1 
1 
1 
6 
2 
1 
3 
3 
8 
9 
4 
6 
1 
1 
1 
5 
1 
1 
2 
1 
7 
6 
1 
5 
1 
1 
1 
1 
1 
1 
1 
1 
1 1 
total 49 1 1 33 6 3 4 1 
Table 3: pT classification and therapy. 
Treatment number Τ classification 
TUR only 
TUR + instillations 
TUR + chemotherapy 
TUR + radiotherapy 
TUR + partial cystectomy 
TUR + cystectomy 
27 
14 
1 
2 
1 
4 
27 =< pTl 
14 =< pTl 
pT3N2Mlgr3 
2 = pT2 
pT3 
lx pT2, 2x pT3, lx pT4a 
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Discussion. 
The incidence of bladder carcinoma in patients less than 40 years of age is 
approximately 1% [48]. In our study it was 2.4%. The presenting symptoms 
(haematuria in 40/49 =81.6%) and IVU abnormalities (7/49) are comparable with 
other studies [51-53]. We had no data about the period of delay between first 
complaints and diagnosis. In some studies a long period of delay is described in 
these young patients [50-52]. The number of pTA tumours is relatively high in this 
group of patients (33 out of 49, 67.3%), compared with the total group of 2068 
patients (788 out of 2068, 38.1%). 
Cherry [52] described 11 patients (40.7%) in a series of 27 with TCC of the 
bladder in the first 4 decade of life, showing hallmarks of aggressive behaviour 
(muscle invasion, recurrences, associated severe epithelial atypia). In our series 47 of 
49 patients had a TCC of the bladder. 14 patients had a recurrence; 1 patient had 
an invading tumor and a recurrence; 1 patient had associated CIS; and 5 patients 
had invading tumor. This gives a total of 21 patients (44.7%) showing these 
hallmarks of aggressive behaviour. All of these patients were between 31 and 39 
years of age. So, like Fitzpatrick [55] and Chang [56] we found that patients 30 
years of age or less have a relatively good prognosis. The prognosis of patients 
between 31 and 39 years, however, is comparable with the elder patient. Therefore 
we advise to do a full diagnostic work up in case of symptoms of a bladder tumor, 
regardless of the age of the patient, and to treat him according to the pathological 
classification. 
In all, 15 of 49 patients had a recurrence (30.6%), of which 3 patients were 
progressive. The patients with progression were between 31 and 39 years of age. 
Fitzpatrick [56] found similar results in his group of 50 patients less than 40 years of 
age: 16 recurrences (32%) of which 3 were progressive, also between 31 and 40 of 
age. McCarthy [50] described a group of 79 patients less than 30 years of age. He 
found 11 recurrences (13.9%). 4 of these patients were not progressive, of 6 patients 
there was insufficient data to determine grade and stage, but 1 patient was 
progressive. Javadpour [48] described in his group of patients less than 20 years of 
age 2.6% recurrences. These data also suggest a relatively good prognosis of 
patients less than 30 years of age. The better prognosis in patients less than 30 
years of age, however, might be explained by the 'Ъеиег" pathological condition of 
these patients. 
Summary. 
We registered and treated 49 patients with bladder cancer less than 40 years of age 
(7 patients less than 30 years of age). Haematuria was present in 40 cases (81.6%). 
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33 of the patients had a pTA tumor (67.3%) 47 Patients had TCC of the bladder, 
of which 21 (44.7%) showed hallmarks of aggressive behaviour (muscle invasion, 
recurrences, associated severe epithelial atypia), all of these patients were between 
31 and 39 years of age. 15 patients had a recurrence (30.6%), of which 3 showed 
progression (all between 31 and 39 years of age). This report supports the view that 
TCC of the bladder is less aggressive in patients less than 30 years of age Patients 
between 31 and 39 years of age have the same prognosis as patients above 40 years 
of age. We therefore advise to do a full diagnostic work up m case of symptoms of 
bladder tumor, and to treat the patient according to the pathological classification, 
regardless of the age. 
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Introduction. 
Cancer statistics show that in 1990 cancer of the urinary bladder accounted for 1.9% 
of all cancer related deaths (9,700 deaths/year) in the USA [1]. 4.7% of newly 
diagnosed cancers are located in the bladder (49,000fyear). The majority of bladder 
tumors will present as superficial transitional cell carcinomas (pTa-1, grade 1-3). It is 
a disease of the elderly, with a male predominance (4:1). The recurrence rate can 
be as high as 70%, most frequently in the first year after transurethral resection of 
the tumor (TUR) [2]. In all, 10-20% of these tumors will show progression to 
invasive and/or metastatic carcinomas [3]. 
Superficial bladder cancer is a heterogeneous group. A minority of patients has a 
relatively benign type of superficial transitional cell carcinoma (TCC), that does not 
recur after TUR. In these patients adjuvant treatment seems to be unnecessary. The 
largest group consists, however, of patients which develop recurrent superficial 
bladder cancer, without progression. Adjuvant treatment, such as intravesical 
instillations, may be given to lower the recurrence rate, and to try to prevent or 
delay tumor progression. A small group of patients, however, has already relatively 
malignant superficial tumors at presentation, and will develop invasive cancer 
despite maximal intravesical treatment. Cutler hypothesized that 25% of all 
superficial bladder tumors are 'Ъаа" tumors from the start [4]. It is important to 
select these patients as early as possible. Prognostic factors may be of use in this 
selection. Many factors have been described in the last decades, but none is able to 
predict recurrence or progression in an individual patient. In this review the 
importance of prognostic factors is discussed. 
Clinical factors. 
Bladder cancer in the first decades of life usually carries a good prognosis, what can 
be explained by the fact we are mostly dealing with low stage tumor in this age 
group [5]. Narayana found that increasing age was of some prognostic value in 
patients with a bladder cancer history (p=0.08) [6]. Age over 70 was found to be of 
prognostic value with regard to bladder cancer related death in two studies [7,8], 
although this disappeared in a multivariate analysis [8]. Sex is not a prognostic 
factor in superficial bladder cancer. Well known environmental risk factors are 
smoking and exposure to aromatic amines. 
The recurrence rate of superficial bladder tumors before adjuvant treatment is 
initiated has a significant impact on the future recurrence rate and progression [4,9-
11]. Cutler studied 404 patients with newly diagnosed bladder cancer and 446 
patients with recurrent bladder cancer [4]. He found that the average time interval 
between the first and second recurrence (13 months, 93 patients), or between the 
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second and third recurrence (12 months, 48 patients) was markedly shorter than 
from initial diagnosis to first recurrence (31 months, 233 patients). Dalesio found 
that the recurrence rate in 190 patients with primary tumors (5.23) was 
approximately half that of the 118 patients with recurrent tumors (10.10, p<0.001) 
[9]. She also found that patients with less than one recurrence per year at entry of 
her study had a similar prognosis to that of patients with primary tumors. Loening 
studied eight prognostic factors in 178 patients, and found that in patients with a 
history of bladder cancer only the pretreatment recurrence rate had influence on the 
later recurrence rate [10]. Lutzeyer studied 315 patients, and found recurrences of a 
primary tumor in 45% within 3 years, and second recurrences in 84% [11]. Tumor 
progression was observed in 20-25% of primary pTa-pTl tumors, whereas 56% of 
recurrent pTl tumors progressed. 
Tumor multiplicity is generally accepted as an important risk factor for a higher 
recurrence rate [4,9,11-16], and progression [11,13]. Dalesio studied 308 patients 
with Tl bladder cancer, treated with TUR and intravesical instillations. In a 
multivariate analysis the number of tumors was the most important prognostic factor 
(p<0.001): 161 patients with 1 tumor had a recurrence rate of 4.75, 71 patients with 
2-3 tumors had a recurrence rate of 7.82, and 68 patients with >3 tumors had a 
recurrence rate of 12.28 [9]. The British Medical Research Council group found 
similar results in a multivariate analysis of 305 patients with superficial bladder 
cancer: the 2-year recurrence rate for 91 patients with a single tumor was 31%, for 
214 patients with multiple tumors this was 58% (p<0.001) [14]. 
The size of the tumor also is of prognostic value [4,6,7,9,10,12-14]. However, the 
"critical" size of a tumor differs from study to study. Combining four factors 
(recurrence rate before entry into the study; number of tumors; tumor size; 
treatment) Dalesio could make a statistical model to predict the number of follow 
up cystoscopies needed to detect a recurrence based on initial characteristics of the 
patient [9]. Tumor localisation is found to be of importance in some studies. 
Patients with a tumor in the trigone tended to have a shorter disease free interval 
than those without trigonal involvement, but this was not statistically significant [10]. 
Stephenson found significant differences among subsides of the bladder [17]. Tumors 
in the bladder neck (n=101) had a significantly poorer prognosis (5-year survival of 
39%, compared to 50-56% for other subsides, p<0.01). Localisation in the dome 
(n=70) was associated with higher grade lesions (p<0.001). However, although 
Stephenson's study concerns a large number of patients (914), the absence of 
correction for other prognostic factors makes these results difficult to interpret. 
Response to intravesical instillations also gives important information [14,18]. 
Recurrent tumor 3 months after intravesical instillations was the most important 
prognostic factor in a multivariate analysis of Pannar: in 258 patients with a 
negative urethrocystoscopy (UCS) at 3 months, the 2-year recurrence rate was 34%, 
while in 47 patients with positive findings on UCS this was 70% (p<0.001) [14]. 
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Herr found similar results in a group of 221 patients with superficial bladder cancer 
treated with TUR and Bacillus Calmette-Guerin (BCG) [18]. If three months after 
BCG therapy a pTl lesion was found, the chance for progression was 82% (14/17 
patients), with a median interval of only 8.4 months, compared to 25% (44/178 
patients) after a median period of >5 years in patients with no tumor or Ta tumor 
after 3 months (p< =0.001). 
In conclusion, recurrence rate before adjuvant treatment, recurrent tumor after 
adjuvant treatment and tumor multiplicity are important prognostic factors. Tumor 
size and localisation can also be of value. 
Histo-pathological factors. 
High grade tumors appear to have a higher recurrence rate [4,9,10] and a higher 
risk for progression [4,6,7,11,12,19-22] and bladder cancer related death [8]. Flamm 
retrospectively studied the 5-year tumor related mortality and found in a 
multivariate analysis a poor differentiation to be an important prognostic factor: 
26/286 deaths occurred in grade 1 and 2 lesions, versus 14/59 in grade 3 (p=0.04) 
[21]. However, the interpretation of tumor grade may differ between pathologists. 
Parmar found tumor grade to be an important prognostic factor when assessed by a 
reference pathologist, but no prognostic value was found when assessed by local 
pathologists (table 1) [14]. Ooms compared the grading results of 7 pathologists in 
57 bladder tumors, and found an inconsistency among pathologists (interobserver 
variability) and for an individual pathologist in time (intra-obscrver variability) of 
about 50% [23]. 
Tumor stage also is of prognostic significance [4,6-8,10-13,20,22,24]. Again the 
limitations of the histologic classification should be taken into account (table 1). 
Cutler found that 25% of the pTl tumors (and 40% of pTl grade 3 tumors) 
developed muscle invasion within two years as compared to 3% of the pTa tumors 
[4]. In a proportional hazards model, Loening found that tumor stage had a 
significant (p<0.01) relation with recurrence rate in patients with no bladder cancer 
history [10]. Malmstrom studied 195 patients, and T-category was the most 
significant predictor of cancer related death in a multivariate analysis (p<0.001) [8]. 
Other multivariate analysis studies showed tumor stage to be the most significant 
determinant for survival [7,24] and cancer related death [20]. 
Identification of histological abnormalities adjacent to the tumor seems to be a 
positive predictor for subsequent tumor progression [25]. At random bladder 
biopsies can give information about concomitant abnormalities of the urothelium, 
which also might influence prognosis. However, urologists should be aware of the 
imprecision and lack of reproducibility in the interpretation of such biopsies [26]. 
There is a correlation between the appearance of the mucosa at cystoscopy and the 
histology of the biopsy. Wallace studied 585 mucosal biopsies in 154 patients [27]. In 
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this study all carcinomas, whether carcinoma in situ (CIS), papillary or invasive 
carcinoma, were grouped together. In normal looking mucosa (399 biopsies) 
histological abnormalities were found in 33%, including carcinoma in 4.5%. In red 
but flat mucosa (98 biopsies) abnormalities were found in 52%, including carcinoma 
in 14%. In 88 biopsies from granular or mossy mucosa these figures were 81.5% 
and 42% respectively. Random biopsies are taken from normal looking mucosa. An 
abnormal biopsy result (dysplasia and/or CIS) suggests a higher chance of 
recurrence [4,13,19,28] or progression [4,12]. In case of an abnormal at random 
biopsy result tumor stage and grade of the primary tumor are found to be higher 
than in case of a normal biopsy result [28]. These studies, however, are dealing with 
small numbers of patients (58-216) and have limited follow up periods (1.6-3 years). 
Furthermore, the relation between biopsy result and the risk of recurrence is not 
adjusted for other prognostic factors. We carried out a study in which random 
bladder biopsies of normal looking urothelium were taken in 1026 patients with 
superficial TCC of the bladder [29]. We studied the risk of recurrent disease in 
patients with an abnormal biopsy result. The results are described in the next 
chapter. 
The EORTC-GU-tract group has done much work in the field of prognostic 
factors. From multivariate analysis of two EORTC studies it appeared that the 
recurrence rate is related to number of previous recurrences, the grade of the tumor 
and the number of tumors. With regard to the risk of progression, the recurrence 
rate, grade, and size of the tumor appeared to be relevant [30]. 
Urine cytology is a useful routine and noninvasive test in the early detection of 
bladder cancer, and in monitoring a patient after treatment, although accuracy 
depends on tumor grade and the experience of the cytopathologist [31,32]. The use 
of monoclonal antibodies in urine cytology might increase its accuracy [32]. The 
prognostic value of cytology is questionable, although Heney found the difference in 
3-year disease free survival between negative (113 pts., >50% disease free) and 
positive (39 pts., <25% disease free) cytology to be statistically significant (p<0.01) 
[12]. 
Combination of some of the factors mentioned above gives clinically useful 
prognostic information. We now know, for example, that a solitary, primary, small 
pTa grade I bladder tumor has a small chance of recurrence, and therefore should 
not be treated additionally after TUR [33]. 
In conclusion tumor stage, and especially tumor grade, are of major importance. 
However, histopathology has its limitations, depending on the experience of the local 
pathologist. The role of random mucosal biopsies remains controversial. Our own 
results indicate that their value is limited. Urine cytology is useful in daily practice, 
but of no prognostic value. Combination of histopathological factors is able to 
identify some subgroups of patients with a certain prognosis. 
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Table 1. Difference in prognostic value of tumor gade and stage as assessed by 
reference or local pathologist [14]. 
Reference 
grade 1 
grade 2 
grade 3 
pTa 
pTl 
pathologist 
-
Local pathologist 
grade 1 
grade 2 
grade 3 
pTa 
pTl 
patient 
number 
188 
91 
26 
254 
51 
182 
110 
13 
151 
154 
2-year rate of 
recurrence 
36% 
38% 
70% 
37% 
48% 
37% 
43% 
30% 
32% 
46% 
P-value 
(logrank) 
0.009 
0.11 
0.4 
0.02 
Blood group antigens. 
In the late seventies a relationship between loss of cell surface ABH blood group 
antigens (BGA) and urothelial malignancy was reported. Loss of BGA expression 
indicated tumor cell dedifferentiation and hence carried a bad prognosis [34]. In 
1979 Emmott published data of BGA status in 76 bladder tumors [35]. 70% of 
grade I lesions were BGA positive, in contrast to none of the 26 grade 3 tumors. 
None of the 48 invasive tumors were positive, compared to 12 of the 16 stage A 
tumors. Of the 9 superficial tumors that progressed, only 1 was BGA positive. Other 
studies found similar results: absence of BGA was associated with a markedly higher 
risk of progression into muscle invasion [36,37]. In a group of 30 superficial bladder 
tumors, Johnson and Lamm found BGA status to predict absence or presence of 
disease progression in 24 patients (p<0.001) [38]. These initial promising results, 
however, have been followed by less positive and even contradictory reports. Fujita 
found that 43% of grade 3 tumors, 43% of invasive tumors and 60% of metastatic 
tumors retained the isoantigen, indicating that it is an invalid predictive indicator 
[39]. Only with the absence of A and B, and presence of H activity in patients with 
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blood group A or В (a total blockade of the conversion of H substance into A and 
В substances), these tumors could be detected. Pauwels analyzed 78 TCC's of the 
bladder [40]. In 51% of the 59 superficial tumors, BGA's were present, whereas all 
19 infiltrating and high grade tumors were negative (p=0.001). However, in 
superficial tumors no correlation was found between antigen expression and tumor 
recurrence or progression. The mode of BGA expression is of no additional 
prognostic value to the grading criteria used, nor when combined with chromosomal 
abnormalities. Nakatsu investigated immunoperoxidase detection of BGA and 
carcinoembryonic antigen (CEA) on preserved paraffin blocks of histopathologically 
verified pTl and pT2 TCC [41]. Absence of BGA was not, but presence of CEA 
was correlated with histologic grade and stage. BGA could not predict poor survival, 
whereas CEA detection could. In a prospective study with 3 years follow up Abel 
studied the prognostic value of BGA expression [42]. He precluded the use of BGA 
as a guide to prognosis when used alone or in combination with pathological stage. 
ABH antigenicity of mucosal biopsies has also been studied [16,22]. In a small series 
Das found ABH antigenicity to be a significant predictor of recurrent disease: in 21 
patients with mucosal biopsies positive for the antigen the recurrence rate was 0.33 
per year, as compared to 1.97 in 13 negative patients (p<0.001) [16]. Its predictive 
value was better than that of number, size, grade and ABH antigenicity of the 
primary tumor. Huland found similar results [22]. Loss of BGA was found in 7 
tumors and 5 biopsies in 8 patients that developed progression, compared to 5 
tumors and 5 biopsies in 14 patients with a non progressive tumors. The possibility 
that ABH isoantigen change is an early event in bladder carcinoma, together with 
the assumption that bladder carcinoma is a heterogeneous disease might be an 
explanation for these controversial findings. 
The limited value of the ABH blood group antigen expression, and its failure in 
blood group О individuals, encouraged the evaluation of other blood group related 
antigens. In a group of 93 tumors a relation was found between an abnormal 
pattern of the Lewis a antigen and tumor stage and grade (p<0.01) [43]. Lewis X 
antigen can be used on exfoliated bladder cells and enhances the detection of 
urothelial tumor cells, particularly from low stage and low grade tumors [44]. The 
prognostic value of blood group related antigens is not clear yet. 
Cytogenetic factors. 
It is thought that disease progression is associated with genomic instability. 
Therefore, measurement of DNA content (ploidy analysis) may be of use to 
determine progression. DNA ploidy seems to be an important marker in predicting 
tumor behaviour. Aneuploidy is associated with invasive and metastatic behaviour, 
whereas tetraplo'fdy appears to express an intermediate grade of clinical malignancy 
with a high recurrence rate, but less invasive tendency [45]. Especially when 
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determined by flow cytometry the diagnostic accuracy of the DNA ploïdy and its 
usefulness in predicting recurrence can be increased [45,46]. Recently, chromosome 
abnormalities have been examined with in situ hybridisation, a new and rapid 
technique, which assesses DNA ploïdy more specific than flow cytometry [47]. Lamb 
was one of the first to report a large series of bladder tumors in which a correlation 
was found between histo-pathology and chromosome counts [48]. When cellular 
differentiation was lost this was associated with a change in the average number of 
chromosomes in the tumor. He also found a wider range of chromosome numbers 
among the individual tumor cells, and an increase in structural chromosome 
abnormalities. Later on more studies confirmed the importance of DNA ploïdy. 
Masters found tumor aneuploïdy to have similar prognostic significance as high 
tumor grade and high proportion of tumor cell nuclei in the proliferative S-phase 
[49]. Progression developed in 35% of patients within 3 years in case of presence of 
one of these 3 features. Of 8 tumors with all these features, 6 became invasive. In a 
retrospective study of 195 évaluable patients Malmstrom found that ABH status and 
DNA ploïdy was of no significant value in a Cox multivariate analysis [8]. However, 
the combination of both (p=0.001) and T-category (p<0.001) were independent 
predictors of early tumor progression. Pauwels also found a consistent correlation 
among chromosomal numbers, tumor grade and stage and clinical course. 
Chromosomal abnormalities, however, were of no additional prognostic value to 
grading [40]. In superficial bladder cancer DNA ploïdy also has been investigated. 
deVere-White found tumor aneuploïdy in pTa grade 1-2 bladder tumors closely 
related to disease recurrence and progression: 6/21 patients with a diploid, 
tetraploïd, or <20%-hyperdiplo"id histogram developed recurrent tumor, compared to 
9/9 patients with aneuploïd/tetraploïd histiograms. Also ploïdy pattern changed 
during recurrent disease in 20/28 cases [50]. This gave prognostic information 
additional to stage and grade classification. In an earlier study using flow cytometry 
Norming found the same DNA ploïdy in random mucosal biopsies and exophytic 
tumors, supporting the concept that, in spite of a normal morphology, intra-
urothelial lesions might develop into frank tumors [51]. Histopathology and DNA 
flow cytometry of random mucosal biopsies were also compared in 290 patients with 
untreated bladder carcinoma [52]. There was a clear relation between histopathology 
and DNA ploïdy. Biopsies with CIS, atypia or no atypia showed aneuploïdy in 76%, 
41% and 10% respectively. The DNA profiles of the aneuploïd cell populations, 
however, were similar, irrespective of the corresponding histopathology. These 
findings suggest that apart from ploïdy other factors, such as DNA profile, may 
appear at an early stage in tumor development. The volume corrected mitotic index 
(M/V index) also carries prognostic value [20]. In a series of 83 bladder cancer 
patients with a mean follow up of 13 years the M/V index correlated with disease 
recurrence, survival, and metastatic potential. In a multivariate analysis the 
combination of stage, grade and M/V index were of significant value (p<0.001). 
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Marker chromosomes are abnormal morphological forms, which are thought to 
occur in diseases that predispose to cancer. Several reports describe that recurrences 
[53-55] and progression [56] in moderately and well differentiated superficial bladder 
tumors only occur in marker chromosome positive rumors. Absence of marker 
chromosomes, however, was of no prognostic value. Falor studied a small series of 
patients, and stated that a combination of tetraploïdy, marker chromosomes and 
submucosal invasive moderately well differentiated carcinoma appeared to cany such 
a lethal prognosis that early radical resection might be necessary: of the 6 patients 
with this combination 3 required cystectomy 9 to 25 months after diagnosis, and 3 
patients (1 after cystectomy) died from metastatic disease within 28 months [53]. 
Sandberg found marker chromosomes in 32 of 50 papillary tumors [55]. Of 12 
recurrent tumors only one was marker chromosome negative. In invasive ТСС a 
correlation was seen between the numbers of marker chromosomes and progression. 
More recently the additional value of marker chromosomes to histopathology could 
not be confirmed. In a study of 50 patients with a maximal follow up of 17 years, 
Falor found that absence of marker chromosomes did not rule out ultimate 
recurrence, and that in case of a recurrence, the marker chromosome was of no 
additional value to histo-pathology [57]. 
Chromosomal abnormalities may be the cause of malignant transformation, or 
may be caused by disease progression or selection because of drug resistance. In 
case a cell culture is used, its influence on chromosomal structures has to be taken 
into account. Deletions in chromosome 1 are common in tumors at most sites, also 
in bladder cancer, indicating that it may be an early event in malignant 
transformation [58]. Deletions in chromosome 11 [58-61] and 17 [59] have been 
identified as poor prognostic factors in bladder cancer. Loss of genetic material from 
the short arm of chromosome 11 might be related to invasive behaviour of a tumor 
[61]. Deletions in l ip might be of special interest in view of the identification of the 
c-Ha-rasl oncogene on this chromosome arm [58]. In this case homozygoty for 
recessive cancer genes might explain the relation between loss of chromosomal 
material and cancer. With the recent identification of the transformation associated 
p53 gene as a possible tumor suppressor gene, located on chromosome 17 [62], a 
possible relation is found between p53 function and invasive behaviour of TCC. 
Deletion in chromosome 9 is seen in all stages of bladder cancer, suggesting that 
loss of a tumor suppressor gene on chromosome 9 might be an early event in 
malignant transformation [59,63]. It is intriguing to note that the genes which 
determine the ABH surface membrane antigens are also located on chromosome 9, 
and that loss of ABH antigen expression is also associated with an increased risk of 
tumor progression. Other important primary chromosomal changes may be trisomy 
13 and trisomy 7 [64]. Several other chromosomal abnormalities have been detected, 
but no definite correlation with bladder cancer has yet been found [64-68]. Perucca 
emphasized that there is a considerable variability among different publications 
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regarding the prevalence of chromosomal abnormalities [68]. However, loss of 
genetic material (tumor suppressor genes?) seems to be the common factor in the 
relation between chromosomal abnormalities and bladder cancer. 
Biochemical factors and tumor associated antigens. 
One of the enzymes involved in the detoxification of aromatic amines, a well known 
environmental risk factor, is liver N-acetyl-transferase. Low N-acetyl-transferase 
activity might be responsible for impaired detoxification of aromatic amines, 
contributing to an increased concentration of this carcinogen [69]. Epidemiologic 
studies suggest a protective effect of high N-acetyl-transferase activity on the 
incidence of bladder cancer [70]. 
Progression is defined as tumor invasion and/or metastasis. Cell motility and 
extracellular matrix (ECM) degradation are thought to be important factors in this 
process. The autocrine motility factor (AMF) is a cytokine that stimulates motility of 
human tumor cells, and may play a major role in tumor cells to become locally 
invasive [71]. AMF can be measured in the urine. Motility values (mean motility) 
are higher in bladder cancer patients (197.3, 22 patients) than in healthy controls 
(47.3, 27 patients, p<0.001), and a correlation has been found between mean 
motility and tumor stage (135.4 in noninvasive TCC versus 229.3 in invasive TCC, 
p<0.002) and recurrence rate (228.2 in patients with recurrences versus 71.7 in 
tumor free patients, p<0.001) [72]. In the ECM degradation plasmin plays an 
important role. Plasmin can degrade some components of the ECM, and activates 
two important enzymes which degrade fibrillar collagen and collagen of the 
basement membrane. The levels of plasminogen activator (which transforms 
plasminogen into plasmin) were found to be higher in bladder cancer as compared 
to normal mucosa [73]. Moreover the levels increased with histological grade. 
Further studies must line out the prognostic significance of the AMF and ECM 
degradation. Immunohistochemical staining of subepithelial basement membrane 
components can clearly show interruption or absence of this membrane, which is of 
value in early detection of microinvasion. In case of a patchy or absent basement 
membrane the incidence of progression was significantly higher, but there was no 
relation with the recurrence rate [24,74]. However, in a multivariate analysis the 
value of basement membrane staining was largely eliminated by tumor stage [24]. 
The value of the epidermal growth factor receptor (EGF-R) has been 
investigated recently [75,76]. Normally, EGF-R is found only on the basal layer of 
epithelial cells. In case of bladder tumors the urinary concentration of EGF can be 
elevated, as well as the EGF-R expression in tumors. Messing found expression of 
the EGF-R on superficial and deeper layers of the urothelium in low and high 
grade TCC, as well as in normal looking urothelium of patients with TCC elsewhere 
in the bladder [76]. This might favour interaction of premalignant and malignant 
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urothelium with urinary EGF. Neal studied 101 patients with newly diagnosed 
bladder cancer, with a follow up of 30 months [75]. He found association between 
strong positive immunohistocheroical staining of the EGF-R (48 tumors) and high 
stage bladder cancer (p<0.001). In case of pTa and pTl bladder cancer (52 
patients) EGF-R positivity was associated with multiplicity, short time to recurrence 
and high recurrence rate. In a multivariate analysis EGF-R positivity was predictive 
of bladder cancer related death in all 101 patients (relative risk 3.42, p<0.001). In 
52 patients with superficial TCC's EGF-R positivity was predictive for time to 
recurrence (relative risk 2.28, ρ < 0.03), and of time to progression (relative risk 
22.12, p<0.001). 
Elevated plasma tissue polypeptide antigen (TPA) levels have been demonstrated 
in malignant and benign conditions. In all stages of bladder cancer plasma TP A 
might be a sensitive marker [77], or even are of prognostic value [78]. Urinary TPA 
had a significant relation to Τ category in a study of 81 bladder cancer patients: 
TPA levels were elevated in 74% of patients with invasive bladder cancer, compared 
to 15% in patients with superficial tumors (p<0.001) [79]. In invasive bladder cancer 
it can be used to monitor therapy [80]. However, the role of TPA in superficial 
bladder cancer is probably limited to detection of recurrent disease. 
Transferrin receptor (TFR) expression is considered to be a marker of 
proliferative activity. Smith found that TFR positivity on the initial primary tumor 
had a significant relation with recurrence rate [81]. Urinary CEA is useful in early 
detection of bladder cancer, and in monitoring treatment, but, like urinary cytology, 
it probably carries no prognostic value. The increase in urinary immunoglobulines 
was found to be of negative prognostic value [31]. Recently Fradet et al. showed 
that monoclonal antibody (Moab) T138, measured by flow cytometry, is a good 
single indicator of cancer progression, better than tumor cell DNA ploïdy [82]. The 
combination of both examinations might give additional information on the 
prognostic behaviour of bladder cancer. Several other Moab's have been used to 
stain TCC. Conn used the Moab HMFG-2 to stain both bladder tumors and 
mucosal biopsies [83]. In 76 bladder tumors there was a good correlation between 
the staining pattern and stage (p<0.01) or grade (p=0.01). In 35 mucosal biopsies 
staining pattern correlated well with histopathology. Staining pattern also proved to 
be a good predictor of subsequent disease progression of superficial tumors 
(p=0.05). 
Conclusions. 
The heterogeneity make bladder tumors complex but interesting to investigate. Many 
prognostic factors for recurrence and progression in superficial bladder cancer have 
been discussed. We have to be aware that the value of a single prognostic factor 
can only be clearly assessed in a multivariate analysis. However, when a factor 
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appears to be important in a univariate analysis, and is easy to assess, it can still be 
of practical use. 
Which factors can be used in daily practice, or might be in the near future? In 
case of known environmental risk factors, an attempt should be made to exclude 
these. Age is always an important factor, which can influence prognosis and the 
choice of therapy. Recurrence rate before and after treatment gives important 
information about the future tumor behaviour. Cystoscopy features, such as tumor 
multiplicity and size have also to be taken into account. The value of histopathology 
depends on the experience of the local pathologist, but tumor grade, and especially 
tumor stage are of great prognostic importance. 
Controversial reports about blood group antigens have made the ABH 
antigenicity unsuitable for daily practice. There is a correlation between DNA ploidy 
and malignant potential of a tumor, but whether this information is additional to 
conventional histopathology remains to be proven. The improvement of techniques 
to study DNA abnormalities will increase its value. The same is true for marker 
chromosomes and other chromosomal abnormalities. Cell motility and extracellular 
matrix degradation are promising factors to study the malignant potential in an early 
phase, as is the epidermal growth factor receptor. This is also the case for several 
biochemical abnormalities found in bladder cancer. 
We can conclude that no single prognostic factor is able to predict prognosis m 
an individual patient with superficial bladder carcinoma Through differences in 
study design and statistical analysis (e.g univariate or multivariate) it is difficult to 
identify specific prognostic factors with direct implications for treatment policy. 
However, by combining several conventional prognostic factors (stage, grade 
multiplicity, recurrence rate before therapy) the nsk for tumor recurrence and 
progression can be estimated. Further studies, with large numbers of patients, 
comparing histo-pathological factors and molecular biological factors in prospective 
trials, are needed to determine the value of each factor 
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Introduction. 
Transitional cell carcinoma (TCC) of the bladder presents as a non invasive disease 
in the majority of patients. After transurethral resection of the tumor (TUR), up to 
60%-70% of the patients develop recurrent disease, most frequently in the 1st year 
after the operation [6]. To prevent or delay tumor recurrence, drugs can be instilled 
into the bladder. However, not all superficial bladder tumors need to be treated 
after TUR. For prediction of tumor behaviour, many parameters can be studied, e.g. 
tumor grade, stage, multiplicity, size, and localisation; primary or recurrent disease, 
and the reaction to intravesical instillations [2,3,5,7,8,10,13-15,17,18,20,22-24]. 
Concomitant abnormalities of the mucosa also seem to have prognostic value. 
Normal looking urothelium can be examined via random bladder biopsies. An 
abnormal biopsy result suggests a worse prognosis [2,4,7,8,22]. However, studies 
carried out to date have dealt with small numbers of patients, have used limited 
follow up periods and have not involved adjustment for other prognostic factors. To 
determine the prognostic value of random bladder biopsies of normal looking 
mucosa with regard to the risk of recurrent disease we carried out a large scale 
prospective study in which patients with a primary pTa or pTl bladder tumor were 
compared with regard to their biopsy results in a multivariate analysis. 
Patients and methods. 
Between January 1983 and December 1990 the bladder cancer documentation 
programme of the Dutch South East Cooperative Urological Group registered data 
on 2705 unselected patients. A total of 45 urologists from 25 hospitals joined the 
study, which was supported by 3 regional Dutch comprehensive cancer centres. 
Selection criteria for this study included: (1) primary TCC of the bladder, (2) 
pTa/pTl with or without carcinoma in situ (CIS), (3) performance of bladder 
biopsies on normal looking mucosa. The items registered were the patient's age and 
sex, complaints, date of diagnosis of the primary tumor, TNM classification, tumor 
grade, number of areas affected by tumor (left and right lateral wall, trigone, 
anterior and posterior wall, dome), number of tumors present, biopsy data, IVU 
results and therapy. TUR was performed as initial therapy to obtain the primary 
histological classification. In addition, the urologist was asked to take 4 random 
biopsies (left and right lateral wall, trigone, dome) of normal looking mucosa. After 
histo-pathologic examination, further therapy was carried out if necessary and 
registered. Histo-pathology results were classified according to the TNM 
classification system [9]. Biopsy results were classified as abnormal in case of 
dysplasia and/or CIS. In cases of a superficial TCC, urethrocystoscopy (UCS) and 
urine-cytology were carried out at regular intervals used to detect recurrent disease. 
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Once yearly follow up data concerning disease state and vital status of the patient 
were registered. In 1991 a final check of all medical files was done to update the 
registration data. 
Statistical analysis. 
The actuarial risk of recurrent disease was calculated for the period between the 
initial diagnosis and the end of the follow up period, July 1991. If no recurrence was 
registered (no recurrence by the end of registration, loss of patient to follow up or 
death due to other causes), the last year of registration was calculated for б months. 
The actuarial risk of recurrent disease was calculated separately for patients with 
normal as opposed to abnormal biopsy results, and both groups of patients were 
compared. With the use of the Cox proportional hazards model [1], other factors 
that might have influenced the risk for recurrent disease were taken into account. 
All of these factors were treated as dichotomous variables. 
Results. 
Of the 2705 patients presenting with a primary bladder tumor, 1745 had superficial 
TOC. In 1044 patients, random bladder biopsies were undertaken. In all, 6 patients 
died within 30 days of the primary treatment and another 12 patients underwent a 
cystectomy; these 18 were therefore not at risk for recurrent disease and were 
excluded from the analysis. 
The analysis was done using data obtained on the remaining 1026 patients. These 
included 842 men (mean age 65.8 years, standard deviation (=SD): 11.2 years), and 
184 women (mean age 65.6 years, SD: 12.9 years). The male to female ratio was 
4.6:1. The mean follow up period was 3.4 years. The patients were divided into 2 
groups: group 1 consisted of 809 patients (78,8%) with a normal biopsy result and 
group 2 comprised 217 patients (21.2 %) with an abnormal biopsy result. The 
characteristics of both groups are listed in table 1. 
An abnormal biopsy result proved to have a borderline statistically significant 
prognostic value with respect to the actuarial risk of recurrent disease (p=0.09, log 
rank test; figure 1). The two year actuarial risk for recurrent disease was 44.5% in 
group 1 and 47.5% in group 2. 
Most other clinical parameters appeared to be related to some extent to the 
recurrence risk when evaluated separately in the Cox proportional hazard model 
(table 2). 
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Table 1: Oumtcteristks 
number of patients 
pTa 
pTl 
grade 1 
grade 2 
grade 3 
adjuvant treatment 
solitary 
multiple 
unknown 
1 area 
2 areas 
3 areas 
4 or more areas 
men/women 
age <70/>70 years 
of group 1 
group 1 
809 
71.9% 
28.1% 
40.8% 
45.9% 
13.3% 
34.7% 
75.5% 
24.1% 
0.4% 
63.0% 
21.9% 
9.0% 
6.1% 
(normal biopsy) and ffoup 2 (abnormal biopsy). 
80.5%/19.5% 
61.6%/38.4% 
Table 2- Relative risk for recurrent 
factor 
biopsy 
therapy 
stage 
grade 
no. of areas 
multiplicity 
age 
sex 
disease. 
Univariate analysis 
relative 
risk 
1.17 
0.85 
1.45 
1.26 
1.49 
1.39 
1.04 
0.94 
Ρ value 
0.14 
0.07 
<0.001 
0.01 
<0.001 
<0.001 
0.69 
0.59 
group 2 
217 
50.2% 
49.8% 
18.4% 
40.6% 
41.0% 
66.8% 
59.9% 
39.6% 
0.5% 
51.2% 
24.9% 
12.9% 
11.1% 
88.0%/12.0% 
48.8%/51.2% 
Multivariate 
: relative 
risk 
1.12 
0.69 
1.42 
1.11 
1.36 
1.20 
-
_ 
total 
1026 
691 
335 
370 
459 
197 
426 
741 
281 
4 
621 
231 
101 
73 
842/184 
604/422 
analysis 
Ρ value 
0.31 
<0.001 
< 0.001 
0.33 
<0.01 
0.09 
-
. 
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Figure 1.: Actuarial risk for recurrent disease in group 1 (normal biopsy), and group 2 
(abnormal biopsy, p=0.09). 
The correlation with recurrent disease was significant for tumor stage, multiplicity, 
and the number of bladder areas affected by tumor (p<0.001), as well as for tumor 
grade (p=0.01) and therapy (p=0.07). Age (<70 vs >70 years, p=0.69) and sex 
(p=0.59) appeared to have little value. Therefore, in the multivariate Cox model, 
the following parameters were included: the biopsy result (normal versus 
dysplasia/CIS), additional therapy after TUR (yes vs no), the tumor grade (grade 1 
vs grade 2 or 3), the tumor stage (pTa vs pTl), tumor multiplicity (solitary vs 
multiple tumors) and number of bladder areas affected by tumor (1 vs >=2). In the 
multivariate analysis four factors had statistically significant prognostic value with 
regard to the risk for recurrent disease: adjuvant treatment (p<0.001), tumor stage 
(p<0.001), number of bladder areas affected by tumor (p<0.01) and multiplicity 
(p=0.09). Biopsy results (p=0.31) and tumor grade (p=0.33) had little additional 
prognostic value (table 2). 
Discussion. 
Prognostic factors are important in the choice of appropriate therapy, especially in 
oncological practice. In superficial bladder cancer this is not different. Intravesical 
instillations are used to prevent or delay tumor recurrence, however, they should 
only be given if the advantages (delay of recurrence and/or progression) outweigh 
1 U U 
80 
60 
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the risks (complications). Several factors influencing tumor recurrence and 
progression have been studied for selection of patients for treatment. Although the 
importance of tumor grade and stage depends on the experience of the pathologist 
[19,20] high grade tumors mostly have a higher recurrence rate [2,3,14] and a higher 
risk for progression [2,5,8,11,13,15,18,22,24]. Tumor stage has also prognostic 
signiflcance [2,7,8,10,11,13,15,18,24]. Several multivariate analysis studies have shown 
tumor stage to be the most significant determinant for recurrence rate [14], survival 
[24] and death due to bladder cancer [13,16]. Tumor multiplicity is generally 
accepted as a risk factor for a high rate of recurrence [2,3,7,8,15,17,20] and 
progression [7,15]. Tumor size also carries prognostic value [2,3,7,8,14,20,24]. Once 
superficial bladder tumors have recurred, this also influences the future rate of 
recurrence and progression [2,3,14,15]. A multivariate analysis of two EORTC-GU 
group studies has shown that the recurrence rate is related to number of previous 
recurrences, the grade of the tumor and the number of tumors. The risk for 
progression is related to the recurrence rate, the tumor grade and the size of the 
tumor [12]. The response to intravesical instillation may also provide important 
information [10,20]. By combining some of these factors, it is possible to identify 
subgroups of patients who are at high or low risks for recurrent disease or 
progression. 
Random bladder biopsies of normal looking mucosa can give information on 
concomitant abnormalities of the urothelium. Biopsies can also be of use in cases of 
urothelial abnormalities on cystoscopy, of positive cytology without visible cause and 
of radical surgery, to exclude concomitant abnormalities of the prostatic urethra. 
However, one should be aware of the lack of precision and reproducibility in the 
interpretation of such biopsies [21]. A correlation between the cystoscopic 
appearance of the mucosa and the histology was found by Wallace et al. [25] in 585 
mucosal biopsies carried out in 154 patients [25]. An abnormal biopsy result 
(urothelial dysplasia and/or CIS) is associated with a higher recurrence rate 
[2,4,7,8,22] or a greater chance for progression [2,8]. Cutler and coworkers studied 
259 patients with primary TCC of the bladder [2]. In 186 patients, biopsies were 
obtained from normal and abnormal looking mucosa. Hyperplasia or mild dysplasia 
was found in 30% of the specimens, and was associated with a higher recurrence 
rate; moderate to severe dysplasia was found in 17% of cases and was associated 
with a higher recurrence rate and an increased likelihood of tumor progression. In a 
small series of 58 patients with superficial TCC, Heney et al. calculated the value of 
selected biopsies [7]. An abnormal biopsy correlated with a significantly higher 
recurrence rate (p<0.01) but did not correlate with progression. In 249 patients with 
superficial TCC, Heney and co-workers studied 183 patients using selected biopsies 
[8]. The difference found in the 2 year disease free percentage of specimens 
between normal mucosa and mucosa showing moderate/severe dysplasia was 
statistically significant: >60% in the normal biopsy group (n=100) vs 25% in the 
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moderate/severe dysplasia group (n=19, p<0.01), whereas the difference between 
mild (n=64) and moderate/severe dysplasia was not significant (p<0.1). A distinct 
increase in progression was found only in abnormal mucosal specimens. 
Two studies have focused particularly on mucosal biopsies. Smith et al. studied 
112 patients with superficial TCC, all of whom underwent random biopsies [22]. 
Normal results were found in 74 patients, dysplasia in 34, CIS in 3, and invasion in 
1. CIS and invasive biopsies were not evaluated separately. The conclusion was that 
any abnormality in the mucosal biopsy reflects a significantly worse prognosis as 
compared with normal biopsy results: the cumulative probability of recurrence after 
3 years was 50% in the normal biopsy group as compared to >70% in the 
abnormal biopsy group (p<0.01). Several other histo-pathologjcal factors had no 
significant prognostic value, the exception being grade 3 disease. Flamm and Dona 
studied 216 patients with primary superficial TCC in whom biopsies were 
undertaken and who were treated with intravesical chemotherapy [4]. In all, 61 of 
165 (37%) patients with negative biopsy results developed recurrent disease. 
Abnormal results were found in 51 patients (24%), 32 of whom (63%) developed 
recurrent disease. Combination of the abnormal biopsy results with cases of grade 3 
disease yielded a recurrence rate of 77%. The cumulative overall rate of recurrence 
was 43%. 
All these studies, however, have dealt with small numbers of patients (58-216) 
and have used limited follow up (1.6-3 years); furthermore, the relationship between 
the biopsy results and the risk for recurrence has not been adjusted for other 
prognostic factors. The present study involved 1026 patients with superficial papillary 
TCC of the bladder, in whom random biopsies of normal looking urothelium were 
undertaken. The 2-year actuarial risk of recurrent disease was 47.5% in patients 
with abnormal biopsy results and 44.5% in patients with a normal biopsy results. 
This difference reached borderline statistical significance (p=0.09) but was clinically 
irrelevant. In a Cox proportional hazards model evaluating the biopsy result, 
therapy, tumor stage, tumor grade, number of areas affected by tumor and tumor 
multiplicity, the relative risk for recurrent disease with abnormal biopsy results was 
1.12 (p=0.31). Statistically significant factors in the multivariate analysis included 
therapy (p<0.001), tumor stage (p<0.001), the number of areas affected by tumor 
(p<0.01) and tumor multiplicity (p=0.09). These findings are in concordance with 
the results of several other studies, in which tumor stage and therapy proved to be 
of prognostic importance. In our analyses we compared tumor grade 1 vs grade 2 
and 3; we also compared grade 1 and 2 vs grade 3 as well as grade 1 vs grade 2 vs 
grade 3. The results were comparable: tumor grade and biopsy results had little 
prognostic significance in the multivariate analysis. Because of the possible 
limitations of pathology results concerning dysplasia and CIS, several other 
calculations were done to determine whether any abnormal biopsy result had 
prognostic value. Even in cases only severe dysplasia and/or CIS was noted as an 
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abnormal biopsy result, little prognostic value was found in the multivariate analysis 
(p=0.37). In case of CIS this might be due to the small number of patients found to 
have CIS in the random biopsy (n=76), as a relative risk of 1.16 indicates the 
possible value of CIS in the biopsy result With regard to the risk of progressive 
disease an abnormal biopsy result had some prognostic value (p=0.03), which is 
described in the chapter 5. Possibly the value of an abnormal biopsy in the 
recurrence model was masked by the influence of therapy. Therapy only lowered the 
risk of recurrences, but had no significant effect on the risk of progressive disease. 
One of the main aims of the present study was to investigate the value of 
random biopsies, and all participating urologists were asked to perform them. 
However, among the 1745 patients with superficial bladder cancer, these random 
biopsies were undertaken in only 1044 patients. Had the cystoscopic findings 
influenced the urologists' performance of the biopsies, this might have influenced the 
results of the study. Fortunately, the patients who underwent biopsies and those who 
did not were comparable in terms of tumor stage, grade, multiplicity as well as risk 
of recurrent disease (p=0.79, log-rank test). 
In this non randomised study, adjuvant treatment was optional. It appeared that 
some urologists almost always gave adjuvant treatment, whereas others never did. 
The 2 year risk of recurrent disease was 42.1% in the group of patients who 
received adjuvant treatment after TUR (n=426, 41.5%) as compared with 47.3% in 
the group of patients (n=600, 58.5%) who did not undergo adjuvant treatment 
(p=0.03). To determine whether therapy might have influenced the results of this 
study, we compared the effect of biopsies in the "TUR-only" group vs the TUR 
with adjuvant treatment" group. This comparison did not significantly change the 
outcome of the multivariate analysis. 
In conclusion, biopsies of normal looking urothelium, undertaken during TUR of 
primary superficial papillary TCC of the bladder in a group of unselected patients 
have no prognostic value additional to that of conventional histo-pathology and are 
therefore of little predictive use to this group of patients with respect to the risk of 
tumor recurrence. 
Summary. 
We prospectively studied random bladder biopsies of normal looking mucosa in 
1026 unselected patients with primary superficial transitional cell carcinoma of the 
bladder. In a univariate analysis, the risk of recurrent disease was only slightly 
higher in case of an normal biopsy result: the 2 year actuarial risk of recurrent 
disease was 47.5%, versus 44.5% in patients with a normal biopsy result (log rank 
test Ρ value: 0.09). However, after correction for other prognostic factors using Cox 
proportional hazards model, an abnormal biopsy result had no additional prognostic 
value to conventional histo-pathology of the tumor with regard to the risk of 
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recurrent disease. Additional therapy after transurethral resection of the tumor 
(p<0.001), tumor stage (p<0.001), number of bladder areas affected by tumor 
(p<0.01) and tumor multiplicity (p=0.09) had significant prognostic value. We 
conclude that random biopsies from normal looking mucosa during TUR of 
superficial bladder cancer are of little additional value with respect to the risk of 
recurrent disease. 
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Introduction. 
The ultimate challenge of prognostication in clinical practice is accurate prediction of 
the clinical course in individual patients [1]. Very often, research into prognostic factors 
has dealt with the identification of high risk and low risk subgroups of patients by 
assessing the statistical significance of one or more host or disease characteristics. 
Occasionally, the accuracy of identification of these subgroups has been quantified. 
Prognostic assessment studies, however, have rarely emphasized the ability to predict 
disease outcome in individuals. This predictive ability in individuals may be very 
disappointing despite the existence of a number of statistically significant prognostic 
factors. We aimed to illustrate this with an example in superficial bladder cancer. 
In 1991, bladder cancer, excluding carcinoma in situ (CIS), was estimated to 
contribute 50,200 new cases of cancer in the United States [2]. Among newly diagnosed 
cases, approximately 65% initially present with superficial transitional cell carcinomas 
(TCC), not invading the muscle layer of the bladder. In more than half of these 
patients, tumors recur after primary treatment with transurethral resection (TUR). 
10%-20% of these patients develop muscle-invasion or metastatic disease [3]. To 
prevent or delay tumor recurrence and (possibly) muscle-invasion, adjuvant intravesical 
instillations with chemotherapeutical or immunotherapeutical agents can be applied. 
In order to optimize treatment policy, much research has been conducted into the 
identification of prognostic factors for the risk of recurrence and progression. For these 
two types of disease outcome, the most important factors appear to be clinical and 
histo-pathological characteristics, such as tumor stage, grade, multicentricity, size and 
(possibly) the presence of abnormalities in cystoscopically normal-looking urothelium 
[4-9]. Several other host and tumor characteristics have been explored for their 
prognostic ability, e.g., blood group antigen expression, DNA ploidy, certain biochemical 
factors and tumor associated antigens [10]. Until now, these characteristics have not 
been used routinely in urological practice, mainly because there is still no agreement 
on their (independent) prognostic relevance. 
In the present study, we prospectively analyzed the clinical course of patients with 
superficial bladder cancer in an attempt to predict future tumor recurrences and 
disease progression. Prognostic index (PI) scores were constructed to determine the 
accuracy of the prediction of the disease outcome, both for groups of patients and for 
individuals. 
Methods. 
The study cohort. 
Between January 1983 and July 1989, the Dutch South-East Cooperative Urological 
Group prospectively documented the patient and tumor characteristics of 2705 cases 
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with primary bladder cancer. Of these, 1745 (64.5%) had histologically verified 
superficial TCC, TNM stage pTa or pTl, with or without concomitant CIS in random 
biopsies of normal-looking urothelium. Patients with primary CIS (n=52) were not 
included in the study cohort because CIS was considered to be different from pTa and 
pTl tumors owing to its relatively aggressive behavior. Muscle tissue from the depth 
of the TUR of the bladder tumor was required to ascertain the tumor stage. The 
following items were registered from each patient: date of birth, gender, date of 
histological diagnosis, grade of differentiation (according to the WHO grading system 
[11]), TNM classification (UICC, 1978), multicentricity, tumor extent and the result of 
random biopsies from normal-looking urothelium at the time of primary surgery. All 
the patients were treated with TUR. The necessity to apply adjuvant treatment was 
judged by the urologist. The patients were followed every three months. At every visit, 
cystoscopy and urine cytology were performed to detect recurrences. The median 
follow-up for the study cohort was 3.5 years. In 1991, all the data from the project 
were reviewed using the medical files. 
Of the 1745 patients with superficial TCC, 1116 were treated with TUR alone and 
558 were treated with adjuvant intravesical instillations (Adriamycin, Mitomycin-C, or 
Bacillus Calmette-Guérin vaccine). The remaining 71 patients were treated with 
interstitial radiotherapy (n=17), external radiotherapy (n=33) and cystectomy (n=21). 
These 71 patients were excluded from the analyses. Baseline characteristics of the study 
population (n=1674) are listed in table 1. 
Analysis of prognostic factors. 
As disease outcomes, a first recurrence and first evidence of progressive disease were 
considered. We defined progressive disease as a shift to a higher disease stage category 
or the development of regional or distant metastases. The follow-up of patients without 
any recurrence and disease progression was censored to the date of the last hospital 
visit. In case of death not related to the bladder cancer, the follow-up was censored to 
the date of death. Cox's proportional hazards model for censored follow-up data was 
used to identify prognostic factors for recurrence and progression [12]. In the model 
development, the following factors were evaluated multivariately for their statistical 
significance, using the likelihood ratio test with a significance level of P=0.10: age, 
gender, tumor stage (pTl versus pTa), tumor grade (grade 3 versus 2 versus 1), 
multicentricity (multiple versus solitary), therapy (adjuvant intravesical instillations 
versus TUR alone), tumor extent, the result of random bladder biopsies and 
interactions between therapy and any of the other factors. In the analyses, we did not 
specify the drug used for intravesical instillations. Although there is some evidence that 
the response rates to BCG are somewhat higher, differences in the efficacy of 
chemotherapeutical agents are known to be small [13-15]. Tumor extent was defined 
as the number of bladder areas involved (3 or more versus 2 versus 1) instead of the 
size of the tumor. We distinguished the following bladder areas: bladder neck, trigone, 
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dome, anterior and posterior wall, and left and right lateral wall. 
Table I. Characteristics at disease presentation of 1674 patients with primary superficial 
TCC of the bladder. 
Gender 
Age 
Stage 
Grade (#) 
Multiplicity 
Area's involved 
Quadrant biopsies 
male 
female 
<= 39 
40-49 
50-59 
60-69 
70-79 
80+ 
pTa 
pTl 
1 
2 
3 
solitary 
multiple 
unknown 
1 area 
2 area's 
3 area's 
>= 4 area's 
(@) no abnormalities 
dysplasia 
CIS 
number 
1351 
323 
46 
99 
278 
525 
526 
200 
1179 
495 
668 
772 
234 
1181 
483 
10 
1015 
357 
156 
146 
793 
137 
71 
percentage 
80.7 
19.3 
2.7 
5.9 
16.6 
31.4 
31.4 
11.9 
70.4 
29.6 
39.9 
46.1 
14.0 
71.0 
29.0 
60.7 
21.3 
9.3 
8.7 
79.3 
13.7 
7.1 
(#) In cases with different grades in one tumour, the highest grade was documented. 
(@) Quadrant biopsies were not taken from 673 patients. 
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Although the urologists who participated in the project were asked to take four random 
biopsies in macroscopically normal-looking urothelium (left and right lateral wall, 
trigone and dome), this was not done in 673 out of the 1674 patients. It appeared that 
some of the urologists took biopsies from all of their patients, irrespective of the 
patient or tumor characteristics, while others never did. As expected, therefore, the 
prognostic profile of the patients (as listed in table 1) in the biopsied group and in the 
not biopsied group was the same. In order to make the series as large as possible, the 
group with no biopsy result was considered to be a separate biopsy category, in 
addition to the categories dysplasia or CIS, and normal. 
Split-sample. 
Preferably, the extent to which one is able to predict disease outcome with one or 
more prognostic factors should be evaluated in a patient series that was not used to 
identify these prognostic factors. To allow assessment of this predictive ability in 
"another" patient series, the data set was split at random into a "training" or model 
development sample, and a "test" or model validation sample. Only the training sample 
was used for prognostic factor analyses. The test sample was used to evaluate whether 
predictions from the model could be replicated on other patient samples or whether 
the model was "tailor-made" to fit all variability in the training sample [16]. 
Prognostic index and its reliability. 
The results of the prognostic factor analyses on the training sample were used to 
construct a prognostic index score for recurrent disease (ΡΓ) and for progressive 
disease (ΡΓ)· Both scores were calculated for each patient by summing the regression 
coefficients (beta values) of the final Cox models on recurrence and progression. 
Regression coefficients were considered for inclusion in the PI scores if at least one of 
the categories of the tumor characteristic was statistically significant. A high score 
indicated that a patient had a poor prognostic profile. 
The value of a prognostic index in clinical practice depends on its predictive 
accuracy, which has two major components: reliability and discrimination. Reliability 
refers to the amount of agreement between the predicted and observed clinical course 
of disease. For instance, if patients with a certain prognostic profile are predicted to 
have a 3-year risk of 50% of recurrence disease, then 50% of such patients should have 
a recurrence within 3 years. We compared the observed and predicted risks of 
recurrence and progression in three subgroups of patients (a low, intermediate and high 
risk group) in the test sample. We first calculated the predicted risks for each patient 
separately using the proportional hazards assumption [12,17]: 
S,(y) = Sfy)""»" where 
S,(y) = the predicted probability of still being disease-free y years after initial 
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treatment for individual i in the test sample 
S
r
(y) = the observed fraction of patients with the best prognostic profile in the 
training sample (the reference group) who were disease-free after y years 
δ PI = the prognostic index score for individual i in the test sample minus the mean 
prognostic index score of the aforementioned reference group. 
Finally, these individual probabilities of being disease-free were averaged for the three 
subgroups. The definition of these three "risk" groups was based on the distribution of 
the prognostic index scores, so that the low and high risk group each represented at 
least 20% of all the patients. 
Prognostic index and its discrimination ability. 
The second component of predictive accuracy, discrimination, refers to the ability to 
distinguish between individual patients who will have a positive disease outcome and 
those who will have a negative disease outcome. This predictive discrimination can be 
quantified through a method proposed by Harrell and associates, in which every 
possible pair of patients in the study is compared with respect to the observed and 
predicted outcome [18-19]. The resulting index "c" (for "concordance") is the probability 
that in a pair of patients chosen at random, the patient with the worst predicted 
prognosis (the higher PI) will indeed have a shorter disease-free follow-up interval, and 
vice versa. С values in the region of 50% indicate that the clinical value of a prognostic 
index to determine which patient has a better prognosis, is as good as the flip of a 
coin. Values of с near 100% indicate perfect prediction of disease outcome. 
We calculated с by comparing the prognostic index score and the observed clinical 
course in all possible pairs of patients in both the training sample and the test sample. 
Results. 
Group level. 
The 3-year actuarial risk of first recurrence in the training sample (n=854) was 55% 
(95% CI: 51%-59%). The 3-year risk of progressive disease was 10% (95% CI: 8%-
12%). From proportional hazards regression, tumor stage, extent and multicentricity 
appeared to have predictive ability for the risk of first recurrence. Age, gender, tumor 
grade and random biopsies had no (significant) additional value for prediction. 
Adjuvant intravesical instillations seemed to lower the risk of first recurrence, but had 
no statistically significant independent effect on the risk of progression. For this risk of 
progression, the most important prognostic factors were tumor stage, grade, 
multicentricity and dysplasia or CIS in random biopsy specimens. In both the 
recurrence and progression model, there were no significant interactions between 
therapy and the other factors. The final models with regression coefficients (beta), 
standard errors and Ρ values based on the training sample are shown in table 2. 
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Table 2- Final regression coefficients (beta), standard errors (SE) and Ρ values of the Cox 
regression analysis in the training sample (n=S54). 
Prognostic factor Recurrence model 
Beta SE Ρ 
Progression model 
Beta SE Ρ 
pTa 
pTl 
grade 1 
grade 2 
grade 3 
solitary 
multiple 
1 area involved 
2 area's involved 
>=3 area's involved 
TUR alone 
instillations 
normal biopsy 
no biopsy performed 
dysplasia / CIS 
0 
0.40 
. 
-
-
0 
0.27 
0 
0.17 
0.52 
0 
-0.43 
. 
-
-
0.10 
0.12 
0.13 
0.14 
0.11 
<0.001 
0.03 
0.18 
<0.001 
<0.001 
0.56 0.23 0.02 
0.56 0.30 0.07 
0.98 0.35 0.005 
0 
0.95 0.22 <0.001 
0 
0.37 
0.64 
0.25 
0.29 
0.15 
0.03 
Note: Tumor grade and random biopsy result had no statistically significant effect in 
the recurrence model; likewise, number of areas involved and therapy were not 
significant in the progression model. 
By summing the beta coefficients, a prognostic index score for progression (РГ) was 
calculated for each patient in the test sample (n=820). For instance: for a patient 
with multiple pTlG2 tumors and dysplasia or CIS in the biopsy specimens, РГ = 0.56 
+ 0.53 + 0.95 + 0.64 = 2.68. РГ for a patient with a solitary pTaGl tumor without 
any abnormalities in the biopsy specimens was 0. Subsequently, all the patients were 
categorized in a low, intermediate, or high risk group according to their РГ (table 3). 
Note that РГ and PIP are not continuous variables. 
Likewise, a PI" was calculated for each patient in the test sample, but now only for 
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the patients who had not received adjuvant intravesical instillations (n=554). We used 
this restriction because we did not want to include therapy (an intervention factor 
instead of a host or tumor characteristic) in a prognostic score. 
Table 3: Observed and predicted actuarial risks of first recurrence and progressive disease 
in the test sampie (n=820) ($) according to Pf and ΡΓ "risk groups". 
Observed (and predicted) risk of first recurrence 
Risk group (1) 1 year 2 year 3 year 4 year 
Low 21% (24%) 32% (37%) 38% (44%) 42% (48%) 
Intermediate 40% (32%) 56% (49%) 60% (57%) 63% (61%) 
High 60% (48%) 71% (66%) 81% (74%) 84% (78%) 
(1) Low risk: РГ=0 (40% of all patients) 
Intermediate risk: РГ range 0.17-0.57 (40% of al] patients) 
High risk: РГ range 0.67-1.19 (20% of all patients) 
Observed (and predicted) risk of progressive disease 
Risk group (2) 
Low 
Intermediate 
High 
1 year 2 year 3 year 4 year 
2% (2%) 3% (2%) 4% (3%) 4% (3%) 
4% (4%) 9% (5%) 10% (6%) 12% (8%) 
9% (11%) 13% (16%) 18% (18%) 21% (22%) 
(2) Low risk: РГ range 0-0.53 (36% of all patients) 
Intermediate risk: РГ range 0.56-1.73 (42% of all patients) 
High risk: РГ range 1.85-3.13 (22% of all patients) 
($) For PIn the test sample consisted of 554 patients treated with TUR only. 
In order to evaluate the reliability of PI" and РГ we compared the observed and 
predicted actuarial risks of tumor recurrence and progression in the test sample (figures 
1 and 2; note that the scales of the Y axis in the Ggures differ). 
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Follow-up period (years) 
Figure 1: Observed (solid curves) and predicted (dashed curves) risk of first recurrence in 
the test sample (554 patients treated with TUR alone) according to three prognostic index 
(Pf) "risk groups". 
so 
40 
30 
High risk 
Intermediate risk 
Low risk 
2 3 4 
Follow-up period (years) 
Figure 2- Observed (solid curves) and predicted (dashed curves) risk of progressive disease 
in the test sample (n=820) according to three prognostic index (PF) "risk groups". 
Both the risks of recurrence and the risks of progression were fairly close to the 
predicted risks, even though the risk of recurrence was somewhat underestimated in the 
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high risk group and overestimated in the low risk group. The risk of progression was 
slightly underestimated in the intermediate risk group. Nevertheless, the reliability of 
the indices seemed to be quite good. For example, if we predict that the 4-year risk 
of progression for a group of patients with a solitary pTa grade 1 or 2 tumor without 
any abnormalities in the random biopsies is 3%, we can be quite sure that in 
approximately 3% of this group progression will be found within 4 years (table 3). 
Individua] leveL 
This high reliability of both ΡΓ and ΡΓ does not necessarily mean that we will be able 
to predict the disease outcome in individual patients. To examine this, we compared 
all possible pairs of patients in the test sample (the number of pairs was 335,790) and 
calculated the с score of predictive discrimination. The с for recurrent disease was only 
57.6%. The с for progressive disease was 67.3%. (In the training sample these 
percentages were 58.2% and 71.9%, respectively.) Thus, in two patients chosen at 
random, the chance that the patient with the worst predicted prognosis will have a 
shorter recurrence-free follow-up interval was no more than 58%, also in the sample 
used for model development. This prediction, therefore, is not much better than a 
guess. The individual discrimination ability for progression was only slightly higher. If 
we compare all the possible pairs of patients with respect to the progression-free 
interval, then in approximately 67% of these comparisons the patient with the better 
prognosis will stay progression-free for a longer period of time. 
Discussion. 
In urologica] practice it is known that the clinical course of superficial bladder cancer 
is rather unpredictable, despite an ongoing search for new prognostic factors. In many 
cases, the significance of prognostic factors has been claimed on the grounds of a small 
Ρ value. This statistical significance, however, reflects the likelihood that a given 
difference in disease outcome could have arisen by chance; it does not measure the 
extent to which the factor can differentiate low risk from high risk subgroups of 
patients. Even if a prognostic factor does have such ability to differentiate subgroups, 
this is no guarantee that prediction of disease outcome for individual patients (the 
ultimate goal of prognostic factors) will be accurate. This predictive accuracy can be 
studied with the aid of a prognostic index. 
In this paper, prognostic indices are presented for the risk of first recurrence and 
for the risk of progressive disease in primary superficial bladder cancer. The former 
index was based on tumor stage, multicentricity and the number of bladder areas 
involved. The latter was based on tumor stage, grade, multicentricity and the result of 
random biopsies. Although adjuvant intravesical therapy also had a statistically 
significant (beneficial) effect on the risk of recurrence, we did not include therapy in 
the prognostic index and applied the index to patients treated with TUR alone. The 
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prognostic index for progression applies to all the patients because intravesical therapy 
did not lower the risk of progression. This supports the hypothesis that intravesical 
therapy does not seem to alter the ultimate outcome of the disease [21-22], but the 
finding has to be interpreted with some caution because our study was not initiated to 
study therapy effects. Furthermore, some evidence exists that especially BCG may 
prevent disease progression in high-risk patients [23]. 
It is shown that the prognostic indices can be used to differentiate subgroups of 
patients with different risks for disease outcome. By summing the prognostic-factor-
specific model coefficients in table 2 one can easily see which risk group a new patient 
belongs to. As is shown in table 3 and figures 1 and 2, where the observed risks of 
recurrence and progression in a test sample are compared to the corresponding 
predicted risks, the prognostic indices are fairly reliable. Nevertheless, especially the 
index for recurrent disease does not have sufficient predictive accuracy for individuals. 
This is not very surprising considering the urological experience that many patients with 
a (relatively benign) solitary small tumor confined to the mucosa develop recurrences 
(in our study approximately 40% within 3 years!), whereas most patients with 
(presumed aggressive) multiple pTlG3 tumors do not develop progressive disease 
(approximately 75%). Even though, this poor individual predictability has not been 
quantified before. It was shown that prediction of recurrence-free survival ("c" = 58%) 
was only slightly better than a guess based on the flip of a coin. Prediction of 
progression-free survival ("c" = 67%) was relatively good but still far from perfect. This 
means that in superficial bladder cancer individual counselling based on a patient's 
prognostic profile is hardly possible. 
If we cannot use a prognostic index for individual counselling, then what is the value 
of such an index? First, it can be used to select a subgroup of patients with a low risk 
of progression so that they can be scheduled for longer intervals between successive 
endoscopies, thus reducing hospital visits and financial cost. According to our study, this 
subgroup consists of patients with a solitary pTa grade 1 or grade 2 tumor without any 
concomitant mucosal abnormalities. Even in this group (with a predicted 3-year risk of 
progression of only 3%) recurrences are very common, but these recurrences can be 
easily managed by repeated resections or fulguration and, therefore, do not require any 
additional measures [24]. However, if we modify the follow-up schedule we are making 
an important assumption, i.e. that the delay of resection or fulguration of recurrences 
will not increase the risk of progression in this subgroup. 
Secondly, prognostic index scores can be used in future studies on new prognostic 
tests. In such studies it might be worthwhile to start with the construction of a 
prognostic index based on the factors already available. Subsequently, a prognostic 
index can be made wich includes the new test. This would enable the evaluation of the 
test to be based on any improvement in the predictive accuracy of the index, instead 
of basing the evaluation on statistical significance only [19]. 
Our results so far show that a prognostic index is not very useful in the planning of 
72 Chapter S 
treatment for superficial bladder cancer. The insufficient predictive accuracy of such 
an index inevitably leads to considerable overtreatment and undertreatment This 
predictive accuracy may improve with more objective criteria for the assessment of 
the prognostic factors already available. Especially the reproducibility of tumor grade 
and concomitant dysplastic changes in normal-looking urothelium is known to be poor 
[8,25-26], but it is also possible for pathologists to make different interpretations of the 
tumor stage category [9,27-29]. However, in addition to obtaining more objective 
criteria for prognostic factors, an ongoing search for new (and stronger) prognostic 
factors is probably necessary. 
Summary. 
The ultimate goal of prognostic assessment is optimalization of individual counselling. 
Very often, however, studies on prognostic factors focus on discriminating between high 
risk and low risk subgroups without considering the relevance of one or more factors 
for predicting disease outcome in individual patients. This ability to predict disease 
outcome on a patient level may turn out to be poor despite the existence of highly 
statistically significant prognostic factors. As an example, we quantified the accuracy of 
prediction of future recurrences and disease progression in individual patients with 
superficial bladder cancer. 
The study cohort consisted of 1674 patients with primary superficial bladder cancer 
who were followed prospectively between 1983 and 1991 in the Netherlands. In each 
patient, tumor stage, grade, extent and multicentricity were assessed. Biopsies of 
cystoscopically normal-looking urothelium were taken from 1001 patients. By analyzing 
one-half of the patients with proportional hazards regression, we computed relative 
risks of recurrence and progression. A prognostic index score based on these relative 
risks was then applied to the other half of the patients to determine whether group 
outcome could be predicted accurately. 
The 3-year risk of first recurrence was 55% (95% CI: 51%-59%). The 3-year risk 
of first progressive disease was 10% (95% CI: 8%-12%). For the risk of first 
recurrence, tumor stage, tumor extent and multicentricity were found to have 
statistically significant prognostic ability. Prognostic factors for the risk of disease 
progression were tumor stage, grade, multicentricity and the result of urothelium 
biopsies. For patients with a prognostic index score which suggested a low risk for 
recurrent and progressive disease, the predicted 3-year risk of first recurrence was still 
44%, but the predicted 3-year risk of progression was only 3%. For patients with a 
prognostic index score which suggested a high risk, the predicted risks were 74% and 
22%, respectively. These predicted risks appeared to be fairly accurate when compared 
to the other half of our case series. However, in any two patients chosen at random, 
the chance that the patient with the worst predicted prognosis would have a shorter 
recurrence-free and progression-free follow-up interval, was calculated to be only 58% 
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and 67%, respectively. 
We conclude that, although the available prognostic factors in superficial bladder 
cancer may be useful for identifying high risk and low risk subgroups, predictability in 
individuals is highly inaccurate. More relevant prognostic factors are needed to reduce 
current overtreatment and undertreatment and to improve the follow-up policy. Future 
prognostic research should place more emphasis on prediction in individuals. 
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Introduction. 
After the treatment of patients with superficial bladder cancer with a transurethral 
resection (TUR), intravesical instillations are used to lower the recurrence rate, and 
possibly to lower the risk of progression. Intravesical instillations, however, are not 
without toxicity. Therefore, a thorough patient selection is mandatory. Selection of 
subgroups of patients is done with prognostic factors. In superficial bladder cancer, 
however, the predictive ability of the available prognostic factors is rather poor. 
Currently the most important prognostic factors with regard to the risk of recurrent 
disease and progression of superficial bladder tumors are recurrence rate before and 
after adjuvant treatment, tumor multiplicity and size, and tumor grade and stage [1]. 
Obviously, pathology plays an important role in some important factors. Pathology, 
however, is not black and white, but grade and stage classifications have limitations [2-
7]. Prognostic factors, as well as treatment efficacy, are often studied in multicenter 
studies. In case local pathology reports are used this will cause inconsistency in the 
pathology results, which might influence study outcome. The use of review pathology 
can solve this problem. To evaluate the influence of pathology inconsistencies we 
compared study outcome using local and review pathology in a multicenter study in 
superficial bladder cancer. 
Patients and methods. 
In a Dutch randomised prospective study we compared the toxicity and efficacy of 
intravesical instillations with mitomycin-C (MMC), Bacillus Calmette-Guerin (BCG) Tice 
strain, and BCG-RIVM (the Dutch BCG strain) in patients with primary or recurrent 
pTa-pTl transitional cell carcinoma of the bladder and primary carcinoma in situ (CIS). 
This multicenter study will be described in detail elsewhere [8]. No intravesical 
treatment prior to the study was allowed. In case of papillary lesions a complete TUR 
was performed. In all cases random mucosal biopsies were taken. A subset of three 
additional representative unstained sections from resected tumor(s) were sent to the 
review pathologist. Random biopsies were only reviewed in case CIS was seen in the 
biopsies. Pathology classification was done according to the TNM system [9], grading 
of the tumors according to Koss [10]. The maximal stage and grade of all tumor 
specimens reviewed were used to characterise each patient, which was CIS in case of 
concomitant CIS. Review of pathology was carried out after the randomisation 
procedure. By means of this randomisation the patient was allocated to one of the 
three treatment arms. MMC was given weekly for 4 weeks, and monthly for 5 months 
(9 instillations in total). BCG was given weekly for 6 weeks. In case of a recurrent 
tumor additional instillations were given according to the protocol. For the final analysis 
of this study the review pathology results were used. In this report study analysis and 
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prognostic factor analysis with local and review pathology are compared. 
Estimation of the cumulative distribution of the disease free interval in separate 
groups was done by the method of Kaplan-Meier. Differences in the distribution of the 
disease free interval were tested with the log-rank test Multivariate prognostic factor 
analysis was done with the proportional hazards model. 
Results. 
469 patients entered the study, 156 patients were allocated to MMC, 154 to BCG-Tice, 
and 159 to BCG-RIVM. Patients' characteristics (not influenced by the pathology 
review) will be described in detail elsewhere [8]. On the basis of local pathology 19 
patients were ineligible. After pathology review 13 additional patients were ineligible: 
in 8 patients no malignancy was found after PA revision, in 5 patients the tumor stage 
was pT2. In table 1 local and review pathology of the 450 patients, eligible with local 
pathology, are compared. 
Table 1. Comparison of local and review pathology in 450 patients eligible with local 
pathology. 
local pTaGl pTaG2 pTaG3 pTIGl pTlG2 рТЮЗ CIS Total 
review 
pTO 
pTaGl 
pTaG2 
pTaG3 
pTIGl 
pTlG2 
рТЮЗ 
CIS 
pT2 
Total 
3 
\55\ 
33 
-
-
4 
-
-
-
95 
4 
22 
\85\ 
3 
-
13 
7 
1 
-
135 
-
-
4 
\5\ 
-
-
5 
2 
-
16 
-
1 
5 
-
V\ 
3 
-
-
-
9 
-
6 
27 
4 
-
\41\ 
12 
-
3 
93 
1 
-
3 
1 
-
11 
\36\ 
-
2 
54 
-
-
-
-
-
-
1 
\47\ 
-
48 
8 
84 
157 
13 
-
72 
61 
50 
5 
450 
The conformity of the pT category was 79.3% (357/450), of the grade 70.2% (316/450), 
and of the combination of both 59.7% (269/450). Undergrading in local pathology was 
seen in 51 patients, understaging in 23 and both in 11. Overgrading was seen in 36 
patients, overstaging in 38, and both in 9. In 9 patients a combination of undergrading 
and overstaging was seen in the local pathology report. In 1 patient the diagnosis CIS 
was incorrect, in 3 patients CIS was missed. 
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Naturally, pathology review did not influence the total numbers in each treatment arm, 
except for the exclusion of 8 patients with pTx tumors and 5 patients with pT2 tumors. 
Risk of recurrent disease for each drug (not significantly different for the three drugs), 
therefore, did not change after pathology review. The recurrence free interval stratified 
by stage and grade category was only marginally influenced by review pathology. As an 
example the Kaplan-Meier curves for pTa and pTl patients are compared for local and 
review pathology (figure 1). Because of the small number of CIS patients and the high 
conformity between local and review pathology in CIS, pathology did not influence the 
results of the analysis in CIS patients significantly. 
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Figure L: Parentage disease free ofpTa and pTl papillary tumors when classified by local 
(=loc) and review (=rev) pathology. Difference not statistically significant. 
Estimation of the value of several prognostic factors with regard to the risk of recurrent 
disease was also done with local and review pathology results. The factors analyzed 
were tumor localisation, multiplicity, size, stage, grade, gender and patient age (table 
2). In the multivariate analysis the value of three statistically significant factors (tumor 
localisation and multiplicity, age) and three non significant factors (history, gender and 
tumor size) remained almost unchanged after correction for review pathology. The 
value of tumor grade also remained statistically not significant. Only the value of tumor 
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stage with regard to the risk of recurrent disease became borderline statistically 
significant (local pathology: hazard ratio 1.21, ρ=.37; review pathology: hazard ratio 
1.54, p=.05). 
Table 2 Multivariate prognostic f actor analysis for local and review pathology results. 
local pathology review pathology 
localisation 
multiplicity 
age 
tumor stage 
tumor grade 
history 
tumor size 
gender 
beta 
coeff. 
0.72 
0.59 
-0.37 
0.19 
-0.02 
0.17 
0.17 
0.36 
hazard 
ratio 
2.05 
1.80 
0.69 
1.21 
0.98 
1.19 
1.19 
1.43 
P-value 
.002 
.004 
.05 
.37 
.93 
.46 
.39 
.11 
beta 
coeff. 
0.70 
0.62 
-0.34 
0.43 
-0.29 
0.15 
0.14 
0.35 
hazard 
ratio 
2.01 
1.86 
0.71 
1.54 
0.75 
1.16 
1.15 
1.42 
P-value 
.002 
.002 
.06 
.05 
.29 
.52 
.48 
.12 
After a median follow up of 32 months only 23 patients showed tumor progression. 
Therefore, we did not study the influence of review pathology on the risk of progressive 
disease. 
Discussion. 
In clinical oncology a proper patient selection is very important, for example to prevent 
unnecessary treatment and toxicity. Although intravesical instillations, the adjuvant 
treatment of choice in many patients with superficial bladder cancer after TUR, are 
usually very well tolerated, they are not without toxicity. Therefore, also in superficial 
bladder cancer a careful patient selection should be done. Patients with solitary, 
primary, small pTaGl bladder tumors for example, have a relatively low risk of 
recurrent disease and subsequent disease progression, and a "wait and watch" policy 
after TUR is allowed [11]. The use of prognostic factors is important in this selection. 
However, the prognostic ability of these factors in superficial bladder cancer is rather 
poor. Therefore, it is important to study large groups of patients in order to find small 
differences in prognostic value. A method to obtain large patient series is to carry out 
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multicenter studies. 
Some of the most important prognostic factors in superficial bladder cancer, such 
as tumor grade and stage, are obtained by pathology. However, pathology evaluations 
are not free of variability, both in tumor stage and grade. Eble and Young for example 
found that grade 1 papillary carcinomas were generally diagnosed as (benign) 
papillomas [2]. Ooms et al. compared the grading results of 7 pathologists, and found 
an inconsistency among pathologists (interobserver variability) and for all individual 
pathologists in time (intra-observer variability) of about 50% [3]. Pannar et al. studied 
several prognostic factors for recurrence of superficial bladder cancer and used these 
for follow up policy [4]. They found tumor grade to be an important prognostic factor 
when assessed by a reference pathologist (p=0.009), but no prognostic value was found 
when assessed by local pathologists (p=0.4). The opposite was found for tumor stage 
(p=0.02 with local pathology, ρ=0.11 with reference pathology). Abel et al. collected 
99 cases of transitional cell carcinoma of the bladder [5]. The slides of these 99 cases 
were reviewed twice. The first reviewer found a different stage in 14 patients (including 
6 from muscle invasive to superficial), and a different grade in 13. A second review 
pathologist disagreed in over half of the cases with both the original report and the 
first reviewer. Lynch et al. reviewed slides from 364 bladder cancer patients who were 
included in a surveillance program [6]. In the original pathology report from 1983, 289 
tumors (79.4%) were classified as muscle invasive. The review classified 97 tumors 
(26.6%) as invasive. These results were validated with comparison of the hazard ratio's 
of muscle invasive relative to noninvasive bladder cancer: 1.70 (0.76-3.79) using the 
original pathology result versus 4.54 (2.57-8.03) using the review pathology result. The 
same problem was found in the interpretation of biopsies of normal looking urothelium 
in patients with superficial bladder cancer [7]. 92 slides were reviewed by 6 pathologists 
with special interest in urological pathology. After 6 months a second review was done 
on 30 of the 92 slides. Richards et al. concluded that the reporting of non-dysplastic 
and dysplastic changes varied very much between pathologists, and on a second review 
the pathologists reproduced their own results in only 62%. Only in case of severe 
dysplasia and CIS consensus could be reached. 
From these studies it is obvious that the present pathology classification system has 
its limitations. What can be the consequences of these limitations in case of a 
multicenter study with several participating pathologists. In case of a randomised trial, 
patients with an "incorrect" local pathology result will be equally divided between 
(treatment) groups because of the randomisation procedure. Therefore, the influence 
of review pathology will be comparable in each group, and comparison of the treatment 
efficacy of each group will hardly be influenced by review pathology. This is also true 
for separate pathology categories, although in that case a difference in prognostic 
relevance between the 2 pathology categories will increase when the distinction between 
these two categories is better with review pathology. Only in case the efficacy results 
of one study are compared to other studies, the variability of pathology should be kept 
Review pathology in superficial bladder cancer 81 
in mind, whether we are dealing with a study with local pathology or with review 
pathology. Theoretically, incorrect pathology will play a role when efficacy results of 
treatment arms are compared for different pathology categories, unless both treatment 
arms are completely identical in all pathology categories. The influence of incorrect 
pathology on the prognostic value of different pathology categories (prognostic factor 
analysis) seems obvious, and in this case review pathology will be of value. Another 
advantage of review pathology in superficial bladder cancer is the fact that no patients 
with muscle invasive tumors are included in a study in which they do not belong, and 
are treated insufficiently. 
In our study, however, the influence of review pathology appeared to be limited. We 
did find substantial changes in pathology results after revision (between 20% and 40%), 
although some of these changes might have been caused by the fact that we reviewed 
other (a representative subset of newly cut sections) slides than the local pathologist. 
Still, the final outcome of the study was hardly influenced by the changes in the 
pathology result. The risk of recurrent disease in separate stage and grade categories 
remained almost identical. In the multivariate analysis with regard to the nsk of 
recurrent disease the prognostic relevance of tumor localisation, multiplicity and patient 
age (significant factors), and tumor size, grade, gender and history (non significant 
factors) was hardly influenced by correction for review pathology Only tumor stage 
became a borderline significant prognostic factor after pathology correction (local 
pathology: hazard ratio 1.21, p=.37; review pathology, hazard ratio 1.54, p=.05). It is 
difficult to find an explanation for these findings Possibly the (prognostic) importance 
of pathology is rather limited in superficial bladder cancer, as it is for prognostic factors 
in general m this type of cancer. In spite of substantial changes in the pathology report 
(181 of 450 patients), not even the difference between the different stage and grade 
groups increased. The fact that the tumor is completely resected and does not 
necessarily represent the remaining bladder mucosa with regard to future behaviour 
might explain the limited value of pathology. Also one might ask whether one review 
pathologist, as in our study, can be considered to be a "gold standard", or that a panel 
of reviewers is required. 
On basis of results in the literature we conclude that review pathology should be 
considered in case prognostic factor analysis in a multicenter study is performed 
However, in our multicenter study dealing with superficial bladder canter the influence 
of review pathology seems limited on the study outcome (risk of recurrent disease) and 
on the prognostic factor analysis 
Summary. 
Review of literature reveals clear limitations with regard to pathology classification 
Differences between local and review pathology in a multicenter study may influence 
treatment efficacy results and results from prognostic factor analysis. We report on a 
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randomised multicenter study in superficial bladder cancer, in which the influence of 
local and review pathology on the study outcome were studied. The conformity between 
local and review pathology of the pT category was 79.3%, of the grade 70.2%, and of 
the combination of both 59.7%. In local pathology undergrading was somewhat more 
frequent than overgrading, overstaging somewhat more frequent than understaging. 
However, the risks of recurrent disease in the separate stage and grade groups 
remained the same after correcting the pathology result A prognostic factor analysis 
with regard to the nsk of recurrent disease was carried out. The Cox hazard ratio's of 
tumor localisation, multiplicity, patient age (significant factors), tumor grade, size, 
history and gender (not significant) remained almost the same after correction for 
review pathology. Only the prognostic relevance of tumor stage increased after 
pathology correction. 
We conclude that, although review pathology caused considerable changes in the 
pathology results, this did not change treatment efficacy results, and hardly changed the 
results of a prognostic factor analysis in this randomised study. 
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Introduction. 
Optimal management of superficial bladder cancer is based on the knowledge of 
epidemiology, presenting symptoms and natural course. Bladder cancer is, after 
prostatic cancer, the most frequent urological cancer. It is 3-4 times more frequent 
in men. As in all epithelial tumors, the incidence rises with age, with the highest 
incidence in the sixth and seventh decade. Several risk factors have been identified, 
of which smoking is the most important. More than 90% of bladder tumors are of 
the transitional cell type. Less than 10% of the tumors are adenocarcinomas and 
squamous cell carcinomas. 
The key symptom is haematuria, whether macroscopic or microscopic. This should 
always raise suspicion of the diagnosis of a malignancy, until proven otherwise. In 
the diagnostic work up history (irritative bladder symptoms, recurrent infections) and 
physical examination should be followed by urine investigations, especially urine 
cytology. Together with intravenous urography (IVU) and urethro-cystoscopy (UCS) 
the initial diagnosis of a (superficial) bladder cancer can be made. 
The treatment of choice is an adequate trans-urethral resection of the tumor 
(TURT) together with random biopsies from the bladder and the prostatic urethra, 
unless there are major contraindications for surgery and/or anaesthesia. Together 
with a bimanual examination before and after operation the T(umor) category and 
grading can be assessed [1]. In case of contraindications against the TURT initial 
therapy could be intravesical instillations of chemotherapeutic or immunotherapeutic 
agents, which are discussed below. If there is any doubt as to whether the initial 
TURT has been complete, a new UCS with TURT has to be planned after 4-6 
weeks. 
Further treatment depends on the pathological classification in which two major 
categories can be identified. Approximately 75% of the primary bladder tumors are 
superficial, invading as far as the lamina propria, and not infiltrating the muscle of 
the bladderwall (pTa, pTl, pTis). The other group of tumors are the muscle 
infiltrating bladder tumors (pT2-pT4b). In case of an infiltrating transitional cell 
carcinoma (TCC) further investigations to determine the presence or absence of 
lymph node involvement (N-status) or metastatic disease (M-status) are necessary. 
Surgery, (neo-adjuvant) chemotherapy or radiotherapy are possible therapeutic 
options, depending on the final TNM classification. 
In case of a superficial TCC, which has been apparently completely resected, up 
to 70% of these tumors will recur, usually in the first year after TURT [2], and 
usually in the same stage and grade. These tumors can be true recurrences 
(regrowth after incomplete resection, or as a result of implant of tumor cells during 
TURT), and new occurrences. In a minority of cases (overall, less than 15%) 
progression to a higher pT stage and/or the development of metastasis may occur. 
To prevent or delay recurrent tumor and eventual progression TURT should be 
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followed by some form of intravesical therapy. An exception to the high recurrence 
rate are patients with a small primary, solitary pTa grade 1 tumor. The chance for 
recurrence or progression is less then 5%, and these patients don not have to be 
treated after the TURT. Cystoscopic and cytologic follow up is sufficient [3]. All 
other superficial tumors should be treated with intravesical therapy, particularly in 
those cases with established high risk factors for recurrence (high stage and grade, 
multifocality, size, previous bladder tumors, positive biopsies). 
Similarly, patients with carcinoma in situ (CIS) represent a high risk group. CIS is 
a highly anaplastic preinvasive malignancy, which is difficult to control with 
transurethral resection. Radiotherapy is not effective. CIS will progress to invasive 
cancer, although this might take several to even 77 months [4]. Intravesical therapy 
therefore is one of the only effective treatment modalities. 
Another high risk group are pTl grade III tumors, especially when there is 
concomitant CIS . Recurrence rate for this group might be as high as 90% for 
multiple tumors, and the risk of progression to invasive cancer and/or metastasis is 
25-30% [5,6]. In these tumors radical surgery might be considered. 
Intravesical prophylaxis and therapy. 
The aim of intravesical prophylaxis is to prevent or delay superficial tumor 
recurrence or progression. In case of therapy for residual tumor or CIS, treatment is 
given on similar lines. A drug is dissolved and instilled into the bladder with the use 
of a transurethral catheter. The catheter is taken out and the drug is left in the 
bladder for 1 to 2 hours. The patient has to change position to allow the drug to 
reach all parts of the bladder. The main advantage of this method is that no or 
little systemic uptake of the drug occurs, while optimal contact between the tumor 
or tissue at risk and the drug is obtained. Disadvantages are the local side effects in 
the bladder because of the high local drug concentration, and the need for transur-
ethral manipulation. Usually a course consists of a number of weekly intravesical 
instillations. Three months after the initial TURT a further control UCS should be 
performed. 
Several drugs have been used in the past and are listed below. They can be 
divided in chemotherapeutic agents (thiotepa, doxorubicin hydrochloride, ethoglucid, 
mitomycin) and immunotherapeutic agents (interferon, Bacillus Calmette-Guerin 
(BCG)). 
Thiotepa. 
Thiotepa has a low molecular weight of 189, so absorption and systemic toxicity 
(myelosuppression) can occur, although this is rare and usually mild [7]. Full blood 
counts should be measured before and during treatment, and treatment should be 
delayed if necessary. The complete response rates for thiotepa are between 35% 
86 Chapter 7 
and 45% [6]. Patients with grade I tumors respond particularly well [8]. 
Doxorubicin. 
Doxorubicin has a relatively high molecular weight of 580, thus absorption and 
systemic toxicity are rare. Its side effects are chemical cystitis in 25% and, 
infrequently, allergic reactions [9]. The long term success rates are not clear. 
Doxorubicin and thiotepa are both significantly inferior to BCG (table 1) [10]. 
Table 1: Remits of three studies dealing with intravesical treatment of superficial 
bladder cancer. 
Author 
Brosman 
[Π] 
Martinez 
Pineiro 
[12] 
Lamm 
[13] 
Agent 
Thiotepa 
BCG Tice 
BCG Past. 
Doxorubicin 
Thiotepa 
BCG Conn. 
Doxorubicin 
Tumor 
pTa/1 
pTa/1 
pTa/1 
CIS 
CIS 
patient 
number 
19 
39 
67 
53 
56 
52 
57 
Follow-up 
months 
24 
24 
34 (3-92) 
40 (5-97) 
34 (6-78) 
Success 
rate 
60% 
100% 
86.6% 
56.6% 
64.3% 
72% 
47% 
Ethoglucid. 
Ethoglucid has also been used for intravesical instillations. It is hardly absorbed at 
all, and systemic side effects are rare. In an EORTC study Kurth found both 
chemical cystitis and mild systemic reactions both in 3% of 96 patients treated with 
ethoglucid [14]. Only one case of serious toxicity was seen. No difference was found 
in this study between doxorubicin and ethoglucid regarding efficacy. Both drugs, 
however, prolonged the mean interval between recurrences, compared with 
transurethral resection alone. 
Mitomycin. 
Mitomycin С (MMC) has a molecular weight of 329, and absorption is minimal. 
Myelosuppression is rare. The most frequent side effects are chemical cystitis and 
allergic reactions (skin rash). Soloway treated 80 patients with persistent superficial 
bladder cancer, which had in most cases recurred following prior therapy with other 
agents [15]. His initial responses at twelve weeks were 37% for pTa, 44% for pTl, 
and 33% for CIS. Failure at twelve weeks was considered to be an important 
negative prognostic sign. 
We carried out a comparative study between MMC and BCG, in 338 patients 
with superficial TCC [16]. Frequency of side effects were not significantly different 
for both groups, nor were the recurrence rates. Chemical and bacterial cystitis were 
noted in 40%-50% in both groups. The recurrence rate for the BCG group was 
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0.28, for the MMC group 0.24 (p=0.40). In our current study MMC is being 
compared with two different BCG strains. 
Huland compared MMC to no intravesical therapy in a randomized trial after 
complete TURT [17]. The percentage of recurrences was 10% in the MMC group 
compared to 51% in the control group. A prospective multicenter trial confirmed 
these results, although the recurrence rate was slightly higher (15.3%) with the same 
method of prophylaxis [18]. 
Future studies have to identify the exact value of these different 
chemotherapeutic intravesical agents. 
Interferon. 
Limited clinical trials with interferon in bladder cancer suggest potential success 
after intravesical instillation, but further investigations are necessary [19,20]. 
Chodak compared high and low dose interferon in the intravesical treatment of 
patients with CIS. After at least six months 9/19 patients in the high dose group 
remained without recurrence. Both 5 patients in the high and low dose group 
underwent cystectomy, although the median time to surgery was longer in the high 
dose group. Glashan also compared two dosages in patients with CIS. Eighty-seven 
patients were treated for a maximum of 1 year. Twenty patients in the high dose 
group (43%) and 2 patients in the low dose group (5%) achieved a complete 
response. 
Bacillus Cabnette-Guerin (BCG). 
The antitumor effect of tuberculosis has been known since 1929, when autopsy 
studies of tuberculosis patients showed significantly fewer malignant tumors than in a 
control group. After several decades these findings were the basis for the use of 
BCG in cancer treatment. Results of animal studies led to the use in men (initially 
in the management of leukaemia). Morales was the first to use dissolved BCG in 
the human bladder in 1976 [21]. 
The mechanisms by which BCG exerts its antitumor activity remain unclear. 
There are non-immunological responses (inflammation), nonspecific and specific 
immunological responses (humoral and cellular), but the activities and interactions of 
BCG with tumor cells are still not understood. 
The efficacy of the BCG vaccine depends on several factors. The two most 
important are: (1) the ability of the organisms to multiply in vivo, the so-called 
viability, which differs in the available strains, and (2) the number of bacilli used in 
each vial, the so called dose. The dose is the number of colony forming units 
(CFU), which is approximately 5 χ 10" CFU in each ampoule. Although the 
antitumor effect increases with the dose, there seems to be an optimal dose, of 5 χ 
10· to 5 χ 10' CFU. 
Intravesical instillation of BCG is accepted as the best route of administration. 
Combination of the intravesical administration with intradermal administration does 
not seem to improve the results. 
The clinical schedule is a course of six weekly instillations after a complete 
endoscopic resection of a superficial bladder tumor. In case of a recurrence after 
BCG therapy, a second course of six instillations or maintenance therapy (e.g. 
monthly instillations for one year) can be given. Both regimens can improve the 
success rates, but the maintenance therapy has more local and systemic toxicity [10]. 
Side effects after intravesical instillations with BCG are local or systemic. Lamm 
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reviewed the data of 1278 patients treated with 5 different strains of BCG [22] The 
local side effects are cystitis-like in nature in over 90% of the patients These 
complaints increase with the number of instillations, but are easily treated with 
nonsteroidal anti-inflammatory drugs. Haematuna is seen in 43% of the patients, but 
is seldom severe. Systemic side effects such as fever (28%), malaise (24%) and 
nausea (8%) generally subside spontaneously. Severe side effects (table 2) are seen 
in about 5% of all patients [21]. It is important that the urologist working with BCG 
is familiar with antituberculous drugs (isoniazid, nfampicin, ethambutol). Only few 
fatal complications have been encountered, and traumatic catheterization seems to 
play an important role in these severe problems. Therefore it is strongly 
recommended that if trauma during catheterization occurs, the treatment is 
postponed for one week. 
Table 2: Severe complications of intravesical BCG instiUations in 2602 patients with 
superficial bladder cancer [23}. 
Fever more than 39.5 "C 
Haematuna 
Granulomatous prostatitis 
BCG pneumonia/hepatitis 
Arthntis/arthralgia 
Epididymo-orchitis 
2.9% 
1.0% 
0 9% 
0.7% 
0.5% 
0.4% 
BCG sepsis 
Skin rash 
Ureteral obstruction 
Contracted bladder 
Cytopenia 
Renal abscess 
0 4% 
0.3% 
0.3% 
0 2% 
0.1% 
0.1% 
The clinical results of BCG are good Without treatment, overall after endoscopic 
resection more than 60% of the superficial bladder tumors recur, usually within the 
first year With BCG the recurrence rates decrease to 35% or less with a minimal 
follow up of one year [10] BCG is superior to thiotepa and doxorubicin After an 
incomplete endoscopic resection BCG can be used to eliminate residual tumor with 
success rates ot 60-70% 
For CIS several chemotherapeutic agents have been investigated, with success 
rates were between 29 and 48%. With BCG success rates between 42 and 83% are 
found (patients at least one year free of recurrences as seen on cystoscopy or 
cytology, after a complete endoscopic resection of tumor), which is very encouraging. 
BCG has also been used successfully in the treatment of ureteral CIS [24], and 
TCC in the prostatic urethra [25.26]. 
Although at this moment BCG seems to be the drug of choice for several forms 
of superficial TCC, many questions remain unanswered, especially about the 
mechanisms of action, the optimal dose and clinical schedule Future and ongoing 
investigations and clinical trials will hopefully give the answers 
Summary and conclusions. 
Superficial transitional cell carcinoma of the bladdei is a heterogeneous group of 
tumors On the one hand there are small primary solitary pTa grade 1 tumors, 
which are very unlikely to progress after they have been treated by TURT, and on 
the other hand there are very aggressive forms, such as pTl grade HI with CIS, 
which have a high recurrence and progression rate. This makes it important for the 
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treating urologist to be aware of the different aspects of superficial bladder cancer. 
There is also a possibility to choose between several intravesical drugs and 
schedules. It is important to know the advantages and disadvantages of these 
treatment modalities, to be able to individualize treatment as much as possible. 
Ongoing clinical trials will give us some answers with regard to efficacy and toxicity 
of several drugs. What has not changed is the need for regular follow up with 
endoscopy and urine cytology. The natural preference for conservative treatment on 
the part of the patient should not prevent a urologist from using more aggressive 
forms of therapy when needed. 
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History. 
The antitumor effect of tuberculosis is known since 1929, when Pearl reported an 
autopsy study, observing that a group of patients suffering from tuberculosis showed 
significantly less malignant tumors than a control group [1]. After animal studies 
Mathé in 1969 was the first to use BCG in man as an immunotherapeutic agent in 
the treatment of acute lymphoblastic leukaemia [2]. Some years later the research 
group of Zbar and Rapp successfully injected BCG in the tumor of a guinea pig 
with a line 10 hepatocarcinoma, and they described the basic principles for optimal 
results in antitumor activity [3,4]: (1) tumor burden must be small; (2) direct contact 
between tumor cells and BCG is essential; (3) the dose of immunizing agent must 
be adequate; and (4) tumors respond better, when confined to the parent organ, or 
in case of metastases, when spread is limited to the regional lymph nodes. 
In 1966, Сое and Feldman had already demonstrated a strong delayed type of 
hypersensitivity reaction in the bladder in guinea pigs [5]. Superficial bladder cancer, 
therefore, appeared to be the ideal tumor model for therapy with BCG, as most of 
the conditions as described above were present in this tumor. Morales was the first 
who used intravesical BCG instillations for superficial bladder cancer in 1976 [6]. 
Now, after 16 years, BCG is widely used in the treatment of carcinoma in situ (CIS) 
and residual tumor after endoscopic resection (therapeutic use), and after complete 
endoscopic resection to prevent tumor recurrences and/or progression (prophylactic 
use). 
Effector mechanisms of BCG in cancer. 
The mechanisms by which BCG exerts its antitumor activity remain unclear. Ratliff 
found that BCG attachment to FN was an important first step for the development 
of an immune response and antitumor activity [7]. Heparin instillation into the 
bladder inhibited BCG/FN binding, possibly through the binding of heparin to the 
heparin binding sites of FN [8]. In a recent study Hudson et al. found that inhibitors 
of fibrin clot formation decreased the efficacy of intravesical BCG therapy in 
patients with superficial bladder cancer [9]. In a similar study, however, we could 
not confirm these results, as is described in chapter 11 [10]. 
BCG therapy exerts non immunologic responses (inflammation), non specific 
immunological responses and specific immunological responses (humoral and 
cellular). In the cellular immune system В and Τ lymphocytes, macrophages, killer 
cells and natural killer cells are effected. Τ lymphocytes, especially T-helper cells, 
appear to be critical for antitumor response [11]. Athymic (nude) mice for example 
fail to respond to intravesical BCG given for the treatment of the experimental 
MBT2 bladder tumor, whereas the administration of syngenic Τ lymphocytes restores 
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antitumor activity [12]. In bladder biopsies of patients treated for superficial bladder 
cancer the ratio of Τ helper to Τ suppressor cells increased from 0.5 before BCG 
therapy to nearly 2.0 after therapy, persisting for 1 year [13]. 
Three different effector mechanisms have been proposed [14]: (1) A specific 
immune response to BCG also stimulates non specific immune mechanisms which 
then destroy tumor cells; (2) a specific immune response to BCG stimulates specific 
antitumor immune mechanisms, e.g. by cross reaction between BCG and tumor 
antigens; (3) the local antitumor action of BCG is simply due to the "toxic" effects 
of severe inflammation leading to ischaemia and sloughing of superficial tumor cells. 
Several aspects of the effects of BCG on the immune system have been 
described. BCG can induce enhanced antibody synthesis, directly via В cells, or 
indirectly via Τ cells [15-19]; increased cytokine production such as IL 2 [20-24], IL 
1 and TNF [23] and IFN gamma [25]; increased cell mediated immunity [17,26]; 
enhancement of macrophage action [17,19,27], NK cells [28-31] and cellular cytotoxi­
city [32]. Further signs that there is a relation between BCG and the immune 
system was found by Sarosdy and Kierum [33]. They found that the 
immunomodulator pyrimidinone (interferon induction) could potentiate the activity 
of BCG in a MBT-2 model system. BCG can also suppress the immune system, 
partly by induction of the Τ suppressor cells [34]. BCG induces a strong level of 
HLA-DR expression by urothelial cells which persisted for several months after 
completion of therapy, suggesting that the whole urothelium is involved in an 
immunological reaction [35]. 
When BCG is used intravesically, (non caseating) granulomatous inflammatory 
reactions and mononuclear cell infiltrations in the subepithelial layer of the bladder 
have been described in man [36]. Van der Meijden demonstrated the same reaction 
in the bladder wall of guinea pigs receiving intravesical BCG, whereas in general the 
mucosal layer covering the inflammatory reactions remained intact. Also the primary 
iliac lymph nodes draining the bladder were enlarged, and in some animals 
granulomas were found in the liver, lung, spleen and distant lymph nodes. No viable 
mycobacteria, however, were detected outside the bladder [37]! Mizutani et al. 
found BCG to activate the tumor killing system through stimulation of effector cells, 
and elevation of target cell susceptibility in bladder cancer patients [38]. This might 
suggest that BCG mediated cytotoxicity may be directed specifically to urinary 
bladder cancer cells. 
In spite of all of these findings many aspects of activities and interactions of BCG 
with tumor cells are still not well understood. 
Viability, dose, appropriate strain. 
The efficacy of a BCG vaccine depends on several factors, of which the two most 
important are: (1) the ability of the organisms to multiply in vivo, the so called 
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viability, which is different in the available strains; and (2) the number of bacilli 
used in each vial, that is the dose. 
1) Different strains of BCG, and also different samples of BCG of the same 
strain are noted to have different numbers of colony forming units (CFU). In the 
Pasteur BCG strain (Institute Armand Frappier, Quebec, Canada) for example the 
numbers of colony forming units differed from 6x10" till lxlO12 per ampule. There is 
a relation between viability and treatment results: patients treated with 6x10* CFU 
per ampule had recurrent tumors in 71%, while patients treated with 3x10" CFU 
per ampule showed recurrences in 25% [39]. Storage of BCG at the correct 
temperature is critical for the survival of the mycobacteria. 
Until now 9 strains of BCG have been used in the immunotherapy of superficial 
bladder cancer: Pasteur (Quebec, Canada), Tice (Chicago, USA), Connaught 
(Toronto, Canada), Pasteur (Paris, France), Glaxo (Greenford, England), Moreau 
(Sao Paulo, Brazil), RIVM (Bilthoven, the Netherlands), Tokyo 172 (Tokyo, Japan) 
and Evans (Glaxo, Danish strain). The first two strains have been used and 
investigated most thoroughly. Studies to compare different strains have been 
initiated, and the first results have been published. Mukherjee et al. studied the 
Glaxo and Pasteur strain of BCG and found no difference in efficacy in a small 
group of 21 patients [40]. We compared Tice and RIVM strain of BCG, and also 
found no difference in efficacy or side effects [41]. 
The culturing methods also differ, resulting in variable ratio of viable organisms 
on one hand and subcellular debris and dead bacilli on the other hand. Since we do 
not know which parts of the BCG bacilli are responsible for the immunologic 
effects, this ratio might also be important, although Hanna demonstrated that BCG 
components were not effective substitutes for whole viable BCG cells to achieve 
systemic tumor immunity [42]. 
2) The number of colony forming units in a preparation of a BCG strain is 
more important than the dry weight of the preparation. Although the antitumor 
activity increases with the dose, there seems to be an optimal dose of SxlO'-SxlO' 
CFU. A higher dose results in decreasing antitumor activity. 
Pagano et al. carried out a study in which he gave maintenance therapy with low 
dose (75 mg) of BCG Pasteur [43]. He compared treatment in CIS patients and 
prophylaxis in superficial tumors after complete transurethral resection (TUR) with 
a TUR only group. A complete response was observed in prophylaxis, treatment 
and control group of 74, 57 and 17% of patients respectively. They concluded that 
the low dose was effective with incidence of complete response, recurrences, and 
progression similar to those reported previously. Toxicity however appeared to be of 
a lower incidence. Cockett et al. also used maintenance low dose BCG (60 mg.) 
[44]. They only found moderately significant remission rates (59%). A second finding 
of this study was the higher efficacy of a combination of intravesical IL-2 and low 
dose BCG (88% remission rate). Morales et al. also compared 2 doses of BCG (60 
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mg. versus 120 mg) [45]. Side effects were significantly less in the low dose group, 
however, efficacy was also significantly less (overall success of 67% for high dose, 
37% for low dose, p<0.02). The optimal dose, therefore, still has to be found. 
Hudson et al. studied the optimal physical conditions for a BCG solution in vitro 
and in vivo in a murine bladder model [46]. They concluded that normal saline with 
pH 7, and retention of the suspension for 2 hours were the optimal conditions to 
maximize intravesical BCG attachment. 
Route of administration. 
There are 5 routes of administration which have been used for BCG in the 
treatment of superficial bladder cancer sofar. 
1) Percutaneous administration has been investigated in a small group of patients. 
Many variables in patient selection and treatment program made it impossible to 
estimate the value of this route of administration, although antitumor effect was 
observed [47,48]. 
2) Intralesional administration has been abolished after it has been used in 2 
patients, of whom one patient developed a serious hypersensitivity reaction, resulting 
in an allergic shock [47,48]. Rosenberg et.al. observed wide spread interstitial 
granulomas in lungs, liver, bone marrow, spleen and heart, found at post-mortem in 
patients who received intratumoral Glaxo BCG immunotherapy for prostatic 
carcinoma [49]. Although these lesions were usually asymptomatic they were 
observed to persist for months after immunotherapy [50]. 
3) The oral administration was studied by Netto and Lemos in 1984 [51]. They 
found a complete response of 70% in a group of 10 patients with invasive bladder 
cancer. Minimal side effects were encountered with oral BCG. In a later study TUR 
only, oral BCG and intravesical BCG were compared in 71 patients after TUR of 
superficial bladder tumors [52]. In all, 8 out of 9 patients in the TUR only group 
experienced a recurrence after 20 months of follow up, 11 out of 28 patients in the 
oral BCG group, and 6 out of 34 patients in the intravesical BCG group. In spite of 
higher efficacy in the intravesical BCG group, the incidence of side effects also was 
higher. Others, however, could not confirm these results. Lamm found no 
measurable antitumor effect of oral BCG in the treatment of superficial bladder 
tumors comparing oral versus intravesical and percutaneous BCG [53]. 
4) Intravesical instillations were initially combined with percutaneous inoculations, 
as described by Morales [6]. With this regime Morales found complete response in 
50% of the patients using BCG as a prophylactic therapy, in 58% of the patients 
with residual disease, and in 77% of the patients with CIS [54]. Other investigators 
found similar results. 
5) At this moment, however, intravesical administration of BCG alone is accepted 
in most centres to be the best route of administration, as percutaneous 
96 Chapter 8 
administration does not increase treatment efficacy in two prospective randomized 
studies [55,56]. Brosman observed conversion of the PPD skin test in patients he 
treated with intravesical instillations of BCG, indicating a svstemically induced 
reaction against BCG [57]. In some studies conversion of the PPD test seems to 
indicate a better response to therapy [39,58-60], although the significance of this test 
is borderline, and should not be used as a prognostic marker in individual patients 
[60]. Lamm et. al. surprisingly found no significant difference in skin test conversion 
in a study using BCG Tice with and without percutaneous administration [61]. 
Clinical schedules. 
The frequency of bladder cancer is approximately 20/100,000 [62]. The recurrence 
rate is between 30% and 80% [63,64]. Tumor progression depends on several 
factors such as tumor stage, grade, size, and multicentricity. A National Bladder 
Cancer Group study for example found that only 4% of patients with Ta tumors 
progressed to muscle invasive tumors, compared to 30% when the initial lesion was 
Tl [65]. With regard to tumor recurrence adjuvant intravesical BCG treatment is 
superior to TUR alone [6,66,67], and to adjuvant intravesical chemotherapy with 
thiotepa [68] or doxorubicin [69]. The initial schedule of BCG is a course of 6 
instillations in 6 weeks, as first proposed by Morales [6]. One course of 6 
instillations might not be optimal. When patients fail this course two different 
schemes can be followed. 
Brosman advocated maintenance therapy in 1982 [57]. His regimen consisted of 
intravesical instillations once weekly for 6 weeks, biweekly for 3 months, and than 
monthly until recurrence or a maximum of 2 years. He found better response rates 
(39 out of 39 patients with superficial bladder cancer and 31 out of 33 patients with 
CIS) than in a 6 week course. Other maintenance regimens have been used. On the 
other hand Badalament and Hudson found no significant difference in reduction of 
recurrent tumors between a 6 week course and maintenance therapy [70,71]. The 
local and systemic toxicity of the maintenance therapy, however, is more severe and 
significantly worse than in other protocols [72]. Our own experience with 
maintenance therapy is discussed in chapter 10. 
The second possibility for the treatment is a second 6 week course in patients 
who fail the first course. The response rates could be improved from approximately 
60% after one 6 week course to approximately 80% after the second course [58,73], 
without the severe toxicity of the maintenance therapy. Khanna also found that 
therapy beyond an initial course of 6 weekly instillations increased the percentage of 
complete responses [74]. He reviewed 13 other studies and found that the greatest 
improvement in percentage of complete responses occurred with the second course 
of treatment. Bretton treated 28 patients who failed one course of 6 weekly 
instillations with a second course [75]. 13 patients showed progression, 10 patients a 
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complete response, and 5 had new tumors. The median duration of response after 
course 1 was shorter in patients with subsequent progression after course 2 
(p=0.05). Therefore, a second course of BCG seems most useful in patients who 
have a sustained response to the initial treatment. The value of an additional 6-
week course in patients who recur after this first course was also demonstrated by 
Sarosdy and Lamm, who studied the long term results of BCG therapy [76]. With 
retreatment of some of the early failures the initial success rate of 78% was 
increased to 89%, with a median follow-up of over 5 years, suggesting a durable 
beneficial response after BCG therapy, rather than simple delay of tumor 
recurrence. The retreatment consisted of a second course, followed by maintenance 
therapy. Copien et al. reported their long term follow up of patients treated with 1 
or 2 6-week courses of BCG [77]. They concluded that one 6-week course may be 
ineffective for some patients, and a second 6-week course provided long tumor free 
survival for many patients failing the initial course. However, in CIS patients failing 
both courses a significantly higher risk for muscle invasion was found. This potential 
danger of repeated BCG courses was also found by Catalona et al., who performed 
a risk to benefit analysis of repeated courses of intravesical BCG [58]. They found 
that the risk of developing invasive cancer or metastasis in patients who had failed 2 
courses of intravesical BCG (respectively 30% and 50%) exceeded the prospects of 
eradicating the superficial cancer with further BCG treatment. So more than 2 
courses might be dangerous with regard to disease progression. 
In conclusion one course of six instillations is not optimal, and a second course of 
instillations may be indicated in some patients. It has less side effects than 
maintenance therapy. Gose follow up, however, is mandatory, because of the risk of 
progression in those patients who fail repeated courses. To identify patients at risk 
Herr et. al performed a multivariate analysis on data from 221 patients with 
superficial bladder tumors who were treated with intravesical BCG [78]. They 
identified significant variables for tumor progression before BCG therapy (Tl tumor 
and disease duration < 1 year), at 3 months after BCG (Tl tumor, disease duration 
< 1 year, positive cytology and multifocality), and at 6 months after BCG (Tl 
tumor, positive cytology and positive biopsy other than Tl tumor). Evaluation of the 
patients at 6 months after BCG identified the probability of tumor progression best. 
They defined prognostic risk groups at 6 months after BCG, based on biopsy and 
cytology studies, and found probabilities of tumor progression after 1, 3 and 5 years 
(the treated natural history). Additional information was obtained by bladder wash 
flow cytometry [79]. Negative bladder wash flow cytometry at 6 months after 
initiation of BCG intravesical therapy was a strong predictor of response to BCG, 
and also progression free survival. A high level of activation of peripheral blood 
monocytes following BCG therapy also might be an indicator for response to BCG 
[80]. More multivariate analysis is needed, however, to identify patients who will or 
will not respond to BCG therapy. Individualization of the therapy is one of the aims 
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for the near future. 
Toxicity. 
Side effects after intravesical instillations with BCG can be divided in local side 
effects, allergic reactions and systemic side effects. Local toxicity can be bacterial 
cystitis (not BCG related), drug induced cystitis (MMC or BCG related) or other 
local side effects, such as haematuria, bladder contracture, prostatitis and 
epididymitis due to contamination with MMC or BCG containing urine. The severity 
of side effects usually is classified according to the need of delay or cessation of 
instillation therapy. Bacterial cystitis should be treated before further BCG therapy. 
The dose and the number of instillations are important factors. Lamm reviewed 
the data of 1278 patients treated intravesically with 5 different strains of BCG [72]. 
More than 90% of the patients suffered from cystitis with frequency and dysuria, 
during the first 2 days after the instillation. Patients found relief with non steroidal 
anti inflammatory drugs. The bladder irritability usually began after 2 or 3 
instillations, and increased with the frequency and number of instillations. 
Haematuria was seen in 43%, sometimes severe (0.5%), requiring catherization. 
Moderate side effects were fever till 39°C (28%), malaise (24%), and nausea (8%). 
They generally subsided spontaneously. Except for the severe side effects this 
toxicity was usually well tolerated, and only sometimes caused delay of treatment. 
Severe side effects were seen in about 5% of all patients, and are listed in table 1. 
These results are updated with a total of 2602 patients [85]. 
Table 1. Complications of intravesical BCG instillations in 2602 patients with superficial 
bladder cancer [85]. 
Fever more than 39.5 "C 
Haematuria 
Granulomatous prostatitis 
BCG pneumonia/hepatitis 
Arthritis/arthralgia 
Epididymo-orchitis 
2.9% 
1.0% 
0.9% 
0.7% 
0.5% 
0.4% 
BCG sepsis 
Skin rash 
Ureteral obstruction 
Contracted bladder 
Cytopenia 
Renal abscess 
0.4% 
0.3% 
0.3% 
0.2% 
0.1% 
0.1% 
In this update granulomatous prostatitis was found in 0.9%. The majority of those 
patients are asymptomatic and require no treatment. The true incidence might be 
even higher, as is suggested by Mukamel et al. [82]. They biopsied 20 of 36 patients 
treated with intravesical BCG and found typical granulomas in 8. 
In case of severe irritative bladder symptoms, fever, chills, or malaise, the dose of 
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BCG should be lowered to half the initial dose, and patients should be treated with 
isoniazid (INH) 300 mg daily starting on the day before instillation and continue for 
3 days or until symptoms resolve [81]. In case of severe systemic side effects the 
treatment with BCG should not be continued, and antituberculous combination 
therapy should be given for 3 months (INH 300 mg orally per day, Rifampicin 600 
mg orally per day, Ethambutol 1200 mg orally per day). Prednisolone 40 mg per day 
can be added to triple tuberculostatics in case of lifethreatening BCG reactions 
[83,84]. In case of acute problems cycloserine (250-500 mg orally twice daily) could 
be given for the first 3-5 days, because it is effective several days before the classical 
combination therapy is [81]. Sparks indicated that antituberculous drugs do not seem 
to interfere with the antitumor effect of BCG in animal studies [85]. We showed, 
however, that there is a possible inhibition of antitumor efficacy by antibiotics in 
general, and tuberculostatic agents in particular [86]. 
When BCG was used in vaccination programs one death per 50 million patients 
was observed [87]. When BCG was used in immunotherapy for cancer a mortality 
rate of one per 12,500 patients was seen, although almost all patients had 
preexisting defects in cellular immunity. In the group of superficial bladder cancer 
patients treated with BCG, at least 7 fatal complications have been described sofar 
[83]. Traumatic catherization seems to play a role in most of these fatal 
complications [88], just like it had to be considered in 3 of 6 severe life threatening 
disseminated BCG infections described by Steg [89]. Therefore it is strongly 
recommended that if trauma during the catheterization occurs, the treatment is 
postponed for one week. Also active tuberculosis and immune deficiency are contra-
indications for BCG use. In patients with low grade (1 and 2) reflux, kidney function 
and morphology did not seem to change due to intravesical BCG therapy [90]. 
Therefore, in these patients BCG instillations seem to be safe. 
The question whether BCG instillations can evoke second primary malignancies 
has not been answered yet, although Guiñan et. al. in a retrospective study, suggest 
that this is not the case [91,92]. 
Clinical results. 
Three different applications have been described in the treatment of transitional cell 
cancer (TCC) of the bladder with BCG. 
1) Prophylaxis. Endoscopic resection remains the first choice therapy for 
bladder tumors. Approximately 60% of endoscopically resected superficial bladder 
tumors however recur, usually within the first years [73]. In prophylaxis BCG is used 
to post-pone or prevent recurrences and/or progression. A safe exception are 
patients with a primary pTa, grade 1, solitary bladder tumor, which is less than 3 
cm. The risk for progression and/or recurrence is very small, so these patients do 
not need to receive adjuvant treatment at all [8,65]. 
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Table 2 Results 
Author 
Brosman [57] 
Haaff [73] 
Herr [93]* 
Pansadoro [95] 
Steg [96] 
Boccon Gibod 
[9η 
Reitsma [98] 
Brosman [99] 
Martinez 
Pineiro [100] 
Lamm [101] 
Debruyne [102 
' of BCG in the treatment of superficial 
Agent 
Thiotepa 
BCG Tice 
BCG 
Past. 
BCG 
BCG Past. 
BCG Past. 
BCG Past. 
BCG Tice 
BCG Tice 
BCG Past. 
Adriamyc. 
Thiotepa 
BCG Conn. 
Adriamyc. 
BCG Conn. 
Adriamyc. 
|MMC 
BCG RIVM 
* six week course, otherwise 
** not statistical significant. 
Tumor 
CIS 
Resid. 
Prophyl. 
high risk 
Residual 
Prophyl. 
pTa 
pTl 
CIS 
+CIS 
pTl 
CIS 
CIS 
pTa/1 
pTa/1 
pTa/1 
pTa/1 
high risk 
CIS 
CIS 
maintenance 
No. 
pts. 
19 
39 
19 
13 
29 
47 
47 
130 
61 
43 
30 
24 
47 
153 
48 
67 
53 
56 
109 
119 
52 
57 
167 
158 
therapy 
bladder cancer. 
FoUow-up 
months 
24 
24 
14 +/- 2 
15 +/- 3 
13 +/- 1 
48(36-75) 
17 (3-49) 
18 
>12 
>12 
>12 
>12 
27(14-64) 
initial 
18 +/- 13 
27 +/- 14 
initial 
35(24-66) 
34 (3-92) 
40 (5-97) 
34 (6-78) 
22 mean time 
Success 
rate 
60% 
100% 
68% 
69% 
90% 
68% 
68% 
85% 
73.8% 
62.8% 
76.7% 
83.3% 
64% 
74.9% 
65.5% 
56.3% 
70.8% 
41.7% 
86.6% 
56.6% 
64.3% 
10 to recurrence 
21.25 
72% 
47% 
64% 
58% · · 
In the prophylactic use several comparative studies found no difference in success 
rates between thiotepa and doxorubicin or thiotepa and mitomycin (MMC). BCG 
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however was superior to thiotepa and doxorubicin [93]. These results are also found 
in several recent studies, of which the results are listed in table 2. BCG is also 
superior to TUR only [94]. 
The success rate of BCG treatment is between 58% and 100%, with a minimal 
follow up of one year. In all but two studies BCG, is given for a longer period, 
usually for one or two years (maintenance therapy). In all studies comparing BCG 
with other agents, BCG is superior in the treatment of superficial bladder cancer. 
The only exception is the study of Debruyne e t al., in which no statistical difference 
is found between MMC and BCG-RIVM for the treatment of superficial bladder 
cancer after 21 months [102]. In a new study in the Dutch south-east co-operative 
urological group BCG-Tice, BCG-RIVM, and MMC are compared [41]. Preliminary 
results again indicate no superiority in treatment efficacy of BCG over MMC, and 
no difference between the two BCG strains. 
BCG can also be used in patients with high risk superficial bladder cancer. Eure 
et al. studied 30 high risk pTl patients (24 patients grade 3, 14 patients associated 
CIS), who received 1 or 2 6-week courses of BCG [103]. After a mean of 39 
months the complete response rate was 66%. 5 patients showed progression and 
had cystectomy, all 5 were among the 16 patients who failed to achieve a complete 
response after the initial course of BCG. Therefore, BCG seems effective in high 
risk superficial bladder cancer, although close monitoring of non-responders is 
mandatory. Klimberg et al. studied 55 patients with recurrent superficial bladder 
tumors, of which 41 (75%) were failures of other intravesical therapy. Thirty-six 
(66%) responded to BCG treatment with a mean follow up of 30.5 months [104]. 
Soloway and Perry found similar results in 30 patients who failed intravesical 
chemotherapy [105]. 50% of these patients had a complete response after one 6-
week course of BCG, with a mean follow up of 16 months. Herr et. al. even suggest 
in a long-term follow-up study of high-risk patients with superficial bladder cancer 
that intravesical BCG alters the prognosis of superficial bladder cancer (delay of 
progression, prolonged bladder preservation, increased overall survival) [106]. 
2) Residua] tumor. BCG also can be used to eliminate residual tumor after 
an incomplete endoscopic resection or in patients who are unfit for surgery. The 
number of tumors seems of no consequence as long as they are small and accessible 
to the action of BCG. Success rates of approximately 60-70% are found (table 2) 
[73,95,107]. 
3) CIS, a preinvasive highly anaplastic malignancy, is a difficult disease to 
control. The time taken for progression from CIS to invasive cancer varies from 
several months to 77 months [108]. Patients can either have CIS as a primary 
disease, or have a papillary tumor with concomitant CIS. The efficacy of three 
chemotherapeutic agents has been defined in clinical trials: Thiotepa has an overall 
complete response rate of 29%, Doxorubicin of 38% and MMC of 48% [98]. With 
BCG encouraging results have been described with success rates between 42% and 
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83% after a minimal follow up of one year (table 2). De Jager et al. recently 
published long term results in CIS patients from 6 phase II trials [109]. 119 patients 
were treated with 6 weekly Tice BCG instillations, followed by 12 monthly 
instillations. In all, 90 patients (75.6%) achieved complete response, including 45 of 
63 patients who failed prior intravesical chemotherapy. 45 of the responding patients 
remained free of disease after a median follow up of >48 months. Cystectomy rate 
in the non responders was significantly higher, time to cystectomy significantly 
shorter. However, there was no difference in survival between BCG responders and 
non responders. They concluded that Tice BCG is effective for CIS, with or without 
prior chemotherapy. Harland et al. also found "impressive" responses in 53 CIS 
patients after BCG therapy (53% complete response after median follow up of 32 
months) [110]. In the group of responders disease progression occurred in 10% of 
patients, whereas in non responding patients progression was seen in 48%. They 
also concluded that CIS could be successfully treated with intravesical BCG, but it 
remains a dangerous disease. Pisters et al. studied the use of intravesical BCG in 20 
patients with CIS after pelvic radiotherapy with at least 6000 cGy [111]. 16 patients 
previously had invasive TCC, 1 patient had recurrent superficial TCC, Initial 
treatment was a 6-week course of BCG. In case of persistent CIS a second course 
of BCG or MMC was given, or radical surgery was done. 14 patients had a 
complete response after 1 or 2 courses of intravesical instillations (mean follow up 
15.7 months). Side effects were comparable to those in not irradiated patients, 
except for 2 cases of bladder contracture, which were probably multifactorial. 
Questions and future perspectives. 
Much work has been done to investigate several aspects of the use of BCG in the 
treatment of superficial bladder cancer. Many questions however remain. 
The effector mechanisms of BCG, for example, still are investigated. The 
importance of attachment of BCG to the bladder mucosa is discussed in chapter 11. 
Ratliff et al. recently demonstrated that BCG is internalized by transitional epithelial 
cells, both in vitro and in vivo [112]. The relationship of this Finding with the 
antitumor activity of BCG is currently investigated. 
The best strain and optimal dose have not yet been identified. The efficacy of 
low dose BCG is reported, but needs further evaluation [43,44,45]. Combination of 
BCG with other immunotherapeutic agents may prove effective for bladder cancer 
[44,113]. No consensus has been reached about the optimal clinical schedule (one or 
two courses of 6 instillations, maintenance therapy). 
Although BCG generally has a higher efficacy as compared to intravesical 
chemotherapy, toxicity also is significantly higher. Therefore, prediction of the 
response to BCG will be very important, as was found in some studies. Bretton et 
al. found negative bladder wash flow cytometry at 6 months after initiation of BCG 
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therapy to be a strong predictor of response to BCG [79]. Dow et al. suggested that 
Τ antigen on bladder tumor cells serves as a target for effector cells generated by 
BCG (plus IL 2) treatment [114]. They found that patients with Τ antigen positive 
tumors had a significantly higher disease free rate (p<0.005) than patients with Τ 
antigen negative tumors. 
An important issue is the question whether BCG alters the final prognosis of 
patients with superficial bladder cancer, as suggested by Herr [106]. Both intravesical 
chemotherapy and immunotherapy can lower the recurrence rate. Chemotherapy, 
however, does not seem to influence disease progression. BCG might do so. Boccon-
Gibod published a nonrandomized historical comparison, in which progression in a 
group of BCG treated patients (21% progression to muscle invasive tumor) seemed 
to be less frequent compared to a group of patients treated with TUR only (34% 
progression) [97]. Herr's long term follow up (>10 years) of 61 high risk superficial 
bladder cancer patients also suggested a beneficial effect of BCG on prognosis 
[115]. Of the BCG treated patients 41% showed progression, compared to 95% of 
the control population. Recently Cookson and Sarosdy reviewed their results in 86 
patients with pTl tumors which were treated with BCG [116]. After a median follow 
up of 59 months, 78 of 86 patients (91%) were free of tumor recurrence, including 
19 patients who ceased having tumors after additional BCG instillations for local 
recurrences. 
In conclusion, BCG can be very valuable in the treatment of superficial bladder 
cancer patients, especially when it alters the prognosis in high risk patients. Several 
aspects of BCG, however, need further research to individualize treatment of 
patients with superficial bladder cancer. 
Localisations of transitional cell carcinoma outside the 
bladder. 
Introduction. 
The route of administration is the intravesical one. However, localisations of TCC 
outside the bladder have also been successfully treated with BCG. BCG has been 
used in the treatment of superficial TCC and CIS of the upper urinary tract [1 Π­
Ι 19], and the prostatic urethra [120-122]. More distal parts of the urethra, however, 
are difficult to reach with BCG, and TUR is difficult to perform. 
A case report is presented of a patient with CIS in the urethra, who was treated 
with intra-urethral BCG instillations after incomplete TUR. 
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Case report. 
A 60 year old patient was treated for a pT2N0M0 grill TCC of the bladder in 1983 
with external beam irradiation. No local recurrence or metastases were found at 
regular follow up during 6 years. In 1989 abnormal urothelium was seen in the 
bulbar urethra, and biopsy revealed CIS. In the bladder no abnormalities were seen. 
The patient was referred to our department. An incomplete TUR was performed. 
In the whole urethra CIS was found, bladder biopsies were normal. Radical surgery 
was refused, so the use of BCG was advised. Twelve biweekly intra-urethral instilla­
tions with BCG were given. 5 χ 10" Colony Forming Units BCG Tice (Organon 
Teknika, the Netherlands) was dissolved in 50 ml. of sterile saline. At every 
instillation 20 to 30 ml. was instilled in the urethra with an 8 French female 
catheter. The penis was clamped with a Cunningham clamp for 30 min. After the 
clamp was removed, the urethra emptied spontaneously. Urine cytology became 
negative during instillations. Six weeks after the last instillation urethrocystoscopy 
(UCS) was normal and urethral biopsies were negative. On UCS, after another 6 
months, however, small area's of abnormal urothelium were seen, and cytology was 
again suspect. Biopsy again revealed CIS. A second course of 12 biweekly intra-
urethral BCG instillations was administered. The cytology became negative, but 
reversed to positive again within six months. Biopsies revealed CIS, with ingrowth in 
Cowper's glands. Radical surgery was advised. Lymphadenectomy and radical cysto-
prostato-urethrectomy were performed. Histologic examination revealed extensive 
CIS in the urethra and Cowper's glands. The bladder and lymph nodes showed no 
tumor. 
Discussion. 
The time taken for progression from CIS to invasive cancer varies from 3 to 77 
months, as outlined in the first part of this chapter. [108]. In the treatment of CIS, 
BCG is one of the best non-surgical therapeutic modality. Radiotherapy is not an 
effective treatment for CIS. 
The urothelium outside the bladder might be at a greater risk for developing 
TCC. Soloway reviewed 63 male bladder cancer patients, treated with intravesical 
instillations, of whom 10 developed TCC in the prostatic urethra [123]. The average 
interval between the first intravesical instillation and the diagnosis prostatic TCC was 
17 months (range 3-42). 
Direct contact between the urothelium and the BCG is prerequisite. Herr et al. 
observed persistence of ureteral CIS [124] and manifestation of TCC in the prostatic 
urethra [93] after successful intravesical therapy for superficial bladder tumors, 
indicating that direct contact of BCG with the tumor is warranted. This means that 
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other localisations of TCC also might benefit from BCG, as long as they are in 
contact with BCG. Herr was the first to achieve long-term remission of CIS in the 
renal pelvis after topical treatment with BCG [118]. Studer also treated the upper 
urinary tract with BCG for CIS, which disappeared in 7 out of 8 patients [117]. 
After percutaneous resection of renal pelvic TCC, BCG can even be used 
successfully as adjuvant therapy [119]. 
TCC of the prostatic urethra is difficult to treat and carries an ominous prognosis 
[125]. Cysto-prostato-urethrectomy is the recommended treatment. However, if only 
the mucosa of the prostatic urethra is involved, and not the ducts, acini or stroma, 
the tumor might respond to BCG treatment Hilfyard et al. treated 8 patients with 
mucosal TCC of the prostatic urethra associated with superficial TCC of the bladder 
[120]. All patients were treated by weekly intravesical instillations with BCG for 6 
weeks. The authors made no attempts to instill BCG in the prostatic urethra, nor to 
resect the prostate or the bladder neck to improve contact with BCG. Complete 
initial response in the prostatic urethra was obtained in 7 out of 8 patients. Bretton 
et. al. had similar experiences with 23 patients who had multifocal superficial TCC 
and concomitant mucosal and/or ductal CIS of the prostatic urethra [121]. TUR was 
performed, and intravesical BCG instillations were given with BCG. Thirteen 
patients had a complete response with a median follow up of 43.7 months. Ten 
patients had progression, but none occurred in the prostatic urethra. Orihuela et. al. 
reviewed 125 male patients with superficial TCC, treated with intravesical instilla-
tions of BCG [122]. 15 patients had mucosal involvement of the prostatic urethra In 
13 a complete response was obtained in both the bladder and the prostate. 
A risk of instilling BCG in the prostatic urethra is the development of 
granulomatous prostatitis. In a recent review of 2602 patients Lamm found 23 cases 
(0.9%) of granulomatous prostatitis [81]. The majority of those patients, however, 
were asymptomatic and required no treatment. To distinguish the induration 
associated with granulomatous prostatitis from prostatic carcinoma, needle biopsy is 
advised. 
From urethrogram studies it is obvious that the urethra can hold a volume of 
fluid. Therefore we performed intra-urethral instillations in our patient. Both courses 
of intra-urethral instillations were initially successful, as illustrated by negative cyto-
logy. After the second recurrence, however, we advised radical surgery. The 
localisation of the CIS in Cowper's glands was one argument. A second argument 
was the risk for progression. Catalona found that the risk of developing invasive 
cancer or metastasis in patients who had failed two courses of intravesical BCG 
(respectively 30% and 50%) exceeds the prospects of eradicating the superficial 
cancer with further BCG treatment [58]. 
We conclude that the (prostatic) urethra is an important localisation of TCC. The 
role of BCG in the treatment of urethral TCC is not well established, but certainly 
has to be kept in mind. We do not advise routinely use of BCG outside the bladder, 
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but in special cases it might be of use. 
Summary. 
A case report of a 60 year old man with carcinoma in situ of the urethra after 
previous successful radiotherapy of an invasive bladder tumor is presented. Intra-
urethral instillations with BCG were given. In spite of initial success, recurrences 
developed after two courses of 12 intra-urethral instillations, and radical surgery was 
performed. The use of BCG is reviewed regarding localisations of superficial TCC 
outside the bladder cavity. 
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Introduction. 
In patients with papillary superficial bladder cancer intravesical instillations have 
been used as prophylaxis to lower the high recurrence rate after complete 
transurethral resection (TUR) of a tumor. Both intravesical chemotherapy and 
intravesical immunotherapy have been used, and are superior to surgery alone in 
preventing tumor recurrence [1-3]. In patients with carcinoma in situ (CIS) complete 
TUR is difficult. In that case intravesical instillations are used "therapeutically". 
Intravesical chemotherapy in this study is done with Mitomycin-C (MMC) because 
of its proven efficacy with regard to prevention of tumor recurrence and high 
response rate in patients with CIS [1,4,5]. Bacillus Calmette-Guerin (BCG) is the 
only immunotherapeutic drug that is widely used for superficial bladder cancer. BCG 
therapy induces an inflammation which consists of immune competent cells reflecting 
both a humoral and cellular response. However, the exact mechanism of action of 
BCG remains unknown. In several studies (median follow up 12-48 months) 63-
100% of the patients treated with BCG for papillary tumors remained disease free 
[6]. BCG is also effective for the treatment of CIS with complete response rates 
(negative cystocopy, cytology and biopsies) of approximately 70% [5,7-9]. 
Only few studies have compared chemotherapy and immunotherapy in a 
randomised setting [7,10-13]. All studies show a higher efficacy of intravesical 
immunotherapy with BCG, although at the cost of more and more severe side 
effects. However, differences in study design (e.g. total BCG dose) and patient 
selection (e.g. recurrent versus non recurrent patients) make it difficult to interprete 
these data. The first study comparing BCG-RIVM with MMC, showed no 
statistically significant differences in both toxicity and efficacy [10]. A possible 
explanation for this lack of difference was the relative high number of pTaGl 
tumors, known to have a low recurrence rate, masking a possible difference for the 
high risk groups. Also the efficacy of BCG-RIVM was questioned. To compare 
toxicity and efficacy of intravesical chemotherapy to intravesical immunotherapy, and 
to compare BCG-RIVM to a BCG strain with proven efficacy (Tice), we carried out 
a prospective multicenter study in patients with superficial bladder cancer. 
Patients and methods. 
The objective of this randomised trial was to compare the toxicity and efficacy of 
intravesically administered MMC, BCG-Tice, and BCG-RIVM. From april 1987 until 
december 1990, 469 patients entered the study from 27 centres of the Dutch South 
East Cooperative Urological Group. All patients had histologically proven papillary 
pTa-pTl transitional cell carcinoma of the bladder, with or without concomitant CIS, 
or primary CIS. In case of a papillary lesion a complete TUR was performed. Every 
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area suspect for CIS was separately biopsied. In all cases selected biopsies of 
normal looking mucosa were taken to find concomitant abnormalities of the 
urothelium. Pretreatment studies included intravenous urogram, plain chest film, 
blood analysis, urine culture and cytology, and PPD skin reaction. Exclusion criteria 
for the study were: any previous local or systemic cancer therapy or radiotherapy; 
any second malignancy, except basal cell or squamous cell carcinoma of the skin; 
untreated urinary tract infections, severe infections or active or cured tuberculosis; 
blood urea or creatinine raised more than twice above the upper limit for the local 
laboratory; expected difficulties in the follow up period of at least 5 years. After 
approval of the medical ethical committee and written informed consent patients 
were randomised to receive one of the three treatment arms. 
All specimens of tumor and bladder biopsies were reviewed by a single 
pathologist for stage and grade. Pathological classification was done according to the 
TNM system [14], grading of the tumors according to Koss [15]. The maximal stage 
and grade of all tumor specimens reviewed were used to characterize each patient. 
Patients presenting with papillary tumors and (concomitant) CIS were classified 
according to the highest tumor stage, which is CIS, and subsequently analysed 
according to the response to CIS. 
Treatment: intravesical instillations were started between 7 and 15 days after 
complete TUR in case of a papillary lesion, or after biopsy in case of CIS. Patients 
with CIS were treated with a similar regimen as those with papillary tumors. After 
instillation the patient was instructed to refrain from voiding for at least one hour. 
Intravesical chemotherapy was done with 30 mg. MMC 'Kyowa' (Cristiaens), 
diluted in 50 ml. normal saline. MMC was given once a week for 4 weeks, and 
thereafter once a month for the next 5 months. In case of a recurrent superficial 
tumor or persistent CIS at 3 months the treatment schedule was not changed after a 
complete TUR (or biopsy). In case of a superficial recurrence or persistent CIS 
after 6 months, 3 additional monthly MMC instillations were given. 
Intravesical immunotherapy was done with BCG-Tice (Organon Teknika) or 
BCG-RIVM (the Dutch BCG strain, Lundbeck). The BCG dose was 5 χ 10" bacilli 
in a solution of 50 ml. of normal saline. BCG was given once a week for 6 
consecutive weeks. In case of the first superficial recurrence or persistent CIS at 3 
or 6 months, a second 6-week course with BCG instillations was given after 
complete TUR or biopsy. In all other cases of recurrences, irrespective of the 
treatment arm, the patient went off study (see above) and treatment was left to the 
consideration of the urologist. 
Side effects were divided in local, allergic, and systemic side effects. Local toxicity 
was defined as the occurrence of culture proven bacterial cystitis (not BCG related), 
drug induced cystitis (MMC or BCG related) or other local side effects, such as 
haematuria, prostatitis and epididymitis. The severity of side effects was classified in 
three categories: requiring no delay, requiring delay, or requiring cessation of 
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instillation therapy. Side effects were scored by using a symptom score, physical 
examination, blood and urine studies during instillations and every 3 months 
thereafter. In BCG treated patients PPD skin reaction was monitored. In all patients 
control cystoscopy studies were performed every three months during the first 2 
years of the study, every 4 months in the third and fourth year, and every 6 months 
thereafter. In case of the first recurrent tumor at or after 9 months of study, in case 
of recurrences both at 3 and 6 months, and in case of recurrent tumor with increase 
of pT category to pT2 or higher, the patient went off study. Progression was defined 
as an increase in pT category, or in case CIS developed after a pTa or pTl 
papillary tumor. A higher tumor grade (upgrading) was not considered progression. 
In case of papillary tumors the response was measured by the duration of the 
disease free interval (negative cystoscopy and cytology). In case of CIS, complete 
response was defined as negative cystoscopy, negative cytology, and negative 
biopsies. Partial response was not defined and not used as an objective in this study. 
Follow up data are analysed yearly. 
Statistica] considerations. 
In order to detect a difference of 50% in the median duration of the disease free 
interval between MMC and the best (smallest hazard Tate) of the BCG treatments 
(assuming the time to recurrence follows an exponential distribution), 90 eligible and 
évaluable patients followed until recurrence were required in each treatment arm 
(error probabilities alpha =.05 and beta =.20). Assuming that 65% of the patients 
will have at least one recurrence during the course of the study, 138 évaluable 
patients per treatment arm are needed, which means a total of 414 évaluable 
patients. For randomisation the restricted blockwise (blocksize 6=3 treatments χ 2 
pts/treatment) randomisation was used. Estimation of the cumulative distribution of 
the disease free interval was performed by the method of Kaplan-Meier for each of 
the three treatment groups and for subgroups. Differences in the distribution of the 
disease free interval were tested with the log-rank test. For testing of the difference 
between sample percentages the chisquare test was used. All statistical computations 
were done by using SAS procedures (Statistical Analysis System). 
Results. 
Of the 469 patients who entered the study, 156 patients were allocated to the MMC 
group, 154 to the BCG-Tice group, and 159 to the BCG-RIVM group. Seventeen 
patients (3.6%) were ineligible because of the following reasons: no malignancy after 
pathological review (n=9), >pTl after pathological review (n=6) and prior 
intravesical chemotherapy (n=2). Another 15 patients (3.2%) were excluded from 
subsequent analysis because of: first instillation more than 15 days after TUR 
(η=4); no instillations started due to haematuria (n=2), medication problems (n=2), 
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refusal (n=2), death (n=l), myocardial infarction (n=l), unknown (n=3). Analysis 
was done with the remaining 437 patients, with a median follow up after 
randomisation of 32 months (range 12-56). 
Patient characteristics, like age and sex ratio, and tumor stage and grade were 
equally distributed between the three treatment arms (table 1 and 2). 
Table I. Patients' characteristics and allocation to treatment. 
No. patients 
Excluded 
Evaluated 
Mean age (years) 
male/female 
MMC 
156 
8 
148 
65.5 
119/29 
Table 2. Tumor characteristics of 
Gl 
pTa G2 
G3 
pTl G2 
G3 
primary 
recurrent 
total papill. tumors 
CIS 
MMC 
(148) 
24 
55 
4 
31 
22 
104 
32 
136 
12 
BCG-Tice 
154 
14 
140 
65.9 
121/19 
evaluated patients t 
BCG-Tice 
(140) 
28 
48 
5 
18 
18 
87 
30 
117 
23 
BCG-RIVM 
159 
10 
149 
66.0 
129/20 
total 
469 
32 (6.8%) 
437 
65.8 
369/68 
ind allocations lo treatment 
BCG-RIVM 
(149) 
32 
54 
4 
23 
21 
108 
26 
134 
15 
total 
(437) 
84 
157 
13 
254 (65.6%) 
72 
61 
133 (34.4%) 
299 
88 
387 
50 
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Of the 437 patients 50 were found to have CIS, 254 patients had pTa tumors, and 
133 pTl tumors (table 2). Of the 84 patients with pTaGl tumors 39 (8.9% of all 
evaluated patients) had a primary solitary pTaGl, and 45 had recurrent and/or 
multiple pTaGl tumors. Of the patients with CIS, 12 received MMC, 23 received 
BCG-Tice and 15 BCG-RIVM. Twenty-five patients had pure flat multifocal CIS 
and 25 also had papillary tumors (concomitant CIS). Patients with pTa or pTl 
papillary tumors were treated with MMC in 136 cases, with BCG-Tice in 117 cases, 
and with BCG-RIVM in 134 cases respectively. 
A total of 197 patients (68x MMC, 60x Tice, 69x RIVM) went off study because 
of the following reasons: first recurrence at or after 9 months (89), protocol 
violation (34), progression in tumor stage to pT2 or higher (23), side effects (14), 
intercurrent death (10), further treatment refusal (7), lost to follow up (2), other 
(18). 
Side effects. 
The number and severity of side effects were comparable in patients with papillary 
tumors and CIS, therefore these groups were not separated. All side effects which 
were encountered during the instillation period (6 months for MMC, 6 weeks for 
BCG) are listed in table 3. Drug induced cystitis (26.5%) and bacterial cystitis 
(22.7%) were the most frequent side effects. Systemic and other local side effects 
were seen in 16.3% and 11.9% respectively. Thirteen allergic reactions (3.0%) were 
seen, more often and more severe in the MMC group. All other side effects were 
more frequent and more severe in the BCG groups. Between the BCG groups there 
was no statistical difference in number and severity of the side effects. For bacterial 
cystitis (p=0.20) and allergic reactions (p=0.30) the difference between the three 
treatment groups was not statistically significant. However, drug induced cystitis 
(p=0.009), other local side effects (p=0.004) and systemic side effects (p<0.001) 
were significantly more frequent in the BCG groups. A more detailed analysis of the 
systemic side effects is shown in table 4. 
Only 35 times (10.0% of all side effects) intravesical instillations were delayed, 
and in 11 patients (3.1% of all side effects, 2.5% of all patients) treatment had to 
be stopped due to the side effect. No haematological toxicity, such as 
myelosuppression in MMC treated patients, was noted. 
Three additional MMC instillations were given to 4 patients, a second course of 
BCG-Tice in 25 patients, BCG-RIVM in 24 patients. The number and severity of 
side effects did not increase during this second course. In this trial no treatment 
related deaths were recorded. 
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Table 3. Side effects during instillation period. 
bacterial cystitis (p= 
no 
yes, without delay 
yes, with delay 
stop treatment 
total yes 
MMC 
(n=148) 
.20) 
121 
25 
1 
1 
27=18.2% 
drug induced cystitis (p=.009) 
no 
yes, without delay 
yes, with delay 
stop treatment 
total yes 
allergic reaction (p= 
no 
yes, without delay 
yes, with delay 
stop treatment 
total yes 
122 
25 
1 
-
26=17.6% 
=30) 
141 
4 
1 
2 
7=4.7% 
other local side effects (p=.0O4) 
no 
yes, without delay 
yes, with delay 
total yes 
systemic side effects 
no 
yes, without delay 
yes, with delay 
stop treatment 
total yes 
141 
7 
• 
7=4.7% 
(p<.001) 
142 
6 
-
-
6=4.1% 
BCG-Tice 
(n=140) 
102 
26 
11 
1 
38=27.1% 
98 
40 
1 
1 
42=30.0% 
137 
2 
1 
-
3=2.1% 
117 
23 
-
23=16.4% 
102 
32 
3 
3 
38=27.1% 
BCG-RIVM 
(n=149) 
115 
24 
10 
-
34=22.8% 
101 
45 
2 
1 
48=32.2% 
146 
2 
1 
-
3=2.0% 
127 
20 
2 
22=14.8% 
122 
24 
1 
2 
27=18.1% 
total 
(n=437) 
338 
75 
22 
2 
99=22.7% 
321 
110 
4 
2 
116=26.5% 
424 
8 
3 
2 
13=3.0% 
385 
50 
2 
52=11.9% 
366 
62 
4 
5 
71 = 16.3% 
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Table 4. Detailed analysis of systemic side effects. 
fever < 38,5 °C 
fever > 38,5 "C 
flu like symptoms 
nausea 
general malaise 
skin symptoms 
arthralgia 
pneumonia 
sepsis 
other 
MMC 
-
-
1 
-
2 
1 
-
-
-
2 
BCG-Tice 
7 
2 
11 
2 
10 
-
1 
-
1 
4 
BCG-RIVM 
4 
1 
4 
1 
5 
-
1 
1 
-
10 
total 
11 
3 
16 
3 
17 
1 
2 
1 
1 
16 
total 6 38 27 71 
Efficacy of treatment 
In the group of 50 patients with CIS the complete response rate in the MMC group 
was 42% (5/12), in the Tice group 70% (16/23), and in the RIVM group 47% 
(7/15). These results were not significantly different (p=0.20), but numbers are 
small! Of all CIS patients 28 had a complete response (56%). 
In case of pTa/pTl tumors 39 of 136 patients (28.7%) treated with MMC 
experienced a recurrent tumor, 50 of 117 (42.7%) in the BCG-Tice group, and 45 of 
134 (33.6%) in the BCG-RIVM group. In total 134 of 387 patients (34.6%) 
experienced a recurrence during the follow up period. The disease free percentage 
in each treatment arm after 1 and 2 years is shown in table 5. 
In patients with grade 3 tumors the efficacy of MMC was borderline significantly 
higher compared with BCG treated patients (p=0.05). In the MMC group 11 
patients had a recurrence at 3 months and 4 patients at 6 months. The latter 4 
patiente received additionally 3 monthly instillations of MMC. Of the patients 
treated with BCG-Tice, 17 showed a recurrence at 3 months and 5 at 6 months, 
respectively. The numbers for BCG-RIVM are 18 at 3 months and 4 at 6 months 
respectively. All recurrent BCG patients received a second course of 6 instillations. 
Treatment efficacy in patients who received additional instillations was not different 
from those without recurrent tumors. 
Progression in stage to pT2 or higher was observed in 8 (5.4%) patients of the 
MMC group, in 7 (5.0%) patients of the BCG-Tice group, and in 8 (5.4%) patients 
of the BCG-RIVM group. 
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Table 5. Treatment efficacy (percentage disease free with standard error). 
AD papillary tumors 
1 year 
2 years 
MMC 
(n=136) 
76% +/- 4% 
65% +/- 5% 
BCG-Tice 
(n-117) 
68% +/- 4% 
54% +/- 5% 
BCG-RIVM 
(n=134) 
69% +/- 4% 
62% +/- 5% 
grade 3 papillary tumors 
1 year 
2 years 
MMC BCG-Tice BCG-RIVM 
(n=26) (n=23) (n=25) 
79% +/- 8% 55% +/- 11% 64% +/- 10% 
(*) 46% +/- 13% 50% +/- 12% 
(*) no failure after 2 years yet. 
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Figure L: Kaplan-Meier plots of the percentage of patients with pTa and pTl, grade 1-3 
papillary tumors, free of tumor after TUR and treatment with MMC (dashed line), 
BCG-Tice (solid line) and BCG-RIVM (dotted line). Log-rank test: p=0.0& 
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No statistically significant difference is observed in the Kaplan-Meier plots (disease 
free percentage) between the three treatment arms (figure 1, p=0.08). 
Discussion. 
This is the first randomised study in which efficacy and adverse effects of 
intravesical instillations with a chemotherapeutic agent and two different BCG 
strains are compared. In most reports intravesical BCG has been found more toxic 
than intravesical chemotherapy for superficial bladder cancer [8]. Severe systemic 
complications and even fatal sepsis have been described. The first reports also 
indicated a high percentage (up to 90%) of BCG induced cystitis and other local 
and systemic side effects [16,17]. However, more recent reports, including the 
present study, indicate that BCG induced cystitis is observed less frequently [11]. 
This can be explained by the fact that severity of local and systemic side effects may 
be judged differently by different investigators. Some urologists will stop instillations 
in case of more or less severe drug induced cystitis or fever, while others believe 
that BCG only works if at least irritative symptoms appear and they will not 
consider these as side effects [18]. Consensus should be reached how to define local 
and systemic toxicity in BCG therapy and how to treat it [11]. Severe local and 
systemic side effects, apart from one case of BCG pneumonitis, were not observed 
in the present study. There was no difference with regard to adverse effects between 
the two investigated BCG strains. However, BCG induced more side effects than 
MMC, both locally and systemically. The exception is culture proven bacterial cystitis 
(not BCG induced). This varies between 18% and 27% in the different groups, 
which indicates that intravesical instillations as such may induce urinary tract 
infection in a considerable number of patients. 
Efficacy results should be interpreted with caution because we have not yet 
reached the median duration of the disease free interval in either of the three 
treatment arms after a median follow up of 32 months. Comparing a 6 week BCG 
schedule to 6 months MMC therapy, however, this interim analysis does not provide 
evidence that BCG offers a better response in the treatment of CIS than MMC 
(p=0.20), although the numbers are small. In the prevention of recurrences after 
complete TUR of papillary tumors BCG is also not superior to MMC (p=0.08). 
The efficacy of MMC in grade 3 tumors is even borderline significantly higher 
(p=0.05). The results in the present study confirm those of a previous reported trial 
in which BCG-RIVM was compared with MMC [10]. Could this difference with 
other studies have been caused by patient selection? In this study 84 patients with 
pTaGl tumors have been treated. Patients with low stage, low grade tumors have a 
low risk for recurrence or progression if the tumor is solitary and primary. However, 
the recurrence rate increases from .17 to .32 if patients present with multiple 
primary pTaGl tumors, or even to .61 if a patient has multiple recurrent pTaGl 
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tumors [19]. Only 39 (8.9%) had solitary primary pTaGl tumors. This indicates that 
91.1% of the patients may have had at least potential benefit of adjuvant 
intravesical therapy after TUR. 
Although intravesical chemotherapy delays the time to first recurrence, it 
probably does not influence progression and survival [20]. For BCG therapy this 
seems to be different, especially when maintenance BCG is used. In case of 
maintenance therapy additional BCG instillations are given after the initial 6-week 
course, for example monthly and/or 3-monthly instillations during 1 or 2 years. 
Several recent studies suggested that maintenance BCG alters prognosis and 
improves survival in stead of simply delaying recurrences [21-23]. During 
maintenance BCG therapy, however, side effects can be more pronounced than 
during one or two 6-week courses. This underlines the importance of the toxicity of 
BCG. The question remains for which selected patients maintenance BCG is 
indicated, because it is obvious that a 6-week course is suboptimal for some 
patients. 
In conclusion, the results of this prospective randomised multicenter study show 
that overall toxicity of intravesical instillations is acceptable. MMC produces 
significantly less drug induced cystitis, other local side effects, and systemic side 
effects than BCG. There is no difference in side effects nor efficacy between BCG-
Tice and BCG-RIVM. Also this study confirms the earlier study that intravesical 
instillations with MMC (4 weekly instillations, followed by 5 monthly instillations) is 
as effective as BCG-RIVM (one or two courses of 6 intravesical instillations) with 
regard to the recurrence rate in patients with pTa/pTl papillary tumors [10]. In a 
subgroup of patients with grade 3 tumors MMC had a borderline significant higher 
efficacy. The absence of an advantage for BCG in CIS patients might be explained 
by small numbers of patients in these groups. 
Summary. 
In a prospective randomised multicenter study we compared intravesical instillations 
with Mitomycin-C (MMC), Bacillus Calmette-Guerin (BCG) Tice, and BCG-RIVM 
in patients with pTa-pTl papillary carcinoma and primary carcinoma in situ of the 
urinary bladder. After complete transurethral resection of all visible tumors 9 
instillations with 30 mg. MMC were given (4 weekly, 5 monthly), or 6 weekly 
instillations with 5 χ 10е colony forming units BCG-Tice or BCG-RIVM. In case of 
an early recurrence 3 additional instillations were given in the MMC group, or a 
second course of 6 weekly instillations in the BCG groups. A total of 437 patients 
are evaluated for toxicity and efficacy with a median follow up of 32 months (12-
56). 
Drug induced (or chemical) cystitis was observed in 26 (17.6%) of 148 patients 
treated with MMC, in 42 (30.0%) of 140 patients treated with BCG-Tice and in 48 
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(32.2%) of 149 patients treated with BCG-RIVM respectively. Bacterial cystitis 
occurred in 18.2% (MMC), 27,1% (Tice) and 22.8% (RIVM) respectively. Other 
local side effects (haematuria, prostatitis and epididymitis) were observed in 4.7% 
(MMC), 16.4% (Tice) and 14.8% (RIVM). Systemic side effects were observed in 
4.1% (MMC), 27.1% (Tice), and 18.1% (RIVM). Allergic reactions in 4.7% (MMQ, 
2.1% (Tice) and 2.0% (RIVM). Number and severity of side effects, tested with the 
chisquare test, were comparable in both BCG groups, but significantly less in the 
MMC group for drug induced cystitis (p=0.009), other local side effects (p=0.004) 
and systemic side effects (p<0.001). No haematological side effects were observed. 
The overall disease free percentage, tested with the log rank test, showed no 
significant difference for the 3 arms for papillary tumors (p=0.08). For carcinoma in 
situ efficacy is also comparable (p=0.20), but numbers are small. Additional MMC 
or BCG instillations did not give excessive toxicity, nor did they improve the 
efficacy. 
We conclude that 6 months of intravesical chemotherapy with MMC causes 
significantly less side effects than 6 weeks immunotherapy with BCG-Tice or BCG-
RIVM. Toxicity and efficacy of both BCG strains are comparable. MMC results in 
an equally effective treatment compared to each of the BCG strains. 
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Introduction. 
The use of Bacillus Calmette-Guerin (BCG) for the treatment of superficial bladder 
cancer was introduced by Morales et al. in 1976 [1]. The initial protocol was a 
course of 6 weekly intravesical and intradermal instillations. Complete response was 
achieved in 50% of the patients using BCG as prophylactic therapy, in 58% of 
patients with residual disease, and in 77% of patients with carcinoma in situ (CIS), 
respectively [2]. 
The total dose of BCG that should be administered, however, remained a 
controversial point for several years. One 6-week course of BCG instillations might 
not be sufficient for some patients, such as high risk patients, or patients relapsing 
shortly after the first course. Especially since BCG seems to alter prognosis instead 
of simply delaying recurrences [3], the issue of the optimal BCG treatment is of 
interest. Concerning treatment after the initial 6-week course, two different schemes 
have been reported, namely maintenance therapy or repeated 6-week courses. In 
1982 Brosman advocated maintenance therapy [4]. The success rate was nearly 
100%, however, at the cost of an increased number of side effects. Several other 
investigators using maintenance treatment found conflicting results with regard to 
efficacy. Toxicity was in most studies significantly higher compared to that of a 
single 6-week course. The second possibility for additional treatment after one 6-
week induction course is repeating one or more 6-week courses of BCG. This 
should be more effective than one course, however, with probably less toxicity than 
maintenance therapy. Another controversial item has been the necessity of 
combination of intravesical BCG with intradermal BCG. Intradermal application of 
BCG has been considered to stimulate the immune response of the patient. At this 
moment, however, intravesical BCG alone is accepted to be the best route of 
administration. 
We carried out a randomized phase 2 study to investigate BCG maintenance 
therapy with or without adjuvant intradermal inoculations of BCG in patients with 
recurrent superficial bladder cancer failing intravesical chemotherapy. Objectives of 
the study were toxicity and efficacy (percentage of recurrent tumors and rate of 
tumor progression). 
Patients and methods. 
The selection criteria of the study were: histologically proven transitional cell 
carcinoma of the bladder, pTa gr I/III and/or CIS; at least 2 recurrences in the last 
5 years despite intravesical chemotherapy; no prior intravesical immunotherapy; no 
prior radiotherapy; complete transurethral resection (TUR) before start of BCG; 
BCG treatment within 3 weeks after TUR. The Dutch BCG strain was used (BCG-
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RIVM, RIVM, Bilthoven, the Netherlands), containing 1 χ 10" viable units in 10.5 
mg. dry weight BCG. BCG was suspended in SO ml. of saline, and instilled for 1 
hour. For intradermal BCG inoculations also BCG-RIVM was used. 7 χ 10' viable 
units in 0.54 mg. dry weight BCG were injected intradermally the skin with a 
multipuncture instrument (4 χ 20 needles, 2 mm deep). Intravesical instillations were 
given according to the first year of the protocol of Brosroan [4]: 6 weekly 
instillations, 6 biweekly instillations and 8 monthly instillations for a total of 20 
instillations in 1 year. Patients were randomized to receive 6 intradermal BCG 
inoculations together with the first 6 intravesical instillations. Extensive investigations, 
including PPD skin reaction and laboratory investigations were performed. 
Urethrocystoscopy (UCS) was done before treatment, on week 7, and thereafter 
every 3 months for 2 years. PPD skin reaction conversion was defined as an 
induration >10 mm. Side effects were recorded as: bacterial cystitis (not BCG 
related); drug-induced cystitis; systemic reactions (such as fever, malaise, headache 
and arthralgia); allergic reactions; and other side effects (such as haematuria and 
abdominal discomfort). In case of a recurrence (histologically proven, same pT 
stage) during treatment the BCG schedule remained the same, although a period of 
10-20 days was mandatory between (complete) TUR and the next instillation. In 
case of progression in pT stage, or a recurrence after completion of the BCG 
scheme the patient went off study. 
Allocation of patients to adjuvant intradermal BCG inoculations was done after 
restricted blockwise (blocksize 2*5 = 10 patients) randomisation. Comparison of both 
groups, with and without intradermal BCG, with respect to the frequency of side 
effects was done with Fisher's exact test. Efficacy was judged by the percentage of 
patients with recurrent tumors, the recurrence rate and the rate of tumor 
progression. 
Results. 
Between june 1986 and june 1989 49 patients were randomized in the study. Mean 
follow up is 41 months (0.5-65). Twenty-five patients received intravesical and 6 
intradermal inoculations (group I), and 24 received only intravesical instillations 
(group II). The results of the tumor histology, tumor multiplicity, and tumor size are 
listed in table 1. Of the pTaGI tumors only 4 were solitary. All 3 patients with CIS 
had twice a superficial tumor in the last 5 years. 
Follow up data are available until march 1992. Sixteen patients did not complete 
the course of 20 instillations in the first year because of side effects (n=10), death 
(n=2), patient refusal (n=2), protocol violation (n=l) and unknown (n=l). In 
group 1, 18 patients completed the BCG therapy, in group 2, 15 patients. 
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Table 1.: Timor characteristics of ой 49 patients. 
Histology Patient number Number of papillary tumors 
CIS 
pTaGI 
pTaGII 
pTaGIII 
3 
24 
21 
1 
solitary 
2-4 tumors 
5-10 tumors 
>10 tumors 
9 
15 
13 
9 
Side effects. 
All patients were evaluated for toxicity. Side effects are listed in table 2. Drug-
induced cystitis was the most frequent encountered side effect, and was seen in 29 
of 49 patients (59%). Although drug-induced cystitis was more frequent in the group 
with intradermal inoculations (72% versus 46%), the difference between the two 
treatment groups was not statistically significant (p=.12). Numbers of patients, 
however, were small. The frequency of bacterial cystitis (12-17%), systemic reactions 
(33-52%), allergic reactions (0-8%) and other side effects (20-21%) were 
comparable in both groups. In 7 patients of both groups (29%) treatment had to be 
stopped due to the side effects (table 2). We did not observe an increasing toxicity 
with an increasing number of instillations. All side effects were transitory, and 
disappeared after stopping BCG therapy. 
Response. 
Forty-two patients are évaluable for response. Seven patients were lost to follow up 
due to intercurrent death (n=2, group 2, not bladder cancer related) or toxicity 
(n=3 in group 2, n=2 in group 1). Median follow up of the évaluable patients was 
43 months for group 1, and 44 months for group 2. Of these 42 patients 14 (33%) 
had a recurrent tumor in the first 2 years of the study (n=9 in group 1, n=5 in 
group 2, p=.58). In both groups 2 patients showed 2 recurrences during this period, 
and 1 patient showed 3 recurrences. In the period after these 2 years in both groups 
7 patients experienced a recurrence after a median period of 37.5 months in group 
1 (25-49) and 35 months in group 2 (26-54). Of the 42 évaluable patients 18 (43%) 
remained free of recurrences (8 in group 1, 10 in group 2) with a median follow up 
of 47 months (18-65). Only 2 patients showed tumor progression from pTa to pTl, 
both in group 1, both in the first year of treatment. One patient (group 1) had a 
muscle invasive bladder tumor in the second year, and died of metastatic disease 
after 47 months. Four other patients died after a median period of 47 months (41-
54) without recurrent bladder cancer. 
Presence or absence of PPD skin reaction conversion had no relation with tumor 
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recurrences. 
Table 2* Overall taxicity of BCG in group I (with intradermal inoculations) and group 
II (intravesical instillations only). 
Group: 
drug-induced cystitis 
p=.12 
bacterial cystitis 
p=.95 
systemic reactions 
p=.30 
total (n=49) 
total 29 (59%) 
no delay 17 
treatment delay 9 
treatment stop 3 
total 7 (14%) 
no delay 3 
treatment delay 2 
treatment stop 2 
total 21 (43%) 
no delay 12 
treatment delay 3 
treatment stop 6 
I (n=25) 
18 (72%) 
11 
4 
3 
3 (12%) 
2 
1 
13 (52%) 
8 
2 
3 
II (n=24) 
11 (46%) 
6 
5 
4 (17%) 
1 
2 
1 
8 (33%) 
4 
1 
3 
allergic reactions 
p=.47 
treatment stop 2 (4%) 2 (8%) 
others total 10 (20%) 5 (20%) 5 (21%) 
p=1.0 no delay 9 5 4 
treatment stop 1 - 1 
Discussion. 
When superficial transitional cell cancer of the bladder is treated with a TUR alone, 
the recurrence rate is 60% to 70% within the first 3 years. Recurrences usually 
appear in the first years. With intravesical instillations of BCG the recurrence rates 
can be decreased significantly [5]. The optimal treatment, however, still has been 
subject of debate. The total dose of BCG and the need for intradermal inoculations 
were unknown at the time we started the study. In case of persistent or recurrent 
tumor the need for additional treatment seems obvious. However, also in case of 
complete response additional treatment might be of value, for example in patients 
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with a high risk of developing new recurrences. Additional BCG treatment may exist 
of a second 6-week course or maintenance therapy. With a second 6-week course 
complete response rates could be improved from approximately 60% after one 
course to approximately 80% after the second course, without the increasing 
reported toxicity of maintenance therapy [6-8]. A second course seemed most useful 
in patients who had a long term response after the initial course [9]. 
Maintenance BCG therapy was addressed by Brosman in 1982 [4]. He treated a 
group of 61 patients with recurrent superficial bladder cancer with BCG-Tice or 
thiotepa. After a 6-week course the drugs were given biweekly for 3 months, and 
monthly thereafter until recurrence or a maximum of 2 years. There were no 
recurrences in the BCG group (39 patients) in contrast to 9 out of 22 patients 
(40%) in the thiotepa group. Side effects in the BCG group were markedly worse 
than in the thiotepa group. All patients treated with BCG had bladder irritability 
and most patients experienced malaise with fever. Eleven patients (28%) suffered 
from severe side effects for which treatment had to be stopped. This severe toxicity 
developed at various times throughout the treatment period. In the thiotepa group 7 
patients had minor irritative bladder symptoms. Brosman concluded that BCG could 
be beneficial, but that toxicity was of major concern. Using practically the same 
protocol, Brosman treated 33 CIS patients [10]. Thirty-one patients (94%) were 
rendered free of disease. The 2 failing patients were 2 out of 6 patients who did not 
complete the initial 12-week induction phase because of adverse reactions. Again, 
most patients experienced side effects, although usually mild. Severity increased with 
the number of instillations. Two other nonrandomized studies suggested an increased 
efficacy of maintenance therapy [11,12]. In both studies side effects were frequent, 
and severe in approximately 20% of the patients [12]. Only Sarosdy and Lamm 
found a low toxicity and a high success rate with maintenance therapy in a small 
group of patients failing the initial 6-week course [13]. Martinez-Pineiro et al. 
compared maintenance therapy (4 weekly and 11 monthly instillations) with BCG, 
doxorubicin and thiotepa [14]. The recurrence rate of the 67 BCG treated patients 
was significantly lower (13.4%), but toxicity was higher, although not limiting. 
Badalament et al. reported a prospective randomized trial comparing 
maintenance versus nonmaintenance BCG therapy in patients with recurrent 
superficial bladder cancer [15]. Forty-six patients received a 6-week course of 
intravesical BCG instillations, 47 patients received additional monthly BCG for two 
years. Significant reduction of tumors per patient-month were found in both groups 
(P<.00001) when compared to the period before the BCG treatment. Both regimens 
were equally effective (p=.77), after a median follow up of 22 months. In the 
maintenance group side effects were frequent, requiring discontinuation of therapy 
in 21 of 47 patients (45%). Side effects in general were more frequent with an 
increasing number of treatments. PPD reactivity patterns added significantly to the 
prediction of recurrence. Hudson et. al. also carried out a prospective randomized 
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trial to compare single course versus maintenance BCG therapy in patients 
responding to an initial 6-week course [16]. No difference in efficacy was found. 
They concluded that their results provided stronger statistical evidence against 
maintenance therapy than other studies [10,11], but they did not exclude the 
possible value of maintenance therapy for selected patient groups. Herr also found 
no advantage of maintenance therapy in patients with recurrent superficial bladder 
cancer over a 6-week course with or without intradermal BCG [17]. 
The present study confirms the toxicity of maintenance intravesical BCG therapy 
reported in the literature. Drug-induced cystitis (59%) and systemic reactions (43%) 
were the most frequent side effects. In 14 patients (29%) treatment had to be 
stopped due to side effects. However, all side effects disappeared after stopping 
BCG therapy. We could not confirm increasing toxicity with an increasing number of 
instillations. All patients had at least 2 recurrences in the 5 years before the study in 
spite of intravesical chemotherapy. For this selected group of patients the results of 
this study suggest a beneficial effect of maintenance BCG. Several results regarding 
recurrence rates and toxicity of the studies mentioned above are summarized in 
table 3. 
Table 3: Results and toxicity of several reports dealing with maintenance therapy. 
study patient high id1 ree. follow irr. malaise severe' 
number risk rate4 up3 blad.4 fever 
[4] 
[10] 
[И] 
[12] 
[13] 
[14] 
[15] 
[16] 
present 49 
study 
39 
31 
23 
63 
10 
67 
47 
21 
yes 
yes 
yes 
yes 
yes 
no 
yes 
no 
yes 
no 
no 
yes 
no 
yes 
no 
no 
no 
yes/no 
0% 
6% 
9% 
43% 
10% 
13% 
-
29% 
33% 
57% 
>24 
50 
30 
14.5 
64 
36 
22 
17.2 
24 
47 
all 
all 
-
88% 
50% 
most 
-
-
15% 
10% 
-42%— 
90% 
43% 
59% 
43% 
10% 
43% 
28%(-) 
19%(+) 
-
30%(+) 
0% 
1.4%(+) 
45%(+) 
10%(+) 
29%(+) 
1) with or without intradermal inoculations 
2) recurrence rate 
3) mean follow up in months 
4) irritative bladder symptoms 
5) severe side effects with (+) or without (-) necessity to stop treatment. 
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An important issue is the question whether BCG alters the final prognosis of 
patients with superficial bladder cancer. Both intravesical chemotherapy and 
immunotherapy can lower the recurrence rate. Chemotherapy, however, does not 
seem to influence disease progression. BCG might do so, as suggested by Herr et al. 
[3,18]. In both studies nonmaintenance BCG was used. Lamm et al. also suggested 
an improved survival in patients treated with maintenance therapy after response on 
the initial 6-week course [19]. The results of these studies, however, should be 
interpreted with care, and they are preliminary. Despite maintenance therapy, 
recurrences and progression do occur, even after a durable response of years. 
Therefore, close follow up remains necessary. 
As reported by others we found no additional value of intradermal inoculations 
[4,15,20]. However, specially for side effects, this may be due to the small numbers 
of patients in both groups. In some studies conversion of the PPD test seems to 
indicate a better response to therapy [6,11,21,22], although the significance of this 
test is borderline. It should not be used as a prognostic marker in individual patients 
[22]. In the present study PPD skin reaction conversion had no correlation with 
tumor recurrences, although our number of patients is limited. 
We conclude that maintenance BCG therapy can be useful in case of high risk 
patients, such as recurrences after prior intravesical therapy and CIS. Side effects 
are frequent, but transitory. The risk of tumor progression is low in this group of 
patients. Intradermal inoculations seem of no additional value. 
Summary. 
To study maintenance Bacillus Calmette-Guerin (BCG) therapy we treated 49 
patients with recurrent superficial bladder cancer pTa and/or carcinoma in situ, 
failing previous intravesical chemotherapy. They received 20 intravesical instillations 
in 1 year, with or without 6 intradermal inoculations. Side effects were frequent, 
causing treatment stop in 14 patients (29%). Drug-induced cystitis was the most 
frequent side effect, seen in 29 patients (59%). Forty-two patients were évaluable 
for response. During the first 2 years of the study 14 patients (33%) had one (n=8) 
or more (n=6) recurrences. A total of 18 patients (43%) remained recurrence free 
with a median follow up of 47 months. Progression was seen in 2 patients from pTa 
to pTl, another patient died of metastatic bladder cancer after 47 months. PPD skin 
test conversion was of no prognostic value. The use of intradermal inoculations 
caused no significant increase of toxicity and had no effect on efficacy, however, 
both groups were small. It caused no local side effects. We conclude that 
maintenance BCG therapy can be useful for patients with recurrent superficial 
bladder cancer failing previous intravesical chemotherapy. 
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Introduction. 
Since the introduction in 1976 Bacillus Calmette-Guerin (BCG) has proven its efficacy 
in the treatment and prophylaxis of superficial bladder cancer in many clinical trials [1-
6]. However, how BCG exerts its antitumor activity is not yet known. The immune 
system is involved in the action of BCG. Τ lymphocytes, especially T-helper cells, 
appear to be critical for antitumor response [7]. Athymic (nude) mice bearing the 
MBT2 bladder tumor, for example, fail to respond to BCG therapy, whereas the 
administration of syngeneic Τ lymphocytes restores antitumor activity [8]. The 
involvement of the immune system is also demonstrated by the increasing urinary 
concentration of several cytokines shortly after intravesical instillations with BCG [9,10] 
and the presence of lymphoid cellular infiltrates in the bladder wall after BCG therapy 
[11]. Not much has been published about the influence of concomitant medication on 
the efficacy of BCG. The role of antibiotics is controversial. Sparks indicated that 
antituberculous drugs do not seem to interfere with the antitumor effect of BCG in 
animal studies [12]. We showed, however, that there is a possible inhibition of 
antitumor efficacy by antibiotics in general, and tuberculostatic agents in particular [13]. 
In a recent study, Hudson et al. addressed the possible role of fibrin clot inhibitors on 
the efficacy of BCG [14]. A number of patients treated with BCG also use anticlotting 
drugs because of cardiovascular disease. An adverse effect on the results of intravesical 
BCG therapy for superficial bladder tumors was found. The rationale for this was their 
observation that BCG attachment to fibronectin (FN) seemed to be an important first 
step for the development of an immune response and antitumor activity [15]. The 
attachment to FN could be decreased by fibrin clot inhibitors [14]. We studied the 
influence of fibrin clot inhibitors in a study on superficial bladder cancer, in which two 
different strains of BCG (Tice and RIVM) were compared to each other and to 
intravesical chemotherapy with mitomycin-C (MMC) [16]. In a subset of the BCG 
treated patients, we investigated the influence of fibrin clot inhibitors on the efficacy 
of BCG therapy. 
Patients and methods. 
From april 1987 until december 1991, 469 patients entered a randomized prospective 
multicenter study of the Dutch South East Cooperative Urological Group. After 
randomization 156 patients were allocated to the MMC group, 154 to the BCG-Tice 
group, and 159 to the BCG-RIVM group. In 183 patients treated with BCG, the effect 
of fibrin clot inhibitors was studied. All possible drugs with known inhibitory effect on 
clot formation were included in this study. All patients had primary or recurrent 
papillary pTa-pTl transitional cell carcinoma of the bladder, with or without 
concomitant carcinoma in situ (CIS), or primary CIS. In case of a papillary lesion, a 
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complete transurethral resection (TUR) was performed, and selected mucosal biopsies 
were taken. Intravesical instillations with BCG-Tice (Organon Teknika) or BCG-RIVM 
(the Dutch BCG strain, Lundbeck) were started between 7 and 15 days after TUR. 
The BCG dose was 5 χ 10e bacilli in a solution of 50 ml. of normal saline. BCG was 
given once a week for 6 consecutive weeks. Adverse effects were registered and divided 
in local side effects, allergic reactions and systemic side effects. Local side effects were 
bacterial cystitis (not BCG related), drug induced cystitis or other local side effects. In 
all patients, control cystoscopy and cytology studies were performed every 3 months for 
the period of the study. In case of papillary tumors, the response was measured by the 
duration of the disease free interval. In case of CIS, complete response was defined as 
negative cystoscopy, negative cytology and negative biopsies. Estimation of the 
cumulative distribution of the disease free interval was done by the Kaplan-Meier 
method for each of the treatment groups. Differences in the distribution of the disease 
free interval were tested with the log-rank test. 
Results. 
Of the 183 patients studied, 93 were treated with BCG-Tice, and 90 with BCG-RIVM. 
42 patients used fibrin clot inhibitors (group 1), and 141 patients did not (group 2). 
The fibrin clot inhibitors that were used were warfarin, aspirin, dipyridamole, 
indomethacin, naproxen and Ibuprofen (table 1). Aspirin (18) and warfarin (15) were 
used most frequently. 
Table 1. Fibrin clot inhibitors used by the 42 patients. 
Aspirin 14 Ibuprofen 3 
Aspirin plus dipyridamole 4 Indomethacin 2 
Coumarin 15 Naproxen 1 
Diclofenac 4 
All other concomitant medications are listed in table 2. 
In group 1, pTa tumors were found in 25 patients (60%), pTl tumors in 13 (31%), and 
CIS in 4 (9%). In group 2, these numbers were 90 pTa tumors (64%), 35 pTl tumors 
(25%) and 16 CIS patients (11%), respectively. Because the percentage of CIS patients 
is rather small and the same in both groups, we analyzed papillary tumors and CIS as 
one group. Of the 42 patients which used fibrin clot inhibitors, 25 were treated with 
BCG-Tice, and 17 with BCG-RIVM. We have shown that the two BCG strains are 
equally effective and have the same number and severity of local and systemic side 
effects [16]. Also, both BCG treatment groups were equally effected by fibrin clot 
140 Chapter 11 
inhibitors (p=0.92), therefore no distinction was made between BCG-Tice and BCG-
RIVM. The mean follow up in group 1 was 22.5 months (range 4.4-49.5), and in group 
2 it was 20.8 months (range 2.6-53.2). In group 1 a second cycle of BCG was given in 
6 patients (14%), in group 2 in 24 patients (17%). Side effects are listed in table 3. In 
both groups, numbers and severity of side effects were equal, except for bacterial 
cystitis, which was more pronounced in group 1 (p=0.002). In general BCG, intravesical 
therapy was very well tolerated. 
Table 3. Number and seventy (requiring no delay, delay or cessation of instillations) of side 
effects. 
group 1 (n=42) group 2 (n=141) 
bacterial cystitis 
(p=.002) 
drug induced cvstitis 
(p=.42) 
allergic reaction 
(p=.26) 
other local side effects 
(p=.83) 
svstemic side effects 
(p=.55) 
no 
yes, without delay 
yes, with delay 
stop treatment 
no 
yes, without delay 
stop treatment 
no 
yes, without delay 
no 
yes, without delay 
yes, with delay 
no 
yes, without delay 
yes, with delay 
stop treatment 
24 (57%) 
10 
7 
1 
30 (71%) 
12 
40 (95%) 
2 
33 (79%) 
9 
29 (69%) 
10 
1 
2 
115 (82%) 
20 
6 
89 (63%) 
51 
1 
140 (99%) 
1 
115 (82%) 
25 
1 
106 (75%) 
33 
1 
1 
In group 1, recurrent tumors were seen in 13 patients (31%), in group 2 in 56 patients 
(40%). The mean time to the first recurrence was 9.7 months in group 1 (range 2.9-
20.4), and 9.4 months in group 2 (range 2.4-43.4). These differences were not 
statistically significant (p=0.28). Kaplan-Meier curves are shown in figure 1. The use 
of antibiotics was significantly different in both groups (18/42 in group 1, 26/141 in 
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group 2). Antibiotics, however, had no influence on treatment efficacy in a multivariate 
analysis (p=0.85). 
Table 2 Other concomitant medication. 
Antibiotics 
Antihypertensive (including b-Blockers, 
diuretics, calcium channel blockers) 
Respiratory 
Sedatives 
Antiarrhythmic 
Paracetamol 
Others (used by 1 patient each) 
group 1. 
(n= 
18 
17 
2 
1 
3 
-
5 
=42) 
group 2. 
(n=141) 
26 
24 
3 
4 
2 
3 
5 
9 0 
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Figure 1.: Kaphm-Mder plots of the percentage free of disease for patients treated with 
( ) and without ( ) fibrin clot inhibitors. Log-rank test: p=0.2& 
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Discussion. 
Although BCG has proven efficacy, the mechanisms of its antitumor activity remain 
unclear. BCG therapy exerts nonimmunologic responses (inflammation), nonspecific 
immunologic responses and specific immunologic responses (humoral and cellular). In 
the cellular immune system, В and Τ lymphocytes, macrophages, killer cells and natural 
killer cells are affected [17]. 
Ratliff found that BCG attachment to FN was an important first step for the 
development of an immune response and antitumor activity [15]. FN is a glycoprotein 
of the extracellular matrix, which is involved in mechanisms that direct cells to their 
final destination during embryogenesis, inflammation and wound healing [18]. FN 
constitutes 4-5% of the blood clot formed at the initial site of an injury. FN has 
multiple binding sites, which have been identified biochemically for eukaryotic cells, 
bacteria and proteins such as collagen and fibrin. In the normal human bladder 
mucosa, FN is only present in the basement membrane and the submucosa [19]. This 
might explain why damage to the urothelium and clot formation is necessary for BCG 
to attach to the urothelium. BCG attachment to damaged urothelium is 200 fold more 
than to intact urothelium, and this attachment is inhibited more than 95% by antibodies 
specific for FN [19]. In mice, Ratliff et al. demonstrated that BCG strains, which were 
grown in the absence of detergents, attached to FN-coated surfaces in vitro and to 
damaged urothelium in vivo [20]. In vitro studies showed that laminin, collagen and 
fibrinogen did not mediate BCG attachment. They concluded that extracellular matrix 
FN or FN in fibrin clots after TUR was likely to mediate BCG attachment to the 
bladder, and modulation of the interaction between BCG and FN might provide a tool 
to influence intravesical BCG therapy. Kavoussi et al. found that chemical disruption 
of the urothelium caused by the use of adriamycin prior to BCG increased the FN 
mediated BCG attachment to the murine bladder mucosa [21]. They also found that 
heparin instillation into the bladder inhibited BCG/FN binding, possibly through the 
binding of heparin to the heparin binding sites of FN. Therefore, in a recent study 
Hudson et al. examined the effect of fibrin clot inhibitors on the clinical efficacy of 
intravesical BCG therapy in superficial bladder cancer [14]. In this study, the tumor 
free percentage of 29 patients using fibrin clot inhibitors was 48%, compared to 67% 
in 120 patients without these drugs (p=0.065). In case of superficial recurrent tumors, 
the difference was even more significant: 35% of patients using fibrin clot inhibitors 
had superficial recurrences, compared to 8% of those without these drugs (p=0.005). 
In their conclusion, Hudson et al. suggested that inhibitors of fibrin clot formation 
decrease the efficacy of intravesical BCG therapy in patients with superficial bladder 
cancer. Two possible explanations for these results were proposed. Firstly fibrin clot 
inhibitors might have an adverse effect on the binding of BCG to FN, and thereby 
inhibit the effect of BCG. Secondly, aspirin like drugs have anti-inflammatory effects. 
The inflammatory effect of BCG might be a necessary step in the antitumor effect, and 
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the inflammatory reaction is also inhibited by these drugs. Some investigators believe 
that BCG only works if at least irritative symptoms appear, and they prolong the 
treatment period or even increase the dose of BCG per instillation when there are no 
side effects [22]. 
Our results, however, do not confirm the results of Hudson et al. In the group of 
42 patients using fibrin clot inhibitors, 13 patients (31%) showed a recurrent tumor 
after a mean period of 9.7 months. In the group of 141 patients that did not use these 
drugs, 56 patients (40%) had a recurrence after a mean period of 9.4 months. There 
is a difference in favour of the users of fibrin clot inhibitors, but this is not statistically 
significant (p=0.28). The type of BCG strain used (Tice or RIVM) did not effect these 
results, nor did the use of antibiotics. 
These results are not in concordance with those of Hudson et al. See and Williams 
recently reviewed particulate adherence to the urothelium as a result of urothelial 
injury and clotting cascade activation [23]. They demonstrated that both tumor cell and 
BCG adherence is limited to the site of urothelial injury [20,24,25]. Tumor cell 
adherence and implantation on injured urothelium can be prevented by heparin, a drug 
which is not cytotoxic [26]. In a noninjured bladder, the surface is neutrally charged, 
because it is covered by an electrically neutral hydrophillic glycosaminoglycan layer. In 
damaged urothelium, the glycosaminoglycan and epithelial integrity are disrupted, and 
the clotting cascade is activated. In the fibrin clot, noncovalent forces are present, and 
they attract and bind particulate matter present in the bladder lumen. Alterations in 
electrostatic forces present at the urothelium/bladder lumen interface resulting from a 
combination of glycosaminoglycan depletion and clot formation appear to predispose 
to a generalized adherence of particulate matter. Alterations in this adherence 
mechanism, induced by anticoagulant and thrombolytic agents, are able to prevent or 
overcome this clot-dependent particulate adherence to injured urothelium, although 
some of these anticoagulants do not interfere with the mode of action of FN. The 
influence of fibrin clot inhibitors might be the same for tumor cell adherence and BCG 
attachment to damaged urothelium. A decreased tumor cell adherence might lower the 
recurrence rate, while a decreased BCG attachment might decrease the efficacy of 
BCG and by that increase the recurrence rate. Therefore, the net result of fibrin clot 
inhibitors is difficult to foresee. Furthermore, adherence of tumor cells to injured 
urothelium in vivo differs from adherence to FN in vitro [27]. FN receptor blockade, 
which inhibits in vitro tumor cell adherence, failed to inhibit in vivo cell adherence to 
injured urothelium. 
There is also a difference in the patient populations of both studies. Hudson et al. 
only treated patients with recurrent or multifocal tumors, whereas in our group also 
primary and solitary tumors were treated. It is possible that in high risk patients the 
influence of concomitant medication is more evident than it is for intravesical therapy 
in general. 
In conclusion, we cannot confirm an earlier report, that the use of fibrin clot 
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inhibitors reduces the efficacy of intravesical BCG therapy, whether BCG-Tice or BCG-
RIVM is used. From a theoretical standpoint, arguments can be found for both study 
results. Therefore, this study raises more questions than it can answer, indicating again 
that the mechanism of action of BCG is very complicated. Only randomized prospective 
studies can answer the question whether fibrin clot inhibitors reduce the efficacy of 
intravesical BCG therapy. 
Summary. 
After transurethral resection (TUR) of superficial bladder tumors, intravesical 
instillations with BCG are successfully used to lower the recurrence rate. The 
mechanism of the antitumor activity of BCG is not completely understood. After a 
TUR, a fibrin clot is formed on the damaged urothelium. Fibronectin (FN) is part of 
the clot. It has been demonstrated that binding of BCG to the bladder wall is mediated 
by FN, and therefore FN seems necessary for the antitumor activity of BCG. This 
binding can be inhibited by fibrin clot inhibitors, like aspirin and coumarin. A reduced 
efficacy of BCG in patients with superficial bladder cancer using these drugs has been 
described. We studied 183 patients with superficial bladder cancer, treated with one or 
two 6-week courses of intravesical BCG instillations. Of the 42 patients that used fibrin 
clot inhibitors, 13 (31%) experienced a recurrent tumor, as compared to 56 (40%) of 
141 patients who did not use these drugs (p=0.28). The mean time to recurrence was 
the same in both groups. These results did not depend on the BCG strain used (Tice 
or RIVM, ρ=0.92), and were not influenced by the use of antibiotics against urinary 
tract infections. We conclude that in our study fibrin clot inhibitors have no adverse 
effect on the efficacy of BCG therapy for superficial bladder cancer. 
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Summary and conclusions. 
Even though the majority of patients with bladder cancer initially present with low 
stage disease, the clinical epidemiology of these so-called superficial bladder tumours 
is not well known. In chapter 2, we describe disease characteristics at initial 
presentation and during follow-up of 1745 primary cases documented prospectively 
in the Netherlands. The risk of recurrent disease after primary treatment is high: 
60% of the patients have at least one recurrence within 5 years. In patients with a 
small solitary pTa grade 1 tumour who are treated with transurethral resection 
(TUR) only, the 3-year risk of first recurrence still is 37%. In patients with multiple 
large high grade pTl tumours, this risk is 77%, despite a significant beneficial effect 
of intravesical instillations. The actuarial risk of disease progression is 10.2% after 3 
years (95% CI: 8.6%-11.8%). Intravesical instillations after TUR did not prevent 
tumour progression, although this finding is difficult to interpret from a non-
randomised study. The five-year relative survival of patients with superficial 
transitional cell carcinoma (TCC) of the bladder is 86% (95% CI: 84%-88%). 
For superficial and invasive bladder cancer we analyzed Dutch mortality rates 
between 1955 and 1988. In 1955, 234 men and 116 women died from bladder 
cancer, in 1988 794 and 317 respectively. After adjusting for the ageing of the Dutch 
population since 1955, female mortality rates per 10s person-years appear to be very 
stable: 2.9 in the period 1955-1959 and 3.0 in 1985-1988. By contrast, an increasing 
trend exists in males: 7.5 in 1955-1959 and 12.4 in 1985-1988 respectively. For men 
in particular, increasing mortality and incidence rates are seen all over the world, 
which might be explained by changes in smoking behaviour. There is, however, a 
decreasing risk of dying from bladder cancer for Dutch men born after 1910, what 
will probably result in a decreasing trend in mortality in the near future. 
We also registered and treated 49 patients with bladder cancer less than 40 years 
of age. TCC was present in 47 patients, of which 21 (44.7%) had high risk tumours 
(muscle invasion, recurrences), all between 31 and 39 years of age. In all, 15 
patients had a recurrence (30.6%), of which 3 showed progression (all between 31 
and 39 years of age). Therefore, TCC of the bladder seems less aggressive in 
patients less than 30 years of age, but patients between 31 and 39 years of age have 
the same prognosis as patients above 40. We advise to do a full diagnostic work up 
in case of symptoms of bladder tumour, and to treat the patient according to the 
pathological classification, regardless of the age. 
In chapter 3 many prognostic factors for recurrence and progression in superficial 
bladder cancer are discussed, with regard to the use in daily practice. Age is of 
importance. The recurrence rate before and after treatment, tumour multiplicity and 
tumour size give important information. The value of histopathology depends on the 
experience of the local pathologist, but tumour grade, and especially tumour stage 
are of great prognostic importance. The value of blood group antigens is 
Summary and conclusions 149 
controversial, the value of DNA ploidy, marker chromosomes and other 
chromosomal abnormalities not yet proven, although promising. Cell motility, 
extracellular matrix degradation and the epidermal growth factor receptor are also 
promising factors to study the malignant potential. In conclusion, no single 
prognostic factor is able to predict prognosis in superficial bladder cancer. 
Combinations of prognostic factors, however, seem useful. 
In chapter 4 we prospectively studied cold-cup random bladder biopsies of normal 
looking mucosa in 1026 unselected patients with primary pTa/pTl TCC of the 
bladder. In a univariate analysis, the risk of recurrence was slightly higher in case of 
an abnormal biopsy result: the 2 year actuarial risk of recurrent disease was 47.5%, 
versus 44.5% in patients with a normal biopsy result (P=0.09). However, after 
correction for other prognostic factors using Cox proportional hazards model, an 
abnormal biopsy result had no additional prognostic value to conventional histo-
pathology of the tumour with regard to the risk of recurrence. Additional therapy 
after TUR (p<0.001), tumour stage (p<0.001), extent of the tumour (p<0.01) and 
tumour multiplicity (p=0.09) had significant prognostic value. Some value of the 
biopsies was found with regard to disease progression. This might be explained by 
the fact that adjuvant therapy does influence the recurrence rate, but not 
progression. This relative importance of therapy with regard to recurrences might 
mask the value of other factors. 
In chapter 5 we used follow-up data of 1674 patients with superficial TCC of the 
bladder, prospectively documented by the Dutch South-East Cooperative Urological 
Group, to construct prognostic indices (PI) for the risks of first recurrence and 
progression. The former is based on tumour stage, extent and multiplicity, the latter 
on tumour stage, grade, multiplicity, and the result of bladder biopsies. These Pi's 
are constructed with the data of half of the study cohort. For patients with a PI 
suggesting low risk for recurrent and progression the predicted 3-year risk of first 
recurrence is 44%, and the predicted 3-year risk of progression is just 3%. For 
patients with a PI suggesting high risk the predicted risks are 74% and 22%, 
respectively. These predicted risks appear to be quite reliable when compared to the 
results in the other half of the study cohort. Thus, with the PI differentiation of low 
risk from high risk patient groups is possible. More relevant, however, is to test 
prognostic factors can in individual patients. A prediction of 50% is no better than a 
flip of a coin, whereas a prediction of 100% is optimal. It is shown quantitatively 
that discrimination of an individual patient who will develop recurrences from one 
who will not is surprisingly inaccurate (58%), even with the available statistically 
highly significant prognostic factors. For progressive disease, such a discrimination on 
the individual level is somewhat better (67%). Pi's as presented have to gain 
predictive accuracy through identification of more and stronger prognostic indicators 
before they can be used for treatment policy in individual patients with superficial 
bladder cancer. 
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Review of literature reveals clear limitations with regard to pathology 
classification. Differences between local and review pathology in a multicenter study 
may influence the results for treatment efficacy results and prognostic factor 
analysis. In chapter 6 we describe randomised multicenter study in superficial bladder 
cancer, in which the influence of local and review pathology on the study outcome 
were studied. The conformity between local and review pathology of the pT 
category was 79.3%, of the grade 70.2%, and of the combination of both 59.7%. In 
local pathology undergrading was somewhat more frequent than overgrading, 
overstaging somewhat more frequent than understagjng. However, the risks of 
recurrence in the separate stage and grade groups remained the same after 
correcting the pathology result. A prognostic factor analysis with regard to the risk 
of recurrence was carried out. The Cox hazard ratio's of tumour localisation, 
multiplicity, patient age (significant factors), tumour grade, size, history and gender 
(not significant factors) remained almost the same after correction for review 
pathology. Only the prognostic relevance of tumour stage increased. We conclude 
that, although review pathology caused considerable changes in the pathology results, 
this did not change treatment efficacy results, and hardly changed the results of a 
prognostic factor analysis in this randomised study. Probably the (prognostic) 
importance of pathology is rather limited in superficial bladder cancer, as it is for 
prognostic factors in general in this type of cancer. 
In chapter 7 we have given some practical guidelines for the treatment of 
superficial bladder cancer. There is a possibility to choose between several intravesi­
cal drugs and schedules. It is important to know the advantages and disadvantages 
of these treatments, to be able to individualize treatment as much as possible and to 
anticipate on the adverse effects. What has not changed is the need for regular 
follow up with endoscopy and urine cytology. Conservative treatment on part of the 
patient should not prevent a urologist to use more aggressive forms of therapy when 
needed. 
In chapter 8 the use of intravesical BCG (Bacillus Calmette-Guerin) therapy is 
reviewed. BCG has been used for superficial bladder cancer since 1976. Still, 
however, the mechanisms by which BCG exerts its antitumour activity remain 
unclear. The role of the attachment of BCG to fibronectin (FN) is discussed in 
chapter 11. BCG therapy exerts non immunologic responses (inflammation), non 
specific immunological responses and specific immunological responses (humoral and 
cellular). BCG can enhance antibody synthesis; cytokine production (IL 2, IL 1, 
TNF, IFN gamma); cell mediated immunity; macrophage action; NK cells and 
cellular cytotoxicity. BCG can also suppress the immune system, partly by induction 
of the Τ suppressor cells. 
The efficacy of a BCG vaccine depends on the viability, dose and strain. 
Different strains of BCG, and also different samples of the same strain, are noted 
to have different numbers of colony forming units (CFU). Until now 9 strains have 
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been used in the immunotherapy of superficial bladder cancer. The first studies 
comparing different strains have not shown any difference in efficacy or side effects. 
The efficacy of low dose BCG (60 mg.) is controversial. Side effects, however, are 
markedly less. 
The optimal route of administration is the intravesical one. Percutaneous 
administration alone or in combination with intravesical administration is of no 
value. Intralesional administration can be dangerous. The value of oral BCG is 
controversial. Recently no measurable antitumour effect of oral BCG was found 
comparing oral versus intravesical and percutaneous BCG. In some studies 
conversion of the PPD test indicates a better response to therapy However, the 
significance of the test is small and should not be used as a prognostic marker in 
individual patients. 
The initial schedule of BCG is a course of 6 instillations in 6 weeks. When 
patients fail this course, two possibilities arise. The first possibility is maintenance 
therapy: biweekly and monthly instillations for 1 or 2 years. Most studies find better 
results with this or similar schedules, although at the cost of more and more severe 
side effects. The second possibility is a second 6 week course. The response rates 
will improve from approximately 60% after one 6 week course to approximately 
80% after the second, without the severe toxicity of the maintenance therapy. A 
second course seems most useful in case of a sustained response to the initial 
treatment. However, in patients failing both courses a significantly higher risk for 
muscle invasion is found. 
Side effects after intravesical instillations with BCG can be divided in local side 
effects, allergic reactions and systemic side effects. Local toxicity can be bacterial 
cystitis (not BCG related), drug induced cystitis (BCG related) or other local side 
effects, such as haematuria, bladder contracture, prostatitis and epididymitis due to 
contamination with BCG containing urine. Bacterial cystitis should be treated before 
further BCG therapy. The bladder irritability usually begins after 2 or 3 instillations, 
and increases with the number of instillations. Moderate side effects can be seen in 
10-30% of patients. Except for the severe side effects this toxicity is usually well 
tolerated, and only sometimes causes delay of treatment. Severe side effects will be 
seen in about 5% of all patients. In case of severe side effects the dose of BCG 
should be halved, and patients should be treated with isoniazid. In case of severe 
systemic side effects the treatment should be stopped, and antituberculous 
combination therapy should be given for 3 months. Prednisolone can be added in 
case of lifethreatening BCG reactions. In case of acute problems cycloserine should 
be given for the first 3-5 days, because it is effective several days before the classical 
combination therapy is. The influence of antituberculous drugs on the efficacy of 
BCG is controversial. In the treatment of superficial bladder cancer with BCG, 
several fatal complications have been described. Traumatic catherization seems to 
play a role in most of these fatal complications. Therefore it is strongly 
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recommended that if trauma during the catheterization occurs, the treatment is post­
poned for one week. 
BCG instillations are superior to intravesical chemotherapy or TUR only. The 
success rate of BCG treatment is between 58% and 100%, with a minimal follow up 
of one year. BCG can be used in patients with high risk superficial bladder cancer, 
although close monitoring of non-responders is mandatory. BCG also can be used to 
eliminate tumour after an incomplete TUR, or in patients who are unfit for surgery. 
Success rates of approximately 60-70% are found. In carcinoma in situ (CIS) with 
BCG encouraging results have been described with success rates between 42% and 
83% after a minimal follow up of one year. Long term results in CIS patients 
showed that 50% of responding patients remained free of disease after more than 4 
years. 
Furthermore in chapter 8 we have presented a case report of a 60 year old man 
with CIS of the urethra after previous successful radiotherapy of an invasive bladder 
tumour. Intra-urethral instillations with BCG were given. In spite of initial success, 
recurrences developed after two courses of 12 intra-urethral instillations, and radical 
surgery was performed. Others have also successfully used BCG instillations for TCC 
in the prostatic urethra, and even percutaneous BCG for pelvic TCC. Therefore, it 
seems possible to use BCG for localisations of TCC outside the bladder cavity and 
this should be kept in mind in case radical surgery is the only alternative. It should 
not, however, be used as a routine procedure. 
In chapter 9 we have presented the results of a randomized prospective study in 
which instillations with MMC (mitomycin-C), BCG-Tice and BCG-R1VM are 
compared in patients with primary or recurrent superficial bladder tumours, 
including CIS. In all, 9 instillations with 30 mg. MMC were given (4 weekly, 5 
monthly), or 6 weekly instillations with 5 χ 10" CFU BCG. In case of an early 
recurrence 3 additional instillations were given in the MMC group, or a second 
course of 6 weekly instillations in the BCG groups. A total of 437 patients are 
evaluated for toxicity and efficacy with a median follow up of 32 months (12-56). 
Drug induced cystitis was observed in 17.6% of 148 patients treated with MMC, in 
30.0% of 140 patients treated with BCG-Tice and in 32.2% of 149 patients treated 
with BCG-RIVM respectively. Bacterial cystitis occurred in 18.2% (MMC), 27,1% 
(Tice) and 22.8% (RIVM) respectively. Other local side effects were observed in 
4.7% (MMC), 16.4% (Tice) and 14.8% (RIVM). Systemic side effects were observed 
in 4.1% (MMC), 27.1% (Tice), and 18.1% (RIVM). Allergic reactions in 4.7% 
(MMC), 2.1% (Tice) and 2.0% (RIVM). Number and severity of side effects were 
comparable in both BCG groups, but significantly less in the MMC group for drug 
induced cystitis (p=0.009), other local side effects (p=0.004) and systemic side 
effects (p<0.001). The overall disease free percentage showed no significant 
difference for the 3 arms for papillary tumours (p=0.08). For CIS efficacy is also 
comparable (p=0.20), but numbers are small. Additional MMC or BCG instillations 
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did not give excessive toxicity, nor did they improve the efficacy. In conclusion, 6 
months of treatment with MMC causes significantly less side effects than 6 weeks 
immunotherapy with BCG, and is equally effective. Toxicity and efficacy both BCG 
strains are comparable. 
In chapter 10 we studied a group of 49 patients with recurrent superficial bladder 
cancer pTa and/or CIS, failing previous intravesical chemotherapy. In these high risk 
patients maintenance BCG treatment has been found to decrease the progression 
rate and increase survival, in contrast to intravesical chemotherapy. The patients in 
this study were also randomised for intradermal BCG inoculations, an aspect of 
BCG therapy that was not clear when this study was initiated (1986). The treatment 
schedule was a course of 20 instillations in 1 year, with or without 6 intradermal 
inoculations during the first 6 instillations. Side effects were frequent, causing 
treatment stop in 14 patients (29%). Drug induced cystitis was the most frequent 
side effect, seen in 29 patients (59%). In all, 42 patients were évaluable for 
response. During the first two years of the study 14 patients (33%) had one (n=8) 
or more (n=6) recurrences. A total of 18 patients (43%) remained recurrence free 
with a median follow up of 47 months. Progression was seen in 2 patients from pTa 
to pTl, another patient died of metastatic bladder cancer after 47 months. PPD skin 
test conversion was of no prognostic value. The use of intradermal inoculations 
caused no significant increase of toxicity or local side effects, and had no effect on 
efficacy. Therefore we can conclude that maintenance BCG therapy can be useful 
for patients with recurrent superficial bladder cancer failing previous intravesical 
chemotherapy. 
The mechanism of antitumour activity of BCG is not completely understood. 
After a TUR a fibrin clot is formed on the damaged mucosa. FN is part of the clot. 
It has been demonstrated that binding of BCG to the bladder wall is mediated by 
FN, and therefore FN seems necessary for the antitumour activity of BCG. This 
binding can be inhibited by fibrin clot inhibitors, like aspirin and coumarin. A 
reduced efficacy of BCG in patients with superficial bladder cancer using these 
drugs has been described. In chapter 11 we studied 183 patients with superficial 
bladder cancer, treated with one or two 6-week courses of BCG. Of the 42 patients 
that used fibrin clot inhibitors 13 (31%) experienced a recurrence, as compared to 
56 (40%) of 141 patients who did not use these drugs (p=0.28). The mean time to 
recurrence was the same in both groups. These results did not depend on the BCG 
strain used (Tice or RIVM, ρ=0.92), and were not influenced by the use of 
antibiotics against urinary tract infections. We conclude that in our study fibrin clot 
inhibitors have no adverse effect on the efficacy of BCG therapy for superficial 
bladder cancer. 
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Samenvatting en conclusies. 
Hoewel de meeste patiënten met blaaskanker zich in een relatief gunstig stadium 
van de ziekte presenteren, is van de klinische epidemiologie van deze zogenaamde 
oppervlakkige blaastumoren weinig bekend. In hoofdstuk 2 worden een aantal 
aspecten van de presentatie en follow up van 1745 patiënten met een primaire 
oppervlakkige blaastumor beschreven. De patiënten zijn prospectief in Nederland 
gedocumenteerd. Het risico op een recidief na de eerste behandeling is hoog: 
gemiddeld 60% van de patiënten heeft tenminste 1 recidief binnen 5 jaren. Nog 
altijd heeft 37% van de patiënten met een kleine, solitaire pTa graad 1 tumor, 
welke alleen met een transurethrale resectie (TUR) zijn behandeld, een eerste 
recidief binnen 3 jaren. Bij patiënten met meerdere grote pTl tumoren is dit risico 
77%, ondanks een duidelijk voordelig effect van blaasspoelingen. Het actuariële 
risico op progressie is 10.2% na 3 jaar (95% betrouwbaarheids interval (BI): 8.6%-
11.8%). Het risico op progressie daalt niet door het gebruik van spoelingen, hoewel 
deze conclusie uit deze niet gerandomiseerde studie moeilijk valt te trekken. De 
relatieve 5-jaars overleving voor patiënten met oppervlakkig blaascarcinoom is 86% 
(95% BI: 84%-88%). 
Voor alle stadia van blaaskanker hebben we de Nederlandse mortaliteit bekeken 
tussen 1955 en 1988. In 1955 overleden 234 mannen en 116 vrouwen aan 
blaaskanker, in 1988 794 en 317. Na correctie voor de vergrijzing van de Nederlands 
bevolking sinds 1955 bleken deze getallen voor vrouwen relatief stabiel: 2,9 vrouwen 
per 10° persoons-jaren tussen 1955 en 1959, en 3,0 tussen 1985 en 1988. Bij mannen 
was daarentegen een stijging te zien van 7,5 naar 12,4 in dezelfde perioden. Voor 
mannen wordt een toename van (sterfte aan) blaaskanker in de hele wereld gezien, 
wat toegeschreven kan worden aan veranderingen in het rookgedrag. Het risico op 
sterfte aan blaaskanker neemt echter af voor mannen die na 1910 zijn geboren, 
zodat we in de nabije toekomst een daling kunnen verwachten van de sterfte aan 
blaaskanker. 
In het laatste deel van dit hoofdstuk beschrijven we 49 patiënten jonger dan 40 
jaar die blaaskanker kregen. Bij 47 patiënten ging het om een urotheelcelcarcinoom. 
Hiervan hadden 21 patiënten (44,7%) agressieve tumoren (spierinvasie, recidieven), 
allemaal in leeftijd tussen 31 en 39. In het totaal kregen 15 patiënten (30,6%) een 
recidief, waarvan 3 patiënten ook progressie hadden (allemaal tussen 31 en 39 jaar). 
Blaaskanker lijkt onder de leeftijd van 30 jaar een relatief gunstig beloop te hebben, 
maar patiënten tussen de 31 en 39 jaar hebben dezelfde prognose als oudere 
patiënten. We adviseren dan ook om, indien een blaastumor wordt vermoedt, een 
patiënt volledig na te kijken, en de patiënt te behandelen op geleide van zijn 
tumorstadium, onafhankelijk van zijn leeftijd. 
In hoofdstuk 3 worden vele prognostische factoren voor recidief en progressie van 
oppervlakkig blaascarcinoom besproken. Leeftijd is van belang. De recidieffrequentie 
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voor en na een aanvullende behandeling, zowel als de grootte en multipliciteit van 
een tumor geven belangrijke informatie. De waarde van de histologie wordt mede 
bepaald door de ervaring van de locale patholoog-anatoom, maar de gradering van 
een tumor, en met name het tumorstadium hebben grote prognostische waarde. De 
waarde van bloedgroep antigenen is controversieel, die van DNA ploïdie, marker 
chromosomen en andere chromosomale afwijkingen nog niet bewezen, hoewel 
veelbelovend. Cellulaire beweeglijkheid, degeneratie van de extracellulaire matrix en 
de receptor voor de epidermale groei factor kunnen ook belangrijk worden om het 
maligne potentieel te bestuderen. In conclusie is geen enkele factor in staat om 
alleen de prognose te bepalen. Combinaties van factoren kunnen echter zinvol zijn. 
In hoofdstuk 4 wordt een prospectieve studie beschreven over 1026 
ongeselecteerde patiënten met een primair pTa/pTl urotheelcelcarcinoom waarbij 
biopten zijn genomen van normaal ogend blaasslijmvlies. In een univariate analyse 
blijkt het risico op het krijgen van een recidief slechts iets hoger te zijn in geval van 
een abnormaal biopt: het actuariële risico op het krijgen van een recidief na 2 jaar 
is 47,5% in vergelijking met 44,5% in de groep met een normale biopsie (p=0.09). 
Als we echter andere prognostische factoren in de analyse betrekken door middel 
van een "Cox proportional hazards" model, blijkt een abnormaal biopt geen enkele 
aanvullende waarde te hebben met betrekking tot het risico op een recidief boven 
de conventionele tumor-histologie. Significante factoren zijn wel additionele 
behandeling na een TUR en het tumor stadium (p<0.001), de uitgebreidheid van de 
tumor (p<0.01) en de tumor multipliciteit (p=0.09). Wel hebben de biopten enige 
waarde voor de kans op progressie. Dit verschil zou verklaard kunnen worden door 
het feit dat blaasspoelingen wel het recidiefpercentage beïnvloeden, maar niet de 
kans op progressie. De relatief grote invloed van deze spoelingen op het 
recidiefpercentage zou de waarde van andere factoren kunnen maskeren. 
In hoofdstuk 5 hebben we met behulp van de gegevens van 1674 patiënten met 
oppervlakkig blaascarcinoom, geregistreerd door het samenwerkingsverband urologen 
zuid-oost Nederland, een prognostische index (PI) gemaakt voor de risico's op het 
eerste recidief en progressie. De eerste is gebaseerd op tumor stadium, 
uitgebreidheid en multipliciteit, de tweede op tumor stadium, gradering, multipliciteit 
en het resultaat van blaasbiopten. De indices zijn gemaakt met behulp van gegevens 
van de helft van de patiënten. Voor patiënten, die volgens de PI een laag risico op 
recidief en progressie hadden, waren de voorspelde risico's op het eerste recidief in 
3 jaar 44%, en op progressie 3%. Voor patiënten die volgens de PI in de groep met 
een hoog risico zaten waren deze getallen respectievelijk 74% en 22%. Deze 
voorspelde risico's bleken goed overeen te komen met de werkelijke risico's die in 
de andere helft van de patiënten werden gevonden. Met deze Pi's is het dus 
mogelijk groepen patiënten met een hoog of laag risico van elkaar te onderscheiden. 
Voorspellingen op individueel niveau zijn echter meer relevant. Een voorspelling van 
50% heeft net zoveel waarde als het toeval, terwijl een voorspelling van 100% 
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optimaal is. Het blijkt dat het voorspellen welke patiënt een recidief krijgt 
verrassend onnauwkeurig is (58%), zelfs met de gebruikte prognostische factoren, 
welke statistisch hoog significant waren. Een voorspelling van progressie op 
individueel niveau blijkt iets nauwkeuriger te zijn (68%). Het is dan ook duidelijk 
dat de gepresenteerde Pi's aan waarde moeten winnen door gebruik te maken van 
meer en betere prognostische factoren. Pas dan zouden beslissingen over de 
individuele behandeling bij patiënten met oppervlakkig blaascarcinoom hierop 
gebaseerd kunnen worden. 
In de literatuur worden duidelijke beperkingen van de huidige histologische 
classificaties beschreven. Eventuele verschillen tussen de beoordeling door de locale 
en "review" patholoog anatoom zouden invloed kunnen hebben op de behandelings 
resultaten en een analyse van prognostische factoren in het geval van een 
rnulticentrische studie. In hoofdstuk 6 wordt een gerandomiseerde multicentrische 
studie over oppervlakkig blaascarcinoom beschreven, waarin de invloed van locale 
en review histologie op het resultaat van de studie wordt onderzocht. De 
overeenkomst tussen de locale en review beoordeling van het pT stadium was 
79,3%, van de gradering 70,2% en van het totale resultaat 59,7%. In de locale 
beoordeling kwam ondergradering iets meer voor dan overgradering, en 
overstadiëring iets meer dan onderstadiëring. Na correctie van de histologische 
beoordeling bleek echter dat het risico op een recidief in de verschillende groepen 
met een bepaald stadium of gradering gelijk bleven. Ook werd gekeken naar de 
waarde van de prognostische factoren met betrekking tot het krijgen van een 
recidief. De waarde van tumor localisatie, multipliciteit en leeftijd van de patiënt 
(significante factoren), tumor gradering, grootte, voorgeschiedenis en geslacht van de 
patiënt (niet significant) bleven bijna gelijk na correctie van de histologische 
beoordeling. Alleen de prognostische waarde van het tumor-stadium nam toe na 
correctie. We kunnen concluderen dat de resultaten van de histologische beoordeling 
weliswaar duidelijk veranderen door review beoordeling, maar dit heeft geen invloed 
op de effectiviteits analyse, en zo goed als geen invloed op de analyse van de 
prognostische factoren. Waarschijnlijk is de prognostische waarde van histologie bij 
oppervlakkig blaascarcinoom tamelijk beperkt, wat overigens voor prognostische 
factoren bij deze ziekte in het algemeen geldt. 
In hoofdstuk 7 geven we enkele praktische richtlijnen voor de behandeling van 
het oppervlakkige blaascarcinoom. De uroloog kan kiezen tussen diverse medicijnen 
en schema's voor blaasspoelen. Het is belangrijk de voor en nadelen van de diverse 
mogelijkheden te kennen, om de behandeling zo goed mogelijk te individualiseren, 
en om op de bijwerkingen te kunnen anticiperen. De noodzaak tot regelmatige 
controle met cystoscopie en urine cytologie blijft echter bestaan. Een zo conservatief 
mogelijke behandeling op verzoek van een patiënt moet een uroloog niet 
weerhouden een meer agressieve behandeling te kiezen indien dit noodzakelijk is. 
Hoofdstuk 8 geeft een overzicht van het gebruik van Bacillus Calmette-Guerin 
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(BCG). BCG wordt voor oppervlakkig blaascarcinoom gebruikt sinds 1976. Het 
werkingsmechanisme van BCG is nog onduidelijk. De betekenis van de binding van 
BCG aan fibronectine (FN) wordt in hoofdstuk 11 beschreven. BCG veroorzaakt 
niet immunologische reacties (ontsteking), niet specifieke en specifieke (humorale en 
cellulaire) immunologische reacties. BCG stimuleert de productie van antilichamen 
en cytokines (IL2, IL 1, TNF, IFN gamma); door cellen geregelde immuniteit; 
macrofagen activiteit; NK cellen en cellulaire cytotoxiciteit. BCG kan het 
immuunsysteem ook onderdrukken, deels door stimulatie van "T-suppressor" cellen. 
De effectiviteit van een BCG vaccin hangt af van de levensvatbaarheid, dosis en 
de stam. Verschillende BCG stammen, en zelfs verschillende monsters van eenzelfde 
stam, blijken een verschillende hoeveelheid kolonie vormende deeltjes (CFU) te 
kunnen hebben. Er zijn al 9 stammen gebruikt voor behandeling van oppervlakkig 
blaascarcinoom. De eerste studies waarin verschillende stammen zijn vergeleken 
laten geen verschil zien in effectiviteit of bijwerkingen. De effectiviteit van een lage 
dosis BCG (60 mg.) is controversieel, de bijwerkingen echter duidelijk minder. 
De optimale toedieningsroute is de intravesicale instillatie ("blaasspoeling"). 
Percutané toediening, alleen of in combinatie met blaasspoelingen, is niet zinvol 
gebleken. Inspuiting in de tumor kan gevaarlijk zijn. De waarde van de orale 
toediening is controversieel. Recent werd geen meetbaar effect gevonden bij een 
vergelijking van orale met intravesicale en percutané toediening. In enkele studies 
wijst een conversie van de Mantoux reactie op een betere respons op de 
behandeling, maar het belang van deze conversie is beperkt en moet niet als een 
prognostische factor voor een individuele patiënt worden gebruikt. 
Het initiële schema van BCG was een cyclus van 6 spoelingen in 6 weken. Indien 
patiënten een recidief krijgen na deze cyclus, zijn er 2 mogelijkheden. De eerste is 
de zogenaamde onderhoudsbehandeling: twee-wekelijkse en maandelijkse spoelingen 
gedurende 1 of 2 jaar. De meeste studies die dergelijke schema's gebruiken vinden 
betere effectiviteit, echter ten koste van meer en ernstigere bijwerkingen. De tweede 
mogelijkheid is een tweede cyclus van 6 spoelingen. Het respons percentage kan 
hiermee worden verhoogd van ongeveer 60% na 1 cyclus tot ongeveer 80% na 2 
cycli, zonder de ernstige bijwerkingen van de onderhoudsbehandeling. Een tweede 
cyclus lijkt het best werkzaam bij patiënten die op de eerste cyclus een langer 
aanhoudende reactie hebben gehad. Indien patiënten onvoldoende reageren op 2 
cycli, zullen zij een duidelijk hoger risico op progressie hebben. 
Bijwerkingen van blaasspoelingen met BCG kunnen worden onderverdeeld in 
locale bijwerkingen, allergische reacties en systemische bijwerkingen. Locale 
bijwerkingen zijn bacteriële cystitis (niet gerelateerd aan BCG), chemische cystitis 
(veroorzaakt door BCG), of andere locale bijwerkingen zoals haematurie, 
schrompelblaas, prostatitis en epididymitis als gevolg van contact met BCG 
houdende urine. Een bacteriële cystitis moet worden behandeld alvorens BCG 
spoelingen te geven. De irritatie van de blaas begint meestal na 2 of 3 spoelingen, 
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en kan toenemen met het aantal spoelingen. Matig ernstige bijwerkingen worden 
gezien bij 10-30% van de patiënten. Met uitzondering van de ernstige toxiciteit 
worden deze bijwerkingen meestal goed verdragen, en slechts zelden moet daarom 
een spoeling worden uitgesteld. Ernstige bijwerkingen komen voor bij 5% van de 
patiënten. In dat geval moet de BCG dosis worden gehalveerd, en moet de patiënt 
worden behandeld met isoniazide. Eventueel moet worden overwogen de 
behandeling helemaal te staken, en moet gedurende 3 maanden tuberculostatics 
worden gegeven, eventueel aangevuld met prednisolone in het geval van een 
levensbedreigende infectie. Ook kan in ernstige gevallen het gebruik van cycloserine 
gedurende de eerste 3-5 dagen worden overwogen, omdat het enkele dagen voor de 
klassieke behandeling werkzaam is. De invloed van tuberculostatic op de 
werkzaamheid van BCG is controversieel. Bij het gebruik van BCG voor 
oppervlakkig blaascarcinoom zijn tot nu toe enkele fatale complicaties beschreven. 
Een traumatische catheterisatie lijkt in de meeste gevallen een rol te spelen, zodat 
in een dergelijk geval wordt geadviseerd de spoeling 1 week uit te stellen. 
Blaasspoelingen met BCG zijn effectiever dan een TUR zonder nabehandeling of 
spoelingen met chemotherapeutica. Het succes percentage van BCG ligt tussen 58% 
en 100%, met een minimale follow up van 1 jaar. BCG kan ook worden gebruikt bij 
patiënten met een hoog risico op progressie, hoewel een zeer nauwkeurige controle 
van de niet responders noodzakelijk is. Met BCG kunnen ook tumoren worden 
behandeld die niet volledig gereseceerd zijn, of bij patiënten die geen operatie 
kunnen ondergaan. In die gevallen heeft BCG een succes percentage van 60% tot 
70%. Ook bij patiënten met carcinoma in situ (CIS) zijn met BCG hoopgevende 
resultaten geboekt met succes percentages tussen 42% en 83% na een minimale 
follow up van 1 jaar. Recente resultaten bij CIS patiënten lieten zien dat 50% van 
de patiënten die op de behandeling reageerden gedurende meer dan 4 jaar vrij van 
recidief bleven. 
In het tweede deel van hoofdstuk 8 beschrijven we een 60 jaar jonge patiënt met 
CIS in zijn urethra, die eerder succesvol was bestraald voor een invasieve 
blaastumor. De man werd behandeld met urethra spoelingen. Ondanks aanvankelijk 
succes kreeg hij toch een recidief na 2 cycli van 12 spoelingen, en werd alsnog 
radicale chirurgie uitgevoerd. Ook anderen hebben met succes BCG spoelingen 
gebruikt voor urotheelcelcarcinoom in de urethra prostatica, en zelfs is percutané 
toediening gebruikt bij tumoren van het nierbekken. Het lijkt dus mogelijk met BCG 
localisaties van urotheelcelcarcinoom buiten de blaasholte te behandelen, en hieraan 
moet dan ook worden gedacht indien radicale chirurgie het enige alternatief is. Het 
moet echter niet tot de dagelijkse routine worden gerekend. 
In hoofdstuk 9 wordt een gerandomiseerde prospectieve studie beschreven waarin 
spoelingen met het chemotherapeuticum mitomycine-C (MMC), BCG-Tice en BCG-
RIVM worden vergeleken bij patiënten met primaire of recidiverende oppervlakkige 
blaastumoren, met of zonder CIS. Met MMC werden 9 spoelingen gegeven (30 mg., 
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4x wekelijks, 5x maandelijks), terwijl BCG (5 χ 10* CFU) 6 keer wekelijks werd 
gegeven. In het geval van een vroeg recidief werden 3 extra spoelingen met MMC 
gegeven, of een tweede cyclus van 6 spoelingen met BCG. In het totaal waren 437 
patiënten evalueerbaar voor bijwerkingen en effectiviteit met een gemiddelde follow 
up van 32 maanden (12-56). Chemische cystitis werd gezien bij 17,6% van de 148 
patiënten die met MMC werden behandeld, bij 30,0% van de 140 BCG-Tice 
patiënten, en bij 32,2% van de 149 BCG-RIVM patiënten. Bacteriële cystitis kwam 
respectievelijk voor bij 18,2% (MMC), 27,1% (Tice) en 22,8% (RIVM). Andere 
locale bijwerkingen werden gezien bij 4,7% (MMC), 16,4% (Tice) en 14,8% 
(RIVM), en systemische bijwerkingen bij 4,1% (MMC), 27,1% (Tice) en 18,1% 
(RIVM). Allergische reacties kwamen voor bij 4,7% (MMC), 2,1% (Tice) en 2,0% 
(RIVM). De frequentie en de emst van de bijwerkingen waren vergelijkbaar in de 
beide BCG groepen, maar significant minder frequent in de MMC groep voor wat 
betreft chemische cystitis (ρ=0.009), andere locale bijwerkingen (p=0.004) en 
systemische bijwerkingen (p<0.001). Het percentage patiënten dat geen hernieuwde 
papillaire tumor kreeg was vergelijkbaar in de drie behandelings groepen (p=0.08). 
Ook de effectiviteit bij CIS patiënten was gelijk (p=0.20), maar de aantallen in deze 
groep zijn klein. Aanvullende spoelingen met MMC of BCG gaven geen extra 
bijwerkingen, noch een verbetering van de effectiviteit. Samenvattend blijken 9 
spoelingen met MMC in 6 maanden significant minder bijwerkingen te hebben dan 
6 weken spoelen met BCG, terwijl de effectiviteit vergelijkbaar is. Beide BCG 
stammen zijn vergelijkbaar met betrekking tot bijwerkingen en effectiviteit. 
In hoofdstuk 10 worden 49 patiënten gepresenteerd met recidiverende pTa 
tumoren en/of CIS, die tevoren zonder succes met intravesicale chemotherapie 
waren behandeld. In deze patiënten met een relatief hoog risico blijkt BCG 
onderhoudsbehandeling de progressie af te kunnen remmen en de overleving te 
kunnen verbeteren, in tegenstelling tot intravesicale chemotherapie. De patiënten 
werden ook gerandomiseerd voor percutané BCG injecties, waarvan het nut ten 
tijde van de start van de studie (1986) nog niet duidelijk was. Het 
behandelingsschema bestond uit 20 blaasspoelingen gedurende 1 jaar, met of zonder 
6 percutané injecties gedurende de eerste 6 spoelingen. Bijwerkingen waren 
frequent, en veroorzaakten het stoppen van de behandeling bij 14 patiënten (29%). 
Chemische cystitis was de meest voorkomende bijwerking, en werd gezien bij 29 
patiënten (59%). In het totaal waren 42 patiënten evalueerbaar voor de respons. 
Gedurende de eerste 2 jaar van de studie kregen 14 patiënten (33%) een (n=8) of 
meerdere (n=6) recidieven. In het totaal bleven 18 patiënten (43%) vrij van recidief 
met een gemiddelde follow up van 43 maanden. Conversie van de mantoux reactie 
had geen prognostische waarde. De percutané injecties hadden geen extra locale of 
systemische bijwerkingen, noch een effect op de effectiviteit van de behandeling. 
Concluderend kan BCG onderhoudsbehandeling van waarde zijn voor patiënten met 
recidiverende oppervlakkige blaastumoren na eerdere intravesicale chemotherapie. 
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Het werkingsmechanisme van BCG is nog steeds onduidelijk. Na een TUR wordt 
op het beschadigde blaasslijmvlies een stolsel van fibrine gevormd. Fibronectine 
(FN) is een onderdeel van dit stolsel. Het is aangetoond dat binding van BCG aan 
de blaaswand door FN wordt geregeld, zodat FN noodzakelijk lijkt voor de 
antitumor werking van BCG. Deze binding kan geremd worden door anticoagulantia 
zoals aspirine en sintrom. Een verminderde werking van BCG bij patiënten die deze 
medicijnen gebruikten is beschreven. In hoofdstuk 11 worden 183 patiënten met 
oppervlakkig blaascarcinoom bestudeerd, die met 1 of 2 cycli van 6 spoelingen" BCG 
zijn behandeld. Van de 42 patiënten die anticoagulantia gebruikten kregen 13 (31%) 
een recidief, vergeleken met 56 (40%) van de 141 patiënten die deze medicijnen 
niet gebruikten (p=0.28). Het gemiddelde interval tot een recidief was hetzelfde in 
beide gToepen. Deze resultaten waren onafhankelijk van de gebruikte BCG stam 
(Tice of RIVM, ρ=0.92), en ook onafhankelijk van eventuele antibiotica tegen een 
urineweg infectie. De conclusie van deze studie is dat anticoagulantia niet de eerder 
beschreven negatieve invloed op de werking van BCG bij oppervlakkig 
blaascarcinoom hebben. 
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1. Although superficial bladder cancer is a relatively benign" malignant disease, 
60% of a group of unselected patients will have at least one recurrence within 
5 years, 16,5% will show progression within 3 years, and the five year relative 
mortality is 12%. 
2. Bladder cancer patients should be treated according to their pathological 
classification, and not according to their age. 
3. The predictive value of prognostic factors in superficial bladder cancer is rather 
poor. 
4. The role of molecular biology in the search for prognostic factors in superficial 
bladder cancer will become very important in the near future. 
5. With current prognostic factors tumor behaviour can be predicted for large 
groups of patients with superficial bladder cancer. This, however, is difficult for 
subgroups of patients, and nearly impossible for an individual patient (the 
ultimate goal). 
6. The value of a new prognostic factor should be based on the inclusion in and 
improvement of a prognostic index, not only on statistical significance. 
7. Review pathology in superficial bladder cancer does not always deserve the 
importance that it is usually given. 
8. High risk superficial bladder tumors, such as a pTlglll tumor, should receive 
adjuvant treatment after TUR. 
9. The comprehensible preference for conservative treatment on part of a patient 
should not keep a urologist from using more aggressive forms of therapy when 
indicated. 
10. BCG instillations can be considered in case of localisations of transitional cell 
carcinoma outside the bladder cavity. 
11. In case of intermediate risk superficial bladder tumors MMC might be the drug 
of choice for the initial treatment because it has significantly less side effects 
than BCG. 
12. The role of concomitant medication during BCG treatment might turn out to 
be very important with regard to efficacy and prevention of side effects. 
13. Prevention of clot dependent tumor cell adherence to injured urothelium during 
TUR will prevent some early recurrences. 
14. The conservative treatment of BPH will ultimately not replace TURP. 
15. The place of laparoscopy in urology, although it remains to be determined, is 
probably small. 
16. Neoadjuvant chemotherapy for locally advanced bladder cancer has interesting 
theoretical aspects, makes bladder preservation feasible in 25-45% of patients, 
but its effect on survival is unknown. Therefore, it remains an investigative 
approach. 
17. The more a study is controlled, the better the chance to avoid bias, but the 
worse the reflection with real-world medicine. 
18. De term "erectiele dysfynctie" (E.D.) suggereert dat er nog enige vorm van 
erectiele restfunctie is. Dit is echter niet altijd het geval, zodat beter gesproken 
zou kunnen worden van "erectiel onvermogen". De afkorting hiervan echter 
(E.O.) suggereert een, vooralsnog onbewezen, relatie met bepaalde 
televisieprogramma's, en lijkt daarom tot mislukken gedoemd. 
19. Het leuke van dicteren is dat je woorden kunt gebruiken die je zelf eigenlijk 
niet eens kunt schrijven. 
20. Dat veel urologen wielrennen kan alleen maar worden verklaard vanuit de 
aanname dat ze het ook in hun vrije tijd niet na kunnen laten het kruis te 
mishandelen. 
21. De verzekering wekt de schade (met permissie van J. Deelder, uit 
Euformismen, De Bezige Bij, 1991) 
22. Een goed operateur is iemand die zijn beperkingen kent. 
23. In een goede anamnese mag tegenwoordig de vraag niet meer ontbreken welke 
omroep de operatie mag filmen. 



